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The study investigates the antimalarial potential of a Southern African traditional 
medicinal plant, Dicoma anoma/a (Sond.). The plant is used to treat a variety of 
treatments including fevers. The extracts of the leaves and twigs have been 
reported to treat malaria and fever but the treatments with the roots are unrelated 
to malaria. 
The plant was collected from four locations (Lesotho, Sterkspruit, Limpopo and 
Reitz). The cold and hot OCM root extracts (IC5o :S 2.48 ~g/ml) and the cold OCM 
leaf and twig extracts (0.68 ± 0.025 ~g/ml :S IC50 :S 3.14 ± 0.12 ~g/ml) showed in 
vitro antiplasmodial activity against the cas strain (010) of P. fa/ciparum. 
Although the selectivity indexes of the extracts were low (ranging from 2 - 9), 
they showed that the activity of the leaf and twig extracts and the root extracts 
were selective to the malarial parasite and therefore the activity was not due to 
cytotoxicity. The cold and hot water root extracts did not show an interesting 
antiplasmodial activity (13.92 ± 0.52 ~g/ml:S IC50 :S 69.46 ± 2.16 ~g/ml), while the 
hot water root extract of Limpopo which showed moderate activity (IC5o=8.44 ± 
0.25 ~g/ml) and very low cytotoxic effects on CHO cells (87.06 ± 6.70 ~g/ml). 
Two water extract fractions (cold extraction) from the roots collected in Lesotho 
showed antiplasmodial activity (4.85 ± 0.18 ~g/ml :S IC50 :S 7.48 ± 0.07 ~g/ml) 
indicating a 3-fold increase in antiplasmodial activity. The fractions had low 
cytotoxic effects on CHO cells (59.60 ± 2.20 ~g/ml :S IC50:S 78.73 ± 1.99 ~g/ml). 
Bioactivity-guided fractionation of the cold OCM root extract of D. anoma/a from 
Lesotho (1.55 ± 0.07 ~g/ml :S IC50 :S 2.48 ± 0.005 ~g/ml) led to the isolation of two 
novel dimeric sesquiterpenes of the guaianolide-type, MF4 and MF7A. The two 
compounds both had molecular mass of [M + Ht =485.1964, which was 
consistent with the molecular formulae C30H28H6. The two compounds were 
therefore isomers since they eluted at different retention times on the HPLC. 
Compounds MF4 and MF7 A were screened for in vitro antiplasmodial activity 
xix 
against three strains of Plasmodium falciparum. Compound MF4 was highly 
active against the COS strain, D10 (0.28 ± 0.01 !-Ig/ml) and the COR strain, 
RSA11 (0.28 ± 0.075 j.,lg/rnl). Compound MF7A was also highly active against the 
COS strain, D10 (0.20 ± 0.01 !-Ig/ml) but was less active against the COR strain, 
RSA11 (0.40 ± 0.07 !-Ig/ml). Both compounds showed lower activity against the 
COR strain, K1 (MF4: 0.94 ± 0.34 !-Ig/ml; MF7A: 0.78 ± 0.20 !-Ig/ml) compared to 
the other two strains. Compound MF4 has shown to be the promising lead 
compound for the development of antimalarials with a selectivity index of 16 
compared to compound MF7 A which had the selectivity index of 2 on CHO cells. 
The study has also shown that the roots of D. anomala contain compounds with 
molecular ion masses [M + Ht of 487,489,491, 524, 526 and 528. The peaks 
with molecular masses of 487,489,491 as well as that of compound MF7A (485) 
differed from each other by 2 amu and similarly for the 524, 526 and 528 masses. 
This indicated the hydrogenation of the double bond/s. The UV spectra of the 
peaks with ion masses of 487 and 489 masses were similar to that of compound 
MF7A, strongly indicating that they have similar chemical structures to compound 
MF7A The peaks with ion masses of 524, 526 and 528 also showed that they 
might have similar chemical structures. 
The study has shown the presence of two novel dimeric sesquiterpene isomers 
which have antiplasmodial activity against chloroquine-sensitive and chloroquine­
resistant strains of P. falciparum. It has also shown that that the roots of Dicoma 
anomala contain compounds with similar chemical structures, which are possible 
dimeric sesquiterpenes and confirmed the traditional use of D: anomala in the 





The resistance of the malarial parasite, P. falciparum to existing antimalarial 
drugs is on the rise, making it difficult to control the disease. This has raised a 
need to develop new malaria remedies. In the fight against malaria, traditional 
medicine has been explored as the potential source of malaria remedies. In 
South Africa, about 80% of patients consult a traditional healer. This study 
investigates the antimalarial potential of a Southern African traditional medicine, 
Dicoma anomala (Sond.). The plant is used for the treatment of a number of 
conditions including fevers, and was collected in Lesotho, Limpopo, Reitz and 
Sterkspruit. The D. anomala from Lesotho was collected in two batches (batch I 
in December 1996 and batch II in October 2003) while the ones from Sterkspruit, 
Limpopo and Reitz and were collected in October 2003. 
The crude extracts of the plant were evaluated for in vitro antiplasmodial activity 
against the chloroquine-sensitive strain, D10 of P. fa/ciparum. The activity was 
measured using parasite lactate dehydrogenase assay and any test sample with 
an IC50 of S10 jJg/ml was considered active. The cold dichloromethane (DCM) 
leaf and twig extracts of D. anomala from Sterkspruit, Limpopo and Reitz showed 
activity ranging from 0.68 jJg/ml to 3.14 jJg/ml and cytotoxicity on chinese 
hamster ovarian (CHO) cells ranged from 3.85 jJg/ml to 31.12 jJg/ml with the 
selectivity index (SI) of 2.78 to 9.91. The SI was measured by the IC50 CHO cellsl 
IC50 D10 strain. The cold DCM root extracts of D. anomala from Lesotho, 
Sterkspruit, Limpopo and Reitz showed antiplasmodial activity of 0.48 jJg/ml to 
2.48 jJg/ml and the SI from 3.84 to 7.29. The hot DCM root extracts from the four 
locations exhibited antiplasmodial activity from 0.42 jJg/ml - 1.44 jJg/ml and the SI 
from 4.48 - 6.90. The SI showed that the crude extracts were more potent 
towards the paraSites than to the cells. It was found that the high performance 
liquid chromatography (HPLC) profiles of the cold and hot DCM root extracts of 
D. anoma/a from Lesotho and Sterkspruit were similar, which would explain the 
similarity in antiplasmodial activity. The cold and hot water root extracts of D. 
xxi 
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anomala from the four locations did not show antiplasmodial activity (IC50 from 
13.92 pg/rnl to >100 pg/ml), except for the hot water root extract from Limpopo 
(IC5o=8.44 pg/ml and 51 =10.32). 
The DCM, ethlyacetate and chloroform root extracts of D. anoma/a from Lesotho 
were active (IC50 = 1.18 pg/ml - 2.48 pg/ml) against the D10 strain of P. 
fa/ciparum but the hexane, petroleum spirit and methanol were not active (IC50 = 
10.67 pg/ml - 39.30 pg/ml). Bioactivity-guided fractionation using solid phase 
extraction method (5PE) was carried out on the cold DCM root extract of D. 
anomala from Lesotho, which showed antiplasmodial activity (IC50) ranging from 
1.55 pg/ml (batch II) to 2.48 pg/ml (batch D. The DCM extracts from both 
batches were fractionated using 10% increments mobile phases of acetonitrile 
and water (MeCN:H20) to obtain 13 fractions (percolate, H20 wash, fractions 10­
100 and acetone wash). The most active fractions were fractions 30, 40 and 50 
with antiplasmodial activities ranging from 0.46 pg/ml - 0.72 pg/ml. No further 
work was done on fraction 30 since it was part of an ongoing research in the 
Division of Pharmacology at the University of Cape Town. The study, therefore, 
continued with fractions 40 and 50. 
The HPLC profiles of fractions 40 and 50 indicated that they needed to be 
purified further since they contained a number of peaks. Further purification of 
these fractions was carried out by fractionating the cold DCM extract using 5PE 
method. The compounds were eluted with 5% and then 1 % increment mobile 
phases of MeCN:H20 in the range 35% - 55% (to expand fractions 40 and 50) 
and in the range 31 % - 35% (to expand fraction 35), respectively. The 
fractionation did not result in pure samples or fractions with fewer peaks as 
shown by their HPLC profiles. Nevertheless, all the 5% fractions showed 
antiplasmodial activity against the D10 strain of P. falciparum ranging from 0.23 ­
1.09 pg/ml. The 1 % fractions exhibited antiplasmodial activity ranging from 0.21 
pg/ml - 8.13 pg/ml against D1 0 strain and three chloroquine-resistant strains, K1, 
R5A11 and FAC8 of P. fa/ciparum. Although further purification of the cold DCM 
xxii 
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root extract by SPE fractionation did not result in pure samples or fractions with 
fewer peaks, the fractionation did not result in the loss of activity of the cold OCM 
root extract but the activity was enhanced in some fractions. 
Two compounds, MF4 and MF7A were isolated from fractions 40 and 50. 
Compound MF4 and MF7 A were both isolated from fraction 40 and only 
compound MF7A was isolated from fraction 50. The compounds were isolated by 
reverse-phase semi-preparative HPLC and purified on analytical HPLC. The 
antiplasmodial activity of the two compounds ranged from 0.20 IJg/rnl to 0.94 
IJg/ml against 010, K1 and RSA 11 strains. The cytotoxicity of the two compounds 
was determined on CHO cells. Compound MF4 showed cytotoxicity of 4.41 IJg/ml 
and compound MF7 A of 0.45 IJg/ml. Of the two compounds, compound MF4 was 
the favourable one with the SI of about 16, indicating that it is more potent 
towards the parasites than the cells. Compound MF7 A showed a very low SI of 
2.3. The two compounds showed a narrow safety margin, which may hamper 
their potential as lead antimalarial compounds. However, there is possibility of 
structural modifications that could result in derivatives that are less cytotoxic with 
high antiplasmodial activity. 
Compounds MF4 and MF7 A, both had a molecular mass [M + Ht of 485.1964, 
consistent with the molecular formula of C30H2s0a, indicating that they are 
dimeric sesquiterpenes. The two compounds eluted at different retention times 
on the HPLC, suggesting that they are possible isomers. This was further 
supported by their ion mass fragmentation patterns that were similar. The 
chemical structure of compound IVIF7A was elucidated by Mass spectrometry and 
10 and 20-NMR spectroscopy and was shown to be a novel dimeric 
sesquiterpene. The chemical structure of compound MF4 could not be fully 
elucidated due to difficulty in carbon and hydrogen assignments. Since the two 
compounds have been shown to be isomers, this means that compound MF4 has 
a similar chemical structure to compound MF7A but the two compounds could 
differ by structural conformation. 
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Research Summary 
The molecular ion masses [M + Ht of 6 peaks (MF5: 524, MF6B: 526, MF6E: 
528, MF7B: 487, MF7C: 489 and MF8: 491) from fraction 40 were obtained. The 
ion masses of peaks NlF7B, MF7C and MF8 as well as compound MF7 A (485) 
differed from each other by 2 amu and similarly for peaks MF5, MF6B and MF6E. 
This indicated the hydrogenation of the double bond/so It was observed that the 
UV spectra of peaks with 487 and 489 masses were similar to that of compound 
MF7A, strongly indicating that they have similar chemical structures to compound 
MF7A. The peaks with ion masses of 524, 526 and 528 also showed that they 
might have similar chemical structures. The compounds producing these peaks 
could not be isolated due to problems encountered with their separation and 
purification. The compound producing peak MF5 was unstable since it changed 
from powder form to oily form minutes after being dried. 
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OVERVIEW OF THE THESIS 

The thesis has eight chapters preceded by a dedication, a declaration, 
acknowledgements, abbreviations, lists of tables and figures, an abstract, 
research summary, a conference presentation, table of contents. 
Chapter 1 reviews the literature on various aspects of malaria. The chapter also 
covers the scope and objectives of the study. 
Chapter 2 discusses traditional medicine and the role of ethnopharmacology in 
the treatment of malaria. 
Chapter 3 focuses on the ethnobotany and ethnopharmacology of a Southern 
African traditional medicine, Dicoma anomala (Sond.). 
Chapter 4 details the methods used in the study. 
Chapters 5, 6 and 7 present the results of the study. Each chapter has an 
introduction, brief details of the methods, discussion and conclusion. 
The general discussion and conclusions are presented in Chapter 8. This 
chapter reviews objectives achieved, problems encountered, future work and 
research prospects that may arise from the study findings. It also summarizes 
essential conclusions from the study. A list of references is attached at the end of 
chapter 8 followed by appendices. 
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Chapter 1 Introduction and Literature Review 
1.1. Brief History of Malaria 
Malaria was once thought to be caused by a stink from the marshes, hence the 
name mal aria (Latin for 'bad air'). The discoveries made by Robert Koch (1843­
1910) and his associates established that microbes and not evil vapours caused 
diseases like anthrax, tuberculosis and cholera. The causative agent of malaria 
shifted from bacterium to the pigment in the blood (haemozoin). A breakthrough 
came in 1880 when a French scientist, Alphonse Laveran (1845-1922) made a 
discovery that the causative agent of malaria is a protozoan parasite not a 
bacterium, he named this parasite ascii/aria malariae. Later, Italian scientists 
named this protozoan parasite Plasmodium malariae. In 1897 Ronald Ross 
discovered that malaria is transmitted via mosquitoes [Sherman, 1998]. 
Parasitic protozoa are single celled organisms known to cause a variety of 
diseases in humans and domestic animals. The parasitic protozoan diseases are 
a major cause of mortality and morbidity worldwide [Johnston et al., 1999]. 
1.2. Plasmodium species affecting humans 
Malaria affects monkeys, rodents, birds, reptiles and humans [Donnelly et aI., 
2002]. There are four species of Plasmodium that cause malaria in humans, 
Plasmodium vivax, Plasmodium malariae, Plasmodium ovale and Plasmodium 
falciparum. Of the four Plasmodium species, Plasmodium falciparum is the most 
prevalent and most virulent. Plasmodium vivax, Plasmodium malariae and 
Plasmodium ovale do not generally cause severe disease although they are often 
linked with anemia and low birth weights. All three species are distributed 
unevenly throughout the tropical regions [Mims et aI., 2004]. 
Plasmodium vivax invades reticulocytes (young red blood cells) and is 
responsible for most of the malaria infections worldwide. It causes an estimated 
70 - 80 million cases of malaria each year. It is also distributed in some 
temperate regions and is predominant in Asia, the Western Pacific and the 
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Americas [Mendis et aI., 2001]. P. vivax does not occur in West Africa as it 
requires Duffy blood group antigens (Ft and Fl) to invade the red blood cells 
[Miller et aI., 1976]. These antigens do not occur in the majority of the population 
in West Africa [Mend is et aI., 2001]. P. vivax has liver forms, hypnozoites 
(dormant stages) which can cause relapses if left untreated [Cogswell, 1992]. 
Plasmodium malariae has a low prevalence even in areas with intense malaria 
transmission. It causes quartan malaria (a pattern of fever with a 72-hour 
periodicity), which is a re-emerging parasitic disease worldwide. It can persist in 
the blood for years if not eradicated completely [Mims et aI., 2004]. 
Plasmodium ovale is rarely reported as a cause of morbidity in malaria endemic 
areas and is mainly confined to tropical Africa and to limited areas of several 
islands of the Western Pacific region areas [Faye et aI., 1998]. P. ovale like P. 
vivax also forms hypnozoites and thus causes relapses. Complications due to P. 
ovale malaria are infrequent and paroxysms of high fever may be uncomfortable 
[Facer & Rouse, 1991]. 
Plasmodium falciparum causes more than 95% of deaths worldwide and may 
result in life-threatening complications which can be fatal. Malaria parasites are 
transmitted in the human host through the bite from the female Anopheles 
mosquito. All four Plasmodium species have similar life cycles. 
1.3. Life cycle of Plasmodium falciparum 
The lifecycle of Plasmodium species is shown in figure 1.1. 
1.3.1. The Sexual Stage of P. fa/ciparum in the Mosquito vector 
During the asexual cycle in the blood, a small percentage of the merozoites do 
not follow asexual multiplication, they develop into male and female gametocytes. 
These cells are only activated to produce gametes in the midgut of the mosquito 
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when ingested as part of the blood meal. The formation of gametes is followed by 
fertilization resulting into a diploid zygote. The zygote undergoes meiotic division 
and develops into a motile ookinete. The ookinete penetrates the cells of the 
midgut wall of the mosquito to form an oocyst on the basal lamina. The oocysts 
are located between the epithelium and the basal lamina of the midgut. Mature 
oocysts burst to release sporozoites into the haemolymph. This process happens 
approximately 17 days after the blood meal. From the haemolymph, the 
sporozoites invade the salivary glands. They then move into the secretory cavity 
where they remain viable until they are transmitted to the host during the 
mosquito's blood meal [Mims et aI., 2004]. 
Figure 1.1. A diagram showing the lifecycle of Plasmodium falciparum. 
Reproduced with permission from TDRlWelicome Trust. 
(http:www.who.intltdr/diseases/malariallifecycle.htm) 
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1.3.2. The Asexual Stage of P. fa/ciparum in the Liver 
Parasites are brought into the human bloodstream through the bite of the female 
Anopheles mosquito. During the bloodfeed, the mosquito probes the skin of the 
host and release sporozoites, which remain in the skin for more than 5 minutes 
[Sidjanski &Vanderberg, 1997]. Upon entering the bloodstream, sporozoites are 
quickly transported to the liver where they invade hepatocytes. This is where the 
sporozoites multiply, mature into schizoints and rupture to produce 10 000 - 40 
000 intrahepatocellular merozoites. Despite this huge number of parasites 
generated, the plasmodial infection of the liver is asymptomatic [Mims et aI., 
2004]. 
1.3.3. The Asexual Stage of P. fa/ciparum in the Erythrocytes 
Merozoites move from the liver to invade erythrocytes (red blood cells) in the 
peripheral circulation approximately a week after infection. Infection of 
erythrocytes by P. falciparum is initiated when the extracellular merozoite stage 
enters the red blood cell to form an intracellular ring. The invasion process takes 
approximately 30 seconds with the attachment of the apical end of the merozoite 
to the membrane of the erythrocyte to form a tight junction. This process is 
mediated by specific receptor-ligand interactions between parasite-encoded 
proteins and erythrocyte surface receptors. This is followed by the invagination of 
the erythrocyte membrane around the merozoite to form a parasitophorous 
vacuole [Dvorak et aI., 1975; Aikawa et aI., 1978]. The ring forms of the parasite 
mature into trophozoites, which develop into schizoints and mature to form 
merozoites which are released back into the circulation. 
After invading erythrocytes, the merozoites multiply to produce up to 32 new 
merozoites, which then re-infect red blood cells every 48 hours. Within the 
erythrocyte, the parasite survives by feeding on the globin component of 
haemoglobin, which is the source of amino acids for the parasite. The haem is 
toxic to the parasite, however, the parasite has developed haem detoxification 
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mechanisms whereby haem is polymerised to form haemozoin, a dark pigment 
within the food vacuole. Haem polymerisation is a nonenzymatic process which 
requires preformed haemozoin, histidine-rich proteins and lipids [Howard et aI., 
1986; Sullivan et aL, 1996; Fitch et aL, 1999; Pandey et aL, 2003]. 
1.4. The Pathogenesis of Malaria 
The initial symptoms of malaria infection such as fever, chills, nausea, vomiting, 
headache, abdominal and back pain appear approximately on day 11 after 
infection by the paraSite [Berman, 2004]. P. fa/ciparum can parasitize a large 
number of erythrocytes if untreated by chemotherapy and uncontrolled by the 
host immunity because the parasite has evolved mechanisms of evading the host 
immune response. P. fa/ciparum has surface proteins called P. fa/ciparum 
erythrocyte membrane protein-1 (PfEMP1) which act by blocking acquired 
immune response to infection and mediate adhesion of infected erythrocytes to 
the microvascular endothelium thus avoiding host clearance in the spleen 
[Langreth and Peterson, 1985]. This result in severe malaria, organ dysfunction, 
coma and death since vital organs such as the brain, liver, lungs, spleen, 
intestine and kidneys are affected [Warrel, 1987]. 
Severe malaria is associated with hyperparasitaemia (> 5%), severe aneamia 
caused by the destruction of red blood cells, cerebral malaria caused by the 
obstruction of small vessels of the brain by sequestered parasites, metabolic 
acidosis leading to metabolic distress, hypogIyceamia, hypopyrexia (>39.8 DC) 
[WHO, 2000]. 
The severity of malaria is believed to be due to the ability of P. fa/ciparum 
infected red blood cells to adhere in the small blood vessels of major organs. 
Several cell adhesion molecules that are involved in this process include 
intercellular adhesion molecule-1 (ICAM-1), CD36, CD31 and P-selectin [Berendt 
et aL, 1989; Oquendo et aL, 1989; Treutiger et al., 1997; Udomsangpetch, 1997]. 
The transmission and survival of the malarial parasite depends on the variable 
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adhesion molecules that are displayed at the surface of P. falciparum infected 
erythrocyte. The most prominent of these variable antigens is P. falciparum 
erythrocyte membrane protein 1 (PfEMP1) [Hayward et aI., 1999]. 
Some people with genetic traits that alter the red blood cell structure are 
protected against malaria. Populations in sub-Saharan Africa, parts of the Middle 
East and India that carry the sickle-cell genetic trait are partially protected 
against severe malaria. Sickle-cell trait is an inheritance of two abnormal 
allellomorphic genes that controls the formation of J>-globin [Cook, 1996]. 
Thalassemia, a disorder of hemoglobin synthesis, renders the red blood cell less 
favourable for the development of malarial parasites. People suffering from 
thalassemia are therefore protected against severe malaria. There is a high 
frequency of thalassemia in populations in parts of Southeast Asia, Africa and the 
Mediterranean region [Cook, 1996]. 
Glucose-6-phosphate dehydrogenase (G6PD) deficiency also protects against 
severe malaria. In red cells, Glucose-6-phosphate dehydrogenase in the hexose 
monophosphate pathway is a source of NADPH (nucleotide adenosine 
diphosphate hydrogen). Deficiency of G6PD exposes the red blood cell to 
oxidation of haemoglobin making it difficult for parasite survival. Populations in 
sub-Saharan Africa, Saudi Arabia and Southeast Asia have an advantage 
against malaria because of high frequency of G6PD deficiency [Cook, 1996]. 
Plasmodium vivax merozoites have a Duffy binding protein which requires a 
Duffy receptor on erythrocytes for invasion of erythrocytes by the merozoites 
[Miller et al.. 1976]. Plasmodium vivax infections are extremely rare in West 
Africa where the population has a Duffy-negative trait and are therefore 
completely protected against vivax malaria [Mendis et aI., 2001]. 
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1.5. Global Situation of Malaria 
Malaria continues to be a life-threatening infectious disease, which is a public 
health problem worldwide and it affects the tropical and sub-tropical regions of 
the world. Malaria does not only affect people residing in these regions, travelers 
to the malaria endemic regions are at risk of being infected as well [Steffen et aI., 
1987; Jelinek et aI., 2002]. 
An estimated 300 - 500 million clinical cases of malaria occur annually 
throughout the world with a mortality of 2 - 3 million deaths per year [WHO, 
1997]. About 90% of these cases and 90% of all malaria deaths occur in Africa, 
in particular sub-Saharan Africa (figure 1.2). Over 75% of these deaths affect 
children younger than 5 years in tropical Africa. The actual figures could be 
higher owing to under-reporting and difficulties in diagnosis. Malaria death toll is 
estimated to double in the next 20 years if no new control measures are 
developed [Breman, 2001]. Falciparum malaria infection in Africa tends to be 
endemic with high transmission rates while in South America, the Indian 
subcontinent, Southeast Asia and China, transmission tends to be lower and 
seasonal in nature [Winstanley, 2000]. 
Pregnant women infected with malaria are also at risk. The risks include maternal 
aneamia, intrauterine growth retardation, congenital malaria infection and low 
birth weight. The low birth weight is the main cause of infant mortality. Infant 
deaths due to malaria infection in pregnancy are estimated at 75 000 - 200 000 
[Bloland et aI., 1996; Parise et aI., 1998; Steketee et aI., 2001]. 
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Estimate of ortd malaria b rden 
Figure 1.2. World map showing the situation of malaria. 
Source: 
http://www.rbm.who.intlcmc_upload/O/OOO/015/363/RBMlnfosheet_10.htm 
1.6. The Economic Burden of Malaria 
Malaria does not only affect the health of the nations, it affects its wealth as well 
with significant direct and indirect costs. Individual or family direct costs include 
spending on insecticide treated mosquito nets, doctors' fees, antimalarial drugs, 
transport to health facilities, accompanying family members and support during 
hospital stays. Public direct costs include spending by government on 
maintaining health facilities and health care infrastructure, vector control, 
research and education. The indirect costs on the other hand include lost 
productivity or income associated with illness or death. This results from the cost 
of lost workdays and absenteeism from work. The future of the children is also 
affected since their education is hampered by absenteeism in schools and 
permanent damage due to severe episodes of malaria [Roll Back Malaria 
Infosheet]. 
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Recently it has been shown that malaria is a major constraint to economic 
development. There is a correlation between malaria and poverty since poverty is 
mostly concentrated in the tropical and subtropical regions where the 
transmission of malaria is high (figure 1.3). 
Estimate of ~ d povert 
Figure 1.3. Map showing the degree of poverty in the world. 
Source: 
http://www.rbm.who.int/cmc_upload/O/OOO/015/363/RBMlnfosheet_10.htm 
Africa is the poorest continent with most of its countries affected by malaria. The 
only parts of Africa free of malaria are the northern and southern extremes, which 
have the richest countries in the continent [Gallup and Sachs, 2001]. The 
economic progress in developing countries affected with malaria is hampered 
because there is less foreign and local investment in such countries. The trade 
and tourism industries bring in money to the country but are affected as travelers 
are reluctant to go to malaria endemic countries [Gallup and Sachs, 2001; Roll 
Back Malaria Infosheet]. 
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Growth of income per capita from 1965 - 1990 for countries with severe malaria 
has been 0.4% per year compared to 2.3% per year for other countries. Of the 
countries with severe malaria, more than a third had negative growth. Data from 
countries that have eliminated malaria have shown that they have had an 
accelerating economic growth [Gallup and Sachs, 2001]. 
Climate and ecology are the main determinants of the severity of malaria. This is 
supported by the fact that wealthy countries still battle with controlling malaria 
because of their geographical location. Oman, which owes its wealth to oil has a 
growth income per capita of almost $10 000 but there is severe malaria 
throughout the country. However, the remote areas of the desert and high 
altitude are not affected. Another country is the United Arab Emirates, which has 
the highest growth income in the world but is battling with malaria control [Gallup 
and Sachs, 2001]. Although it is acceptable that malaria is linked to poverty, 
there are also additional factors such as the geographical location, economic 
policies and other major tropical diseases. 
1.7. Malaria in South Africa 
Malaria transmission in South Africa is seasonal due to local climate. The malaria 
season is experienced between October and May with peak transmission 
between January and February. Mpumalanga, Limpopo (formerly Northern 
Province) and KwaZulu-Natal are three provinces in South Africa which are 
malaria endemic areas (figure 1.4). The North West and the Northern Cape 
Provinces occasionally experience limited malaria transmission [DoH, 2000; DoH 
National Malaria Update, 2003]. 
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Figure 1.4. Map of the endemic malaria areas within South Africa. 
Source: http://www.malaria.org.za/Malaria_RiskJRisk_Maps/risk_maps.htm 
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South Africa had a significant increase of malaria cases and deaths since 1996 
and experienced malaria epidemic in 2000 followed by a decrease in the number 
of malaria cases in 2001 (figure 1.5). Among all the provinces, KwaZulu-Natal 












~ M ~ ~ m ~ M ~ ~ m ~ M ~ ~ m ~ M 
500 
400 ~ ... 
I'll 
Q)







~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ 8 8 
~ ~ ~ ~ r r r r r r r r , , , N N 
Total no rralaria cases -+- Total no rralaria deaths I 
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Figure 1.6. Annual malaria cases in South Africa (1989-2004). 
Source: http://www.malaria.org.zalMalariaRisklCases/cases.html 
Malaria in KwaZulu-Natal is hypoendemic, meaning that the transmission 
intensity and incidence of malaria are sufficiently low that the population has little 
or no immunity. Transmission occurs during the rainy season (January to June) 
with peak transmission in April. Chloroquine was replaced as the first-line drug 
with sulfadoxine-pyrimethamine in KwaZulu-Natal in 1998 due to chloroquine­
resistant parasites [Roper et aI., 2003]. Sulfadoxine-Pyrimethamine started losing 
its effectiveness during 1995 - 1999 period in KwaZulu-Natal. The number of 
patients who did not clear the parasites within 14 days of treatment increased to 
70% in 2000 [Bredenkamp et aI., 2001] causing the province to switch to co­
artemether in 2001. The introduction of artemisinin-based combinatorial therapy 
in KwaZulu-Natal, resulted in over 75% reduction in malaria cases and deaths 
within one year [Malaria Research Programme; DoH, 2001]. 
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Limpopo Province borders on Zimbabwe in the north and Mozambique in the 
east. It is a high risk area for malaria during the summer months of November to 
May. People in the north-eastern region are mostly affected with 85% of the 
cases being due to P. falciparum infections [Vogetseder et aI., 2004]. 
Mpumalanga is bordered by Mozambique and Swaziland in the east. The high 
seasonal malaria transmission peaks between October and April. In 1997 
Limpopo and Mpumalanga Provinces changed treatment from chloroquine to 
sulfadoxine-pyrimethamine as the first line treatment [Malaria Research 
Programme]. 
In October 1999, the Lubombo Spatial Development Initiative programme, which 
comprises of South Africa, Mozambique and Swaziland was launched [DoH 
Report, 2001/2002; Malaria Research Programme]. The objective of this initiative 
was to control malaria in Maputo Province, Mozambique and to reduce malaria in 
the border areas of South Africa and Swaziland. The eradication of malaria in 
these areas will contribute towards the economy development through tourism as 
well as creating sustainable employment. Reduction in malaria cases has been 
observed since the inception of this programme. A 90% reduction in Swaziland, 
an 88% reduction in Maputo Province, Mozambique, a 90% reduction in 
KwaZullJ-Natal and a 75% reduction in Mpumalanga, South Africa [Malaria 
Research Programme]. 
The change of the first-line treatment to co-artemether in some areas, the re­
introduction of DDT spraying and the regional approach to malaria control in the 
Lubombo Spatial Development Initiative are thought to be partly the reasons in 
the reduction of malaria cases. The World Health Organization awarded the 
South African Health Department a price for the best managed malaria control 
programme on the African continent, owing to the sharp decrease in malaria 
morbidity and mortality [WHO-OMS; Malaria Research Programme]. 
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1.8. Antimalarial Drugs: Modes of Action and Mechanism of 
Drug Resistance 
Drug resistance is the ability of the malaria parasite to survive and multiply in the 
presence of drug levels that normally destroy or prevent the multiplication of 
parasites [Bruce-Chwatt et aI., 1981]. 
1.8.1. Quinolines 
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Quinine 
Figure 1.7. Chemical structures of quinolines. 
1.8.1.1. Quinine 
Quinine was the first antimalarial drug obtained from the bark of Cinchona spp. 
which is native to South America. This alkaloid was first isolated in 1820 by 
French chemists, Joseph Pelletier and Jean Biename Caventou [Foley and Tilley, 
1998]. Quinine is still used today for severe cases of chloroquine-resistant 
malaria in Africa. However, it is used as a second or third line drug in Africa but 
less so in Southeast Asia due to widespread resistance in the region [Winstanley, 
2001, Wongsrichanalai et al., 2002]. Treatment with quinine is not well tolerated 
due to being extremely bitter. Quinine has maximum effects on late rings, 
trophozoites and early schizoints [Skinner, 1996]. It is also gametocidal for P. 
falciparum and P. vivax. It acts by inhibiting the formation of the malaria pigment, 
haemozoin. 
1.8.1.2. Quinidine 
Quinidine is also an alkaloid obtained from the bark of Cinchona spp. or it can be 
prepared from quinine. Like quinine, it has schizontocidal effect and is 
gametocidal for P. fa/ciparum and P. vivax but is more active than quinine for P. 
faiciparum. Quinidine is not used as an antimalarial in most African countries, it is 
mainly used as such in the US. It is also used as an antiarrhythmic drug. 
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1.8.1.3. Chloroquine 
Chloroquine is a synthetic antimalarial of 4-aminoquinoline derivatives. It is a 
blood schizonticidal agent and has gametocidal effects on P. ma/ariae and 
P. vivax [AHFS Drug Information, 2000]. Chloroquine was first introduced as an 
antimalarial drug in 1945 due to its potency and low cost [Foley and Tilley, 1998]. 
1.8.1.3.1. Mechanism of Action of Chloroquine 
The mechanism of action of chloroquine is uncertain but it is widely acceptable 
that chloroquine acts by inhibiting haemozoin formation in the food vacuole of the 
parasite [Fitch et al., 1982]. Free heme is toxic to the parasites, hence the 
parasite has developed a mechanism of heme detoxification by polymerizing 
heme to form haemozoin. Chloroquine accumulates in the parasite digestive 
vacuole by pH gradient and kills trophozoites by forming a complex with heme 
thereby inhibiting heme detoxification [Fitch et aI., 1982; Dorn et aI., 1998]. 
1.8.1.3.2. Mechanism of Resistance to Chloroquine 
Resistance of P. fa/ciparum to chloroquine developed slowly over the years. It 
was first observed in 1950s - 1960s in Asia and Americas and in the 1970s in 
Africa [Su et al., 19971. Chloroquine has widespread resistance in Southeast Asia 
and in most parts of Africa but it is still used for economic reasons even though 
its efficacy is on the decline [Winstanley, 2001; Trape, 2001]. 
Accumulation of chloroquine in the vacuole is diminished in chloroquine-resistant 
strains. Opinion is divided on the mechanisms involved in accumulation of less 
chloroquine in chloroquine-resistant parasites. Resistance reversal of chloroquine 
by drugs such as verapamil, desipramine and chlorpromazine suggests that an 
enhanced chloroquine efflux by a multidrug resistant mechanism may be 
implicated [Reed et aI., 2000]. Resistance of P. fa/ciparum to chloroquine has 
been linked to mutations in the P. fa/ciparum multidrug resistance (pfmdr1) gene 
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and to the P. falciparum chloroquine related transporter (pfcrt) gene [Foote et aI., 
1990; Sidhu et aI., 2002]. 
1.8.1.4. Amodiaquine 
Amodiaquine is a chloroquine analogue used since the 1940s [Ngouesse et a!., 
2001 J. Amodiaquine was discontinued in the 1980s due to its prophylactic use 
resulting in neutropenia and hepatitis [Hatton et al., 1986]. The prevalence of 
chloroquine-resistant strains has resulted in the reinvestigation of the 
prophylactic use of amodiaquine in regions of chloroquine resistance. 
Amodiaquine, like chloroquine, inhibits haemozoin formation. 
1.8.1.5. Primaquine 
Primaquine is a synthetic 8-aminoquinoline derivative that was introduced in the 
early 1950s for the treatment of liver hypnozoites in P. vivax and P. ovale 
infections. In Glucose-6-phosphate dehydrogenase deficient persons, primaquine 
can cause fatal haemolysis. It acts by interfering with the DNA of the parasite 
[AHFS Drug Information, 2000]. 
1.8.1.6. Mefloquine 
Resistance of chloroquine during the 1960s - 1970s in the Americas and 
Southeast Asia led to the development of mefJoquine. Mefloquine, a fluorinated 
4-quinolinemethanol derivative, is a substituted analogue of quinine which is 
active against schizoint stages of the parasite. It has similar mode of action to 
that of chloroquine and quinine. Mefloquine is well tolerated but expensive. 
Resistance to mefloquine has been linked with the pfmdr-N86Y mutation [May 
and Meyer, 2003]. 
1.8.1.7. Halofantrine 
Halofantrine was also introduced in the 1960s - 1970s due to chloroquine 
resistance. Halofantrine is better tolerated than mefJoquine [White, 1996]. The 
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adverse effect of halofantrine is cadiotoxicity. As with mefloquine, halofantrine is 
expensive and the resistance to this drug has also been linked to the pfmdr-N86Y 
mutation. 
1.8.2. Antifolates 
The antifolate drugs (pyrimethamine, proguanil, cycloguanil, sulfadoxine) interact 
with the folate synthesis pathway by inhibiting the synthesis of folic acid, which is 
the essential precursor in the de novo synthesis of pyrimidines needed for DNA 
replication and transcription [AHFS Drug Information, 2000]. The two enzymes, 
dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) are 
involved in the folate synthesis pathway of Plamodium falciparum. Malarial 
parasites are unable to take up pyrimidines as well as derivatives of folate from 
the host, therefore in the presence of antifolate drugs the two enzymes are 
inhibited resulting in the inhibition of pyrimidine synthesis thereby killing the 
parasite. Figure 1.8 below shows the chemical structures of antifolate drugs used 
for the treatment of malaria. 





Chapter 1 Introduction and Literature Review 










Figure 1.8. Chemical structures of proguanil and cycloguanil. Cycloguanil is derived in 
vivo from the pro-drug, proguanil. 
1.8.2.1. Mechanism of Antifolate Action 
Proguanil acts by inhibiting pyrimidine biosynthesis by blocking DHFR through its 
active metabolite cycloguanil, therefore leading to the inhibition of nucleic acid 
synthesis. Pyrimethamine binds with high affinity to the enzyme, DHFR thereby 
inhibiting the activity of the enzyme [Hyde, 1990]. Sulfadoxine acts on DHPS by 
competing with the enzyme substrate, p-aminobenzoic acid [Wang et aI., 1997]. 
1.8.2.2. Mechanism of Resistance to Antifolates 
Resistance of P. fa/ciparum to pyrimethamine has been linked to point mutations 
in the dihydrofo/ate reductase (dhfr) gene at codon 108 (serine-asparagine), at 
codon 51 (asparagine-isoleucine) and at codon 59 (cysteine-arginine). 
Resistance to sulfadoxine has been linked to mutations in the dihydropteroate 
synthase (dhps) gene at codon 437 (alanine-glycine), at codon 540 (glutamic 
acid-lysine), at codon 436 (serine-alanine or phenylalanine), at codon 581 
(alanine-glycine) and at codon 613 (alanine-threonine/serine) [Brooks et aI., 
1994, Khalil et al., 2002; Kublin et aI., 2002]. 
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Due to increasing resistance to antifolate drugs and other antimalarial drugs, 
combination therapy was introduced. An effective combination therapy will 
consist of a drug with a short half-life and one with a long half-life. The short 
acting drug eliminates parasites rapidly and the long acting one will ensure that 
the remaining parasites are also eliminated. 
1.8.2.3. Sulfadoxine-pyrimethamine 
Sulfadoxine-pyrimethamine, also known by the brand name Fansidar®, 
Fansidar®, is a fixed combination of two antifolate drugs, sulfadoxine and 
pyrimethamine used for the treatment of uncomplicated falciparum malaria. 
Fansidar® is an affordable and accessible drug that was used until recently in 
malaria endemic countries for the treatment of chloroquine-resistant strains. It 
was introduced in the 1980s and has until recently become the first-line drug in 
many countries. Eight African countries (Malawi, Kenya, Botswana, Zambia, 
Ethiopia, Tanzania, Zimbabwe and South Africa) switched to Fansidar® as the 
first- line treatment drug against uncomplicated malaria but the drug is expected 
to be ineffective by 2006 - 2007 since failure rates of 20% - 45% and 60% in 
separate trials were observed [Winstanley, 2001; Winstanley et aI., 2002]. In the 
middle 1980s Fansidar was discontinued in the United States as its prophylactic 
use resulted in erytherma multiforme, Stevens-Johnson syndrome and toxic 
epidermal necrolysis in American travelers [Miller, 1986]. 
When Fansidar® is administered, the two drugs act synergistically to disrupt 
folate synthesis. Resistance to Fansidar® has evolved worldwide, it occurs 
frequently and is already well established in Southeast Asia, South America and 
is rapidly increasing in East and Central Africa [Talisuna et aI., 2004, 2002; Roper 
et aI., 2003; TaKecki et al., 2001; Nzila et al., 2000; Plowe et aI., 1998; Ronn et 
aI., 1996]. The slow elimination of sulfadoxine-pyrimethamine (100 - 200 hours, 
respectively) has an advantage in providing for chemoprophylaxis after treatment 
but on the other hand this slow elimination favours the selection of resistant 
parasites [Watkins and Mosobo, 1993]. 
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A study by Nzila and others showed that patients who are at the risk of high 
treatment failure are those infected with the dhps double mutant (Gly-437/Glu­
540) and dhfr triple mutant (Asn-108/1Ie-51/Arg-59). This quintuple mutant has 
been suggested as the most specific molecular marker for failure of sulfadoxine­
pyrimethamine treatment of uncomplicated P. falciparum malaria {Kublin et aI., 
2002]. 
1.8.2.4. Chlorproguanil-dapsone 
Another fixed combination of low cost, chlorproguanil-dapsone (LAPDAP) was 
investigated due to the increasing resistance to sulfadoxine-pyrimethamine. 
Dapsone, like sulfadoxine, also acts on the folate synthesis pathway by 
competitively inhibiting DHPS while chlorproguanil inhibits DHFR through its 
active metabolite chlorcycloguanil [Nzila et aI., 2000]. Although resistance to 
LAPDAP has developed, it is less than that seen for Fansidar. This may be 
attributed to the shorter half-life of LAPDAP (12 - 48 hours) as compared to about 
100 - 200 hours of Fansidar {AHFS Drug Information, 2000; Winstanley et aI., 
1997]. 
1.8.2.5. Atovaquone-proguanil 
In 2000, Malarone® (atovaquone-proguanil) was introduced in fixed combination 
and has a half-life of 12 - 48 hours. Atovaquone is a selective inhibitor of parasite 
mitochondrial electron transport while proguanil inhibits DHFR via the active 
metabolite, cycloguanil {Srivatava & Vaidya, 1999]. Proguanil, independent of its 
metabolism to cycloguanil, has been shown to enhance the activity of 
atovaquone [Srivastava et al., 1999; Thapar et aI., 2003]. 
Atovaquone is an analogue of ubiquinone, an electron-carrying co-enzyme which 
is involved in cytochrome bC1 complex of the mitochondrial electron transport 
chain [Srivastava & Vaidya, 1999]. Several metabolic enzymes are linked to the 
mitochondrial electron transport chain via ubiquinone and thus they are indirectly 
inhibited by atovaquone. The inhibition of these enzymes leads to the inhibition of 
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nucleic acid synthesis and the synthesis of biological energy, ATP (adenosine 
triphosphate). 
Malarone® has high efficacy against sensitive strains of P. fa/ciparum, including 
multi-drug resistant strains, however resistance to Malarone has been reported 
[Farnert et aI., 2003; Fivelman et aI., 2002]. Atovaquone resistance has been 
shown to be due to single point mutations in the cytochrome b gene (cytb) 
[Korsinczky et aI., 2000; Vaidya and Mather, 2000]. This may be the gene that 
confers resistance to Malarone® but there, may also be other mechanisms since 
cytb could not be detected in one patient where there was treatment failure after 
Malarone® administration [Farnert et aI., 2003]. Resistance to cycloguanil occurs 
with mutations at codon 16 (Ala-+Val) and codon 108 (Ser -+Thr). 
1.8.3. Artemisinin 
Artemisinin (qinghaosu) was isolated in 1972 from the leaves of Artemisia annua, 
a Chinese plant used traditionally as herbal tea and as a treatment for fever and 
malaria for over 2000 years [Li and Rieckmann, 1992]. Artemisinin and its 
derivatives (figure 1.9) are highly potent antimalarials which are active against 
multi-drug resistant malaria [Klayman, 1985; Balint, 2001]. 
o OH 
(1) artemisinin (2) dihydroartemisinin 
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Figure 1.9. Chemical structures of artemisinin and its derivatives (1 - 5). 
Artemisinin and its derivatives are used for the treatment of severe malaria and 
are very effective in rapidly reducing the parasitaemia and fever. Artemisinin can 
reduce parasite loads within 48 hours, has a short half-life of 13 hours when 
taken orally [van Agtmael et aI., 1999] and cures falciparum malaria in 7 days. 
The artemisinin-based drugs have the ability of an excellent safety profile, short 
half-life and some gametocidal activity. 
Artemisinin is a sesquiterpene lactone endoperoxide. It has been suggested that 
the antimalarial activity of artemisinin-based drugs is due to the peroxide group, 
in the form of a 1,2,4-trioxane, which involves the generation of an oxidative 
stress [Meshnick et aI., 1996; O'Neill et aI., 2001]. It was hypothesized that 
artemisisnins specifically inhibit P. fa/ciparum sarcoplasmic/endoplasmic 
reticulum Ca2 +-ATPase (SERCA) because artemisinin is structurally similar to 
thapsigargin, an inhibitor of SERCA [Eckstein-Ludwig et aI., 2003]. Another 
proposed mechanism is that, after activation, artemisinin causes local production 
of reactive oxygen species and depolarization of the mitochondrial membrane [Li 
et aI., 2005]. 
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Despite the widespread clinical use of artemisinin and its derivatives in the 
treatment of falciparum malaria, resistance to these drugs has not been reported. 
This has created the notion that resistance to artemisinin does not occur but 
evidence that artemisinin resistance can develop is now accumulating. In vitro 
resistance to artemether has been observed in isolates from French Guiana 
[Jambou et aI., 2005]. An in vivo study has shown that stable resistance to 
artemisinin develops after selection pressure [Afonso et aI., 2006] and a clinical 
study by Menard et al. has demonstrated that there is a link between reduced in 
vitro artemisinin susceptibility and loss of clinical efficacy of artesunate 
monotherapy. In light of this, the WHO has requested pharmaceutical companies 
to end the marketing and sale of 'single-drug' artemisinin malaria medicines 
[WHO mediacentre, 2006]. It is therefore crucial that the decreased in vitro 
susceptibility and the potential emergence of resistance to the artemisinins be 
thoroughly investigated. 
1.8.3.1. Artemisinin-based Combination Therapy (ACT) 
Although artemisinin and its derivatives are effective against multi-drug resistant 
parasites, their short half-lives lead to recrudescence commonly encountered 
after treatment with these drugs. Recrudescence rates of 44% - 54% for 3 day 
dosing regimens have led to recommendations that artemisinins be used in 
combination with drugs with long half-lives [White & Olliaro, 1996; van Agtmael, 
1999]. The introduction of ACT has shown to increase cure rates and decrease 
the development of drug resistance [White and Olliaro, 1996; van Agtmael et aI., 
1999; White 1999]. The WHO has recommended that countries with high 
resistance to conventional drugs should use ACT [WHO, 2001] and most 
countries have now switched to artemether-Iumefantrine as first-line treatment of 
uncomplicated malaria [Olumese, 2006]. 
There is concern that artemisinin derived compounds may result in neurotoxicity, 
based on animal studies that demonstrated that artemisinins can damage brain 
stem nuclei of the auditory centers [Nontprasert et aI., 2002]. A number of studies 
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have investigated these claims [Toovey et aI., 2004; Kissinger et al., 2000; van 
Vugt et al., 2000; Price et al., 1999] but the findings gave conflicting reports and 
some studies did not report on important tests, which are required to reliably 
assess hearing [Winstanley & Molyneux, 2004]. Novartis Pharmaceuticals 
Corporation said that their safety database revealed no significant adverse 
effects of co-artemether treatment on the auditory system therefore they found no 
evidence that co-artemether is associated with hearing impairment [Reinhart and 
Hughson, 2005]. 
However, there is a consenslJs that further studies need to be undertaken to 
provide evidence concerning ototoxicity and neurotoxicity of artemisinins, which 
are undoubtedly clinically effective. Thus, there is no convincing evidence that 
artemisinin derivatives results in neurotoxicity in humans. It is therefore crucial 
that safety issues concerning the use of artemisinin derivatives are resolved to 
prevent any impairment that might arise due to the use of these drugs. 
1.9. Eradication and Control of Malaria 
Efforts to eradicate malaria began in the 1950s under the WHO and were 
successful, but by the 1970s the disease was resurgent again [Onori, 1993]. 
Malaria control and eradication is hindered by resistant strains of P. falciparum 
parasites to commonly used antimalarial drugs, as well as cross-resistance to 
structurally unrelated drugs, resistance of mosquitoes to insecticides, the rise of 
malaria transmission and the lack of an effective vaccine [WHO, 1989; Hyde, 
2002; Ito et aI., 2002]. 
Due to multi-drug resistant strains of Plasmodium, which are now becoming 
increasingly prevalent around the world, antimalarial drugs that are commonly 
used are losing their effectiveness [Hyde, 2002; Winstanley, et aI., 2002; 
Wongsrichanalai et aI., 2002]. Another contributing factor is the lack of industrial 
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interest in developing malaria vaccines for poor endemic countries especially for 
the asexual stage and for blocking transmission [Kilama, 2003]. 
It is very important to understand resistance mechanisms involved so as to 
develop new drugs that would minimise or circumvent drug resistance. 
Knowledge of resistance mechanisms may also identify new targets for drug 
development [Klokouzas et aI., 2003]. 
1.9.1. Mass Administrations of Antimalarial drugs for Malaria Control 
In an attempt to combat resistance, combination therapy has been used. For 
more than 70 years mass administrations of antimalarial drugs have been used 
to control malaria. Mass drug administrations have proved to be ineffective in 
stopping the transmission of malaria, however, in reducing malaria morbidity and 
possibly mortality they were effective [von Seidlein and Greenwood, 2003]. This 
form of treatment had successes and failures. The mass drug administrations 
could once again be used to control malaria as shown by the development of 
artemisinin-based combination therapies that are less likely to induce drug 
resistance and which reduce infectiousness in treated patients. 
The control of malaria depends on the development of new, potent and 
affordable antimalarials to developing countries where malaria is prevalent. The 
spread of malaria could be controlled by rendering the mosquitoes ineffective 
since they are obligatory vectors. This would help in blocking malaria 
transmission [Ito et aI., 2002]. There is also a need for new structural classes of 
antimalarial agents including those from plants with novel and different 
mechanisms of action. New malaria control techniques, new strategies to combat 
malaria and new low cost antimalarial drugs that are effective against multi-drug 
resistant P. fa/ciparum strains are also urgently needed. 
Malaria transmission by mosquitoes has also been controlled by residual 
insecticides such as DDT (dichlorodiphenyltrichloroethane), which has residual 
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activity for months. Measures have also been taken to prevent human-vector 
contact by using insecticide treated bed-nets and topical insect repellents such 
as diethyltoluamide [Cook, 1996]. 
1.9.2. Search for new antimalarial drugs 
Malaria treatment is limited to schizontocidal therapy and to the relief of 
symptoms such as fever, headache and hypoglyceamia [Vogetseder et aI., 
2004]. The availability of the complete genome sequence for P. fa/ciparum will 
facilitate the development of new drugs for malaria. The genome sequence will 
enable understanding of host-pathogen interaction and the identification of new 
therapeutic targets through proteomic-genomic studies of this parasite [Florens et 
aI., 2002; Gardner et al., 2002]. 
Few new antimalarials that are cost effective and potent towards drug-resistant 
parasites are being developed [Winstanley et al., 2002]. The number of 
innovative products from big pharmaceutical companies declined relative to that 
of smaller companies. The low productivity in pharmaceutical research could be 
attributed to the fact that potential productive research inquiries have been 
abandoned because of the focus being on the benefits to the company instead of 
health [Taylor, 2003]. 
1.9.3. Scope of the Project 
The emergence of resistance to currently available antimalarial drugs has made it 
difficult for effective treatment and eradication of malaria. There is an urgent need 
to address this problem. The discovery of new antimalarials through organic 
synthesis or from natural sources is needed. 
Research has explored traditional medicine as a potential source for new and 
novel antimalarial drugs. Scientific follow-up of plants known for their traditional 
medicinal uses has led to the discovery of a high number of useful plant-derived 
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drugs. The antimalarial drugs, quinine and its derivatives originate from the 
Cinchona bark while artemisinin and its derivatives originate from Arlemisia 
annua. More than 50% of all the drugs used clinically in the world are natural 
products and their derivatives [van Wyk et al., 1997; Farnsworth et aI., 1985]. 
In searching for new antimalarials, this project investigated a traditional medicine 
plant, Dicoma anomala, which is used for the treatment of fevers and other 
ailments in Southern Africa. The aim of this project was to isolate antiplasmodial 
compounds from Dicoma anomala and the objectives were: 
• 	 To screen the leaf and root extracts of D. anomala for antiplasmodial 
activity against the CQS strain of P. falciparum. 
• 	 To isolate antiplasmodial compounds from D. anomala and screen them in 
vitro against the CQS and CQR strains of P. falciparum. 
• 	 To determine the chemical structures of the compounds using 
spectroscopic methods such as Mass Spectrometry and NMR. 
• 	 To determine the cytotoxicity of the compounds on CHO cells. 
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Chapter 2 Traditional Medicine 
2.1. Traditional Medicine and Traditional Healing 
The well-being of people in ancient times depended on traditional medicines. 
Traditional medicines are mainly medicinal plants growing in the wild and used by 
traditional healers in different ethnic groups. Some of these plants have been 
used for a long time and are still used today [Mukherjee, 2002]. 
After years of the introduction of Western medicine, people, in particular, those in 
rural areas of Latin America, Asia and Africa still consult traditional healers for 
their ailments. This is because traditional medicine has formed part of their 
tradition and culture but most importantly, traditional medicines are affordable 
and easily available than modern medicine. It is estimated that 80 % of people in 
developing countries use traditional medicine [WHO, 2002] as a source of 
primary health care where modern health care facilities are lacking or are not 
easily accessible. 
In addition to cultural and traditional beliefs, the use of traditional medicine in 
developing countries could be attributed to traditional medicine having fewer 
adverse effects and that no resistance to whole-plant extracts has been recorded 
[Willcox &Bodeker, 2000]. Complaints of side effects are less frequent in patients 
given herbal medicines than in the case with allopathic medicines. Common 
complaints are gastrointestinal disturbances with oral medicines and sneezing 
with inhalants [Edinburg, 1998; Mukherjee, 2002]. 
Due to their traditional beliefs, people residing in urban areas still consult 
traditional healers even though western medicines are easily available. Patients 
will normally seek help from medical doctors for a particular disease and when 
their health deteriorates or does not improve, a traditional healer is consulted 
[Katz & Kimani, 1982; de Wet, 1998]. Some consult the traditional healers before 
or after consulting the medical doctor. There are still those patients who only 
consult traditional healers [van Wyk et aI., 1997; Kale, 1995]. 
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Traditional healing is intertwined with religion and cultural beliefs and the healing 
practices vary widely between different African countries. Traditional healers 
believe that the western medicine treats symptoms, while their herbal remedies 
cure the body off the sickness. Traditional healing has a holistic approach to 
illness since not only the physical condition is catered for, but also the 
psychological, spiritual and social aspects of individuals, families and 
communities [Abdool Karim et aI., 1994] are addressed. 
Traditional healers when consulted are the first to tell the patients of what they 
are suffering from and the patient will admit or deny this and give details. The 
traditional healer will then throw bones (though not all traditional healers can do 
this) that will give himlher more information about the patient and the disease or 
the problem. Traditional medicines are always paid for but the payment is not 
fixed and it varies according to sickness. Some traditional healers will state that if 
the medicine is not paid for, it will not work. In addition to the payment of 
medicinal herbs, a patient may be asked to bring or slaughter an animal like a 
white chicken, a goat or a sheep. Slaughtering of animals is mostly done to 
appease the ancestors and this is served together with home-brewed beer [Katz 
&Kimani, 1982]. 
Although traditional medicine is affordable, in some instances the payment may 
be higher than that paid for biomedical treatment. In this case a patient can pay 
in small amounts or pay an initial fee and the rest of the fee is paid when 
treatment is complete or when the patient is healed [Green & Makhubu, 1984; 
Obbo, 1996]. 
If modern medicines have failed to cure a patient or do not improve a patient's 
health, this is attributed to the problem being due to a spirit of an unhappy 
ancestor or due to witchcraft [Gessler et al.. 1995; Felhaber & Mayeng, 1997]. 
The illness can also be caused by the transgression of certain taboos and 
societal norms [Yangni-Angate, 1991]. The source or cause of illness is removed 
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by rituals to appease the ancestors, the neutralization of the sorcerer in cases of 
witchcraft or by using herbal mixtures. 
It has been strongly suggested that traditional healers be integrated into the 
modern health since they could be of great help in the fields of psychology, 
psychiatry and in primary health care. Success in treating psychological problems 
using traditional medicines is well known and often recognized [Pearce, 1982; 
Kale, 1995]. 
Traditional healers are popular for providing medical care in a personal way. The 
reasons people gave for visiting traditional healers are that the consultations with 
doctors or hospital staff are too short, little opportunity to express their own 
concerns and being given medicine without explanation as to the cause of their 
illness [Gessler et aI., 1995]. Traditional healers spend more time with their 
patients and take time to get involved in the patients' sickness. They have no set 
opening times, work throughout including public holidays and are within the 
communities and in most instances speak the same language and have the 
same culture. 
Medicinal plants are not only obtained through traditional healers. Mild ailments 
arising within a family are treated using medicinal plants grown in the family 
backyard [Madureira et aI., 2002]. They can also be purchased from market 
places and road-side stalls. Many of the people who sell these plants are not 
necessarily herbalists or traditional healers but are people with the knowledge of 
traditional medicinal plants. Information on the use of medicinal plants can be 
obtained in two ways. One is by literature search whereby there are no problems 
with intellectual property rights since the information is in the public domain. 
Another one is by enquiring from elderly folk, the community and traditional 
healers, an ethnobotanical approach. This is where intellectual property rights 
become an important issue. Information on medicinal plants is given to a person 
who the community or traditional healers can trust because the healers are 
reluctant to give away their secret plants or methods [Soerjarto, 1996). 
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The knowledge of medicinal plants is passed on to other generations in two 
ways. One is by word of mouth from one generation to another and the other one 
is by training of traditional healers [van Wyk et aL, 1997]. 
2.2. Collection of Medicinal Plants 
Traditional healers collect plants under the guidance of an ancestral spirit 
[van Wyk et aL, 1997]. These plants are collected for a particular patient or a 
particular disease at a certain time and location according to the information the 
healer received through a dream. Some plants are collected at night when they 
are most potent. Chemical constituents are known to vary diurnally [Edinburg, 
1998]. The locality, type of soil and its moisture, time of day, the aspect of the 
mountain slope and the season of collection play a very important role in the 
chemical constituents of plants [van Wyk et. aL, 1997]. Chemical constituents in 
plants vary because of the age of the plant, the season, photo-periodicity and 
geographical area of collection [Farnsworth et aI., 1985]. These factors, known to 
scientists, are also known to traditional healers in influencing the potency of their 
medicinal plants. 
2.3. Plant Parts Used in the Treatment 
Different parts of the plant are used for medicinal purposes, the whole plant is 
rarely used. Plant parts used by traditional healers, pharmaceutical and 
commercial industries are the roots, stems, leaves, barks, bulbs, rhizomes, 
tubers, fruits, seeds, flowers, gums, exudates and nectar. Leaves and twigs are 
normally used together. Chemical compounds in a plant are not equally 
distributed and one part may contain compounds that are not found in other parts 
of the plant. This is what makes other parts of the plant to be toxic or non-toxic 
and active or inactive than the other parts. Some parts may be more toxic or 
more active than the others [van Wyk et aL, 1997]. 
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2.4. Preparation Methods for Medicinal Plants 
Plant material may be used fresh while most are used dry. The plant material is 
cut into small pieces and dried in the sun or in the shade away from direct 
sunlight. The dried plant material is then stored as it is or is ground to powder 
and stored in newspapers, paper bags, glass jars and tin cans. The plant material 
is prepared in water as decoctions or infusions. Infusion is maceration of the 
plant material in cold or boiling water for a short period of time. Some plant 
materials are prepared as inhalations (respiratory problems), lotions (skin 
application), ointments (wounds and skin application), enemas (rectal injections) 
powders and pastes (skin application and oral intake) and as snuffs [van Wyk et. 
aL, 1997; Hedberg & Staugard, 1989]. Instructions on the use of the remedy 
prepared by the healer are given verbally to the patient. 
Commercially, the plant material is available as extracts of fractions which 
contain active ingredients, inhalations which contain volatile ingredients, lotions, 
nasal drops, ointments, tintures containing active ingredients in alcohol and 
snuffs. These products are marketed as standardized products which have been 
tested for safety and efficacy. Medicinal plants are administered orally, 
sublingually, rectally, topically, nasally, by smoking, by steaming them for 
inhalation, by bathing in water mixed with herbal mixtures for maintaining good 
health or for treating skin diseases [van Wyk et aI., 1997; Kale, 1995]. Some 
medicinal plants are placed in a small incision in the skin to enhance the onset of 
action [Edinburg, 1998]. 
2.5. Traditional Medicine: A Global Perspective 
Traditional medicine was outlawed in some countries during colonial times 
[Obbo, 1996]. Today traditional medicine and traditional practitioners are 
recognized and respected in most countries while in others they are merely 
tolerated. In China, Democratic Republic of Korea, the Republic of Korea and 
Vietnam traditional medicine has been integrated into the national health system 
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[WHO, 2002]. Countries such as Mali, Nigeria, Ghana, India, Sri Lanka, Canada 
and the United Kingdom among others recognize traditional medicine and have a 
national policy on traditional medicine [WHO, 2002]. Japan, Germany and USA 
do not have a national policy on traditional medicine but regulate traditional 
medicine and herbal products [WHO, 2002]. In Cuba traditional medicine is illegal 
[[abuti et aI., 2003]. 
The World Health Organization supports the integration of traditional medicine in 
the health care system. WHO established the Traditional Medicine Programme 
(TRM) in 1977 to help the developing countries where most people depend on 
traditional medicine to incorporate it into national health systems. In 1978, the 
WHO made a declaration at Alma-Ata, committing itself to implementing the 
primary health care strategy by employing useful methods such as indigenous 
practices and mobilising resources such as traditional practitioners and birth 
attendants [WHO, 1978]. 
WHO recognizes that traditional medicine is an acceptable, safe and 
economically feasible way to achieve health coverage for all. WHO believes that 
integration of traditional medicine and orthodox medicine into the national primary 
health care system would increase manpower and therefore increase health 
coverage [WHO, 1978,2002]. 
Before being integrated or offered an equal status to the orthodox medicine, 
traditional healers would have to undergo basic training in hygiene and orthodox 
healthcare practices to serve as primary health care workers. This would require 
the formulations of policies, the provision of legal recognition and social equality 
for traditional healers. All healers would need to be registered including their 
premises of work and clinics. The training of traditional healers would be 
standardized and laws and regulations for traditional healers codes of conduct 
would be established [WHO, 1978, 1995,2002]. 
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The traditional healers need to be registered to traditional healers associations so 
that they can be easily identified for inclusion in the public health care system 
and for regulation and monitoring. The identification, registration and regulation of 
all healers is very important to check for harmful practices and eliminating 
dishonest practitioners. This will ensure a high level of professional ethics and 
practice and the avoidance of dangerous and damaging practices [WHO, 1978; 
Abdool Karim et aI., 1994]. 
WHO support for research and development in all fields of traditional medicine is 
shown through its collaboration with a global network of institutional centres. It is 
also involved in the research of medicinal plants through its programs, Traditional 
Medicine Programme and Research and Training in Tropical Ois~ases (TOR). 
Research on traditional medicine is also being carried out at universities, 
institutes and industry. 
2.6. Traditional Medicine and Traditional Healing in South Africa 
Medicinal plants form an important part of the South African cultural heritage and 
they contribute to primary health care throughout the country. South Africa has 
over 30 000 species of higher plants. The Cape region, with nearly 9 000 
species, is rich in species and has the most diverse flora on earth. Of the 3 000 
species of plants used medicinally in SA, 350 species are commonly used and 
traded medicinal plants. South Africa has a local and a global market for 
medicinal plants. Some of these plants include Cape aloes (Aloe ferox) , buchu 
(Agathosma betulina) and devil's claw (Harpagophytum procumbens) [van Wyk 
et aI., 1997]. 
With the development of phytomedicines, it is important and necessary for the 
cultivation of plants on farms for their sustainable use. Cultivation of plants 
ensures that rare and valuable plants are conserved from extinction. Some of 
these plants include pepper-bark (Warburgia salutaris) , wild ginger 
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(Siphonochilus aethiopicus) and buchu (Agathosma betulina) [van Wyk et. aI., 
1997]. 
Traditional healers who are believed to be spiritually empowered are commonly 
known as 'dingaka' (Setswana, Sesotho and Sepedi), 'izinyanga' and 'isangoma' 
(Zulu), 'ixwele' and 'amaquira' (Xhosa), 'bossiedokter' (Khoi-San) [van Wyk et aI., 
1997]. Inyangas are herbalists and 90% of them are male, whereas isangomas 
are diviners who determine the cause of illness by ancestral spirits and 90% of 
them are female [van Wyk et aI., 1997]. Most healers nowadays practice both 
arts of healing. Apart from healing by dingaka or isangoma there are other 
mediums of healing such as healing offered by intuitives, dreamers, spirit 
mediums, prophets and spiritual healers 'abathandazi' who are faith healers 
healing by prayer, holy water or ash. There are also traditional birth attendants 
who are elderly women who carry out most of the deliveries in rural areas. Elderly 
folks especially in rural areas help to treat small ailments within their families 
because of their knowledge of medicinal plants [Kale, 1995; van Wyk et. aI., 
1997]. 
Traditional healers are respected in their communities and their existence in 
South Africa dates back to 1ih century [Kale, 1995]. Compared to 25 000 
medical doctors of modern medicine, South Africa has about 200 000 traditional 
healers who render their services to about 80% of the black population [Kale, 
1995]. They are consulted for various diseases including sexually transmitted 
diseases, divulgence of secrets, immunization against witchcraft, prophecies of 
future events. 
It has been reported that in South Africa, 80% of patients consult a traditional 
healer before consulting a medical doctor and that about 60% of all the babies 
are delivered by traditional birth attendants [Abdool Karim et aI., 1994]. 
Traditional healers were banned in South Africa by the Health Act of 1974. 
Despite this law many organizations registered traditional healers. These 
organizations include the Congress of Traditional Healers of South Africa, 
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Southern African Traditional Healers Council, African Dingaka Association, the 
association of Traditional Healers Council and the African Skilled Herbalists 
Association [Freeman & Motsei, 1992]. 
The South African government recognizes the use of African traditional 
medicines and the research on traditional medicine at universities and science 
councils. In 2003 the Traditional Health Practitioners Act was implemented to 
make provision for control of the registration, training and practices of traditional 
health practitioners in the Republic of South Africa and to register African 
traditional medicine and regulate them under the Medicine Control Council 
[Department of Health]. The Department of Health has also established the 
National Reference Centre to evaluate therapeutic claims of traditional medicine. 
2.7. Medicinal Plants as Source of Drugs 
It is estimated that there are 250 000 plant species of higher plants in the world, 
of which 220 000 are flowering plants [Wilson, 1988]. Approximately 119 
chemical agents, which are clinically used worldwide were obtained from 
flowering plants and less than 90 species of the medicinal plants have been 
identified as the source of these drugs [Farnsworth et aI., 1985]. The World 
Health Organization estimates that about 20 000 plant species are used 
medicinally throughout the world in about 90 countries, of which 250 species are 
widely used or have been analyzed for the identification of active components 
[WHO, 1978]. This means that most species have not been studied chemically 
and pharmacologically. The greatest biodiversity in the world is found in the 
tropical rain forests [Wilson, 1988]. 
Natural products are products derived from plant, animal, microbe and mineral 
sources [Soejarto, 1996; Edinburg, 1998]. Microorganisms and fungi have 
provided antibiotics such as penicillin, neomycin, streptomycin and 
cephalosporin-C. Products obtained from animals include the human growth 
hormone, ovine and porcine insulin [Mukherjee, 2002]. There are therefore good 
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chances of finding new drugs through the investigation of natural products. In a 
survey done between 1959 and 1980 in the US it was estimated that about 25% 
of all medicines dispensed from community pharmacies contained plant extracts 
or their active principles [Beecher et aI., 1989]. Previous research results showed 
that about 40% of all drugs approved between 1983 and 1994 were natural 
products or derived from natural products [Cragg et aI., 1997]. 
The structural diversity in natural products increases the chances of finding a 
compound with activity [Harvey, 1999]. Some compounds are not confined to one' 
species or one family. Compounds related or similar to the ones isolated from a 
particular plant could also be isolated from varieties within the same species, 
species of the same genera and genera within the same family. This is 
advantageous when that particular compound has activity since the bioassays 
and screening in higher animals would not be limited by the availability of the 
plant material. 
The bioactive molecules found in medicinal plants are secondary metabolites 
which are synthesised by the plant for its survival against predation and infection 
[Williams et al., 1989]. These biologically active secondary metabolites often 
have highly complex chemical structures. Active ingredients that have been 
isolated from medicinal plants include glycosides, amino acids, lectins, tannins, 
quinines, flavonoids, terpenoids, alkaloids and coumarins. 
Drugs that have been derived from plants include quinine (Cinchona spp) an 
antimalarial drug, vinblastine and vincristine (Catharanthus roseus) anticancer 
drugs, aspirin (Salix spp) an analgesic, atropine (Atropa belladonna) an 
anticholinergic and morphine (Papaver somniferum) an analgesiC that is mostly 
converted to codeine which is used to treat headaches and is an ingredient of 
COUgh syrups. Aloe bitters from Aloe vera are used as laxatives and aloe gel 
which has healing properties is obtained from (Aloe ferox) [Farnsworth, 1988; van 
Wyk et aI., 1997]. 
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Not all medicinal plants or their products are used as extracts or pure drugs, 
some are used as starting material for the semi-synthetic preparation of other 
drugs. The synthesis of oral contraceptives and other steroid hormones are such 
examples. Plant steroids, diosgenin from Dioscorea spp and hecogenin from the 
leaves of Agave sisalana are used in the synthesis [Chevallier, 1996]. 
2.8. Medicinal Plants as Source of Antimalarial Drugs 
There is a rapid spread of Plasmodium falciparum resistance to available 
antimalarials, and this has called for a need for alternative antimalarials. 
Medicinal plants are used in the treatment of malaria in Africa, Americas and Asia 
[Phillipson et aI., 1987]. However, few scientific data are available to assess the 
efficacy of these medicinal plants. Table 2.1 shows traditional medicinal plants 
that are used to treat malaria and fevers in South Africa. In search for new 
antimalarial drugs, these medicinal plants have to be thoroughly investigated and 
their efficacy confirmed. Some of the medicinal plants that are used traditionally 
for the treatment of fevers and malaria have shown antiplasmodial activity in vitro 
against P. falciparum (table 2.2). 
It is therefore, important that medicinal plants that are known to have antimalarial 
properties are investigated in order to determine their potential as sources of new 
antimalarial drugs [Gessler et aI., 1994]. There is also a need to confirm the 
therapeutic effects of traditional medicine through controlled studies [Mukherjee, 
2002]. The search of drugs from medicinal plants and the recognition and 
validation of traditional medical treatments could therefore lead to new and better 
interactions for controlling malaria. 
Since plant species provide with chemical diversity, traditional medicine is likely 
to lead to compounds or classes of compounds that can be developed as new 
antiplasmodials [Wright and Phillipson, 1990]. Antiplasmodial activity has been 
observed in different classes of plant metabolites as shown in table 2.3. 
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Indigenous plants therefore play an important role in being a source of novel 
antiplasmodial compounds. 
Table 2.1. Plants used traditionally in South Africa to treat malaria and fevers. 
Botanical Name Family Local Name Medicinal Uses 
Acacia burkei Benth. Fabaceae Mkhaya The roots are burnt and the ash is mixed with 
an equal amount of Bopusia scabara herbs 
and a little fat or oil for eruptive fevers. The 
plant is used for dysentery, conjunctivitis and 
diarrhoea [Bryant, 1966; van Wyk et aI., 1997]. 
Dicoma anomala Sond Asteraceae Tlhonya, 
Hloeya, 
Nyongwana 
Colic, toothache, diarrhoea, colds, stomach 
ailments [van Wyk et aI., 1997; Hutchings, 
1996]. The leaf and twig extracts are used for 




Pedaliaceae Sengaparile Emetic, blood purifier, eczema, acne and for 
sprains and fractures [van Wyk et aI., 1997]. 
Leonotis leonurus (L.) 
R.Br. 
Lamiaceae Klipdagga Used for the treatment of skin diseases, 
coughs and colds, influenza, bronchitis, 
asthma, high blood pressure, epilepsy, 
headaches and viral infections [van Wyk et 
aI., 1997]. 
Lippia asperfolia Reichb. Verbenaceae Umsuzwane Febrile complaints, measles, gangrenous rectitis 
and as an antidote to food poisoning [Bryant, 
1966, van Wyk et aI., 1997]. 
Mentha longifolia (L.) L 
subsp. Capensis (Thunb.) 
Briq 
Lamiaceae Koena Cold, coughs, fevers, asthma, indigestion, 
headaches, hysteria, respiratory ailments, 
flatulence, delayed pregnancy, painful 
menstruation, urinary tract infections [van Wyk 
et aI., 1997]. 
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Table 2.2. Examples of traditional medicinal plants that have shown in vitro anti plasmodial activity against P. falciparum strains. 
Lippia javanica 	 Malaria, headaches, Acetone extract of the IC50 =4.26 !-Ig/m'l against Prozesky et aL, 2001 

diarrhoea, coughs and 	 leaves CO-resistant strain PfUP1 
colds in South Africa 
Casearia el/iptica 	 Malaria and fever in Ethanolic extract of the IC50 =9 !-Ig/ml against CO- Simonsen et aL, 2001 

India leaves sensitive strain 307 

Cinchona succirubra 	 Malaria and fevers in Ethanolic extract of the IC50 $ 10 !-Ig/ml for the do Ceu de Madureira et 

the islands of Gulf of bark and fractions crude and fractions against aL, 2002 

Guinea CO-resistant strain Dd2 

Terminalia Malaria, fever, nausea Water extract of the IC50 =1 !-Ig/ml against CO- Sanon et aL, 2003 





Coscinium Malaria in Vietnam Methanolic extract of EC50 =0.5 !-Ig/ml against Tran et aL, 2003 

fenestratum the stem CO-sensitive strain FCR-3 

Croton lobatus Malaria in Benin 	 Methanolic extract of IC50 =0.38 !-Ig/ml against Weniger et aL, 2004 

the aerial parts CO-sensitive strain 307 

Fagara macrophylla 	 Malaria and fever in Ethanolic extract of the IC50 =2.3 !-Ig/ml against Zirihi et aL, 2005 
central west Ivory Coast stem bark CO-resistant strain FcB1 
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Table 2.3. Some of the isolated phytochemical constituents that has shown in vitro antiplasmodial activity against P.fa/ciparum 
strains and in vivo activity against P. berghei. 
Funtumia elastica Alkaloids Significant inhibition in vitro. I Zirihi et aI., 2005 
Stephania erecta An alkaloid Moderate activity in vivo. I Tamez et aI., 2005 
Cichorium intybus Sesquiterpene lactones Complete Inhibition of parasite growth in I Bischoff et aI., 2004 
vitro. 
Eurycoma longifolia Quassinoids and an alkaloid Highly active in vitro. I Chan et aI., 2004 
Azorella compacta Diterpenes Active in vivo with 60% and 42% I Loyola et aI., 2004 
parasitaemia inhibition, respectively. 
Milletia usaramensis Flavonoids Potent to moderate activity in vitro. I Yenesew et aI., 2003 
Gardenia saxatilis Triterpenes Very good activity in vitro. I Suksamrarn et aI., 2003 
Pleiocarpa mutica Alkaloids Highly active in vitro. One alkaloid Addae-Kyereme et aI., 
showed moderate activit in vivo. 2001 
Hannoa chlorantha Quassinoids Highly active in vitro. Parasitaemia Fran90is et aI., 1998 
suooressed in vivo from 4 - 7 
45 
Chapter 2 Traditional Medicine 
2.9. Safety of Medicinal Plants 
For herbal medicines to be considered safe they should be free from botanical 
contaminants (other plants or compounds from other plants), residual pesticides, 
fumigation agents, pathogenic microorganism and microbial toxins. They also 
have to be standardized. 
Toxicity is of a great concern since no scientific data are available on the toxicity 
of herbal remedies and medicinal plants. The improper identification of herbs and 
medicinal plants may lead to toxicity. This is caused by individuals collecting the 
plant by themselves or improper botanical identification, where a wrong plant that 
looks similar to the correct one is collected [Mukherjee, 2002 J. 
Research done in rural areas of Africa has shown that a quarter of the corneal 
ulcers and childhood blindness is caused by the instillation of traditional 
medicines used for the eye treatment [Yorston & Foster, 1994; Lewallen & 
Courtrlght, 1995J. 
An edible plant, Matteuccia struthiopteris is generally considered non-toxic, but 
when cooked lightly, blanched or lightly sauteed it causes gastrointestinal toxicity 
[Mukherjee, 2002]. Therefore, thorough cooking is required to render the plant 
non-toxic. Another example is Xanthium strumarium, a chinese herb used for the 
treatment of allergic rhinitis, atopic dermatitis and headache caused by wind­
dampness. Xanthium strumarium is non-toxic when stir-fried without the spikes 
[Mukherjee, 2002; Dharmananda, 2002]. 
Another safety concern is that of people who use herbal medicines together with 
other drugs. These people are at risk as a result of herbal-drug interactions. For 
an example, the roots of Salvia miltorrhiza used in Chinese traditional medicine 
for the treatment of coronary diseases, can enhance the anticoagulant activity of 
warfarin, when both are taken together [Lo et al., 19941. 
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A great safety concern with medicinal plants is that most of the herbal products 
sold at herbal markets are not monitored. Arsenic and mercury have been found 
as constituents in Indian herbal remedies [Muzi et aL, 2001; Kew et at., 1993]. 
Heavy metals have also been found in Chinese herbal remedies together with 
undeclared pharmaceuticals, which include methyltesterone, phenacetin 
chlorpheniramine and ephedrine [Ko, 1998]. Some of these metals and 
pharmaceuticals are added deliberately to enhance the activity of the products 
while some are purely as a result of contaminants. 
2.10. Challenges of using Traditional Medicine 
National policies on traditional medicine are needed for the legislation and 
regulation of herbal products and therapies. Once regulated, it would be easier to 
evaluate herbal products for safety, efficacy and quality. The identification of 
effective herbal therapies requires sustainable cultivation of medicinal plants if 
the isolated constituents cannot be synthesized. Traditional practitioners would 
have to be trained in order to provide reliable information for consumers on the 
proper use of herbal products and therapies [WHO, 2002]. 
The greatest problem with the use of traditional medicine is the isolation of active 
compounds from medicinal plants because the isolation of active compounds for 
in vitro and in vivo bio-assays depends on the availability of a large quantity of 
the plant material. This quantity is critical if large amounts of the active 
compounds cannot be obtained through chemical synthesis. Another challenge is 
that species could be lost due to the destruction of habitat. The global 
conservation organization, the World Wide Fund for Nature estimates that of all 
the total plant species, 50 000 species are being lost every year through 
destruction of tropical forests. Most of these species have not been tested for 
biological activity. 
Due to deforestation, plant and animal species are heading for extinction and 
since the highest biological diversity is found in the tropical rain forests, species 
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that were going to provide with useful drugs would be lost. The continual growth 
of human population makes it difficult to conserve forests or natural resources 
due to housing, agricultural and industrial developments needed to sustain life. 
Sometimes this may be the end to finding lead compounds especially if the plant 
is rare [Soejarto, 1996]. 
Another contributing factor is plant gathering for herbal medicine and other 
natural health care products, which after a while results in over-harvesting. The 
knowledge of traditional uses of plants could also be lost with the gradual loss of 
indigenous cultures [Mukhe~ee, 2002]. Financial constraints on the other hand 
make it impossible for all plant species to be screened. 
Medicinal plants are abundant, culturally acceptable and affordable in developing 
countries, which are rich with information on these plants. It is therefore crucial to 
obtain scientific data on medicinal plants that have shown to exhibit 
pharmacological activity. 
2.11. Drug Discovery and Drug Development 
2.11.1. Drug discovery 
There are three ways which could be used to select medicinal plants for the 
discovery of drugs, (1) Ethnopharmacological- where plants are selected based 
on their medicinal use by an ethnic group, (2) Chemotaxonomical - where plants 
are chosen according to a chemical class in a genus or family and (3) 
randomised - where any plant is studied for therapeutic use [Farnsworth, 1988]. 
Of these, .the ethnopharmacological approach offers an opportunity of 
discovering compounds with new structures and new activities [Malone, 1983]. 
According to Farnsworth et at, 1985 this is a good approach as compared to 
massive screening of plants for biological activity, new compounds or structures. 
There is another method used by pharmaceutical companies to find lead 
compounds from medicinal plants. This is called the 'shotgun' method whereby 
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thousands of compounds being from plants or from chemical synthesis are 
screened for biological activities or for lead compounds. While there may be a 
chance of finding a lead compound with this method these chances are very low 
and the approach is considered very expensive [Soerjarto. 1996]. Although this 
method is expensive, it led to the discovery of taxol from Taxus brevifolia by the 
United States National Cancer Institute. The screening programme took place 
between 1960 and 1982. Although taxol was the only drug discovered from all 
the plant extracts screened, the National Cancer Institute program played a role 
in the development of two antitlJmolJr drugs, vinblastine and vincristine. [Cragg et 
aL, 1994]. 
During an ethnobotanical survey, medicinal plants are collected by personal 
contact with local traditional healers and old people who have knowledge of 
medicinal plants. The collection of medicinal plants is dependent on the 
permission by healers, village chiefs, landowners and government and it take 
place under the guidance of the traditional healers [Madureira et aL, 2002]. 
Informal interviews are conducted, recorded on tape and/or filmed. Information 
collected on medicinal plants includes vernacular name of the plant, plant parts 
used, mode of preparation, form of administration, the diseases and symptoms 
treated by the particular medicinal plant. Information on these plants is stored in 
the form of voucher number, collecting locality and date of collection [Madureira 
et aL, 2002]. Once activity is found, medicinal plants are collected from the same 
location since activity will differ due to factors such as type of soil, humidity, 
rainfall and the amount of sunlight [Soejarto, 1996]. 
2.11.2. Drug Development 
The active compounds in the active extract are identified by purifying the extract 
using chromatographic methods such as Solid Phase Extraction (SPE), High 
Performance Liquid Chromatography (HPLC) and preparative Thin Layer 
Chromatography (TLC). All the isolated compounds are screened again for 
49 
Chapter 2 Traditional Medicine 
activity and the promising compounds are identified by spectroscopic methods 
such as Nuclear Magnetic Resonance and Mass Spectroscopy. 
The pure compounds are then screened for in vivo activity and toxicity in animal 
models. The compound with activity and less toxicity or non-toxic effects on the 
animal model is taken for clinical trials (Phase I, Phase II and Phase III) and then 
registered and marketed as a drug. 
Target Identification 
Clinical trials 
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Chapter 3 The ethnobotany and ethnopharmacology of Dicoma anomala 
3.1. Dicoma anomala (Sond.) subspecies anomala 
3.1.1. Description of the plant 
Dicoma anomala is a perennial herb, which grows up to a length of 0.3 m at an 
altitude of 152 - 2200 nl. The herb grows on hillsides and on flat grasslands 
(Netnou and Herman, 2003]. 
The Dicoma species is widely distributed throughout Africa. It is found in 
Botswana, Zimbabwe, Namibia to Democratic Republic of Congo and Uganda in 
the North. In South Africa it is distributed from the provinces of the Eastern Cape, 
Kwazulu-Natal, Mpumalanga, Limpopo, Gauteng, North West and Free State 
through Lesotho and Swaziland [Netnou and Herman, 2003]. 
Dicoma species belongs to the Mutisieae tribe of the Asteraceae family, one of 
the largest angiosperm family. The Asteraceae is only absent from the Antarctica 
and has about 1 535 genera and 25 000 species, which are distributed over three 
subfamilies and 17 tribes in the Asteraceae family (Bremer, 1994; Herman et aI., 
2000]. In South Africa there are about about 246 genera and 2305 species of the 
Asteraceae family (Herman et aI., 2000]. Secondary metabolites synthesized in 
this family are polyacetylenes, flavonoids and terpenoids. Terpenoids in particular 
sesquiterpene lactones are the most studied secondary metabolite and are used 
as taxonomic markers [Seaman, 1982]. 
3.2. The collection of the plant 
The roots and leaves of D. anomala were collected from three provinces in South 
Africa (Eastern Cape, Free State and Limpopo) and in Lesotho during the month 
of October 2003. The map of the nine provinces of South Africa and the country 
of Lesotho are shown in Figure 3.1. 
The plant was collected with the assistance of Mrs Lentsoe in Sterkspruit, a 
community member with the knowledge of the plant. In Lesotho we met with a 
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traditional healer Mr Tumelo and a community member, Mr Lekhelebane who 
helped us with the collection of the plant roots. 
=~1Swana 
LJplng 




Figure 3.1. A map showing all the nine provinces of South Africa and the country of 
Lesotho, which is surrounded by the Republic of South Africa. 
Source: http://www.routes.co.za/map.html 
The roots of D. anomala from Lesotho were collected in the fields of Morifi 
village, in the region of Mohale's hoek. This was the second batch of plant roots 
collected. The first batch was collected in December 1996. The plant material 
was taxonomically identified and authenticated by the Department of Botany, 
University of Cape Town. Voucher specimens of the plant (98142) have been 
deposited in the herbarium of the same department. To avoid obtaining different 
experimental results, the second batch (batch II) of the plant material was 
collected in October 2003, closer to the time the first batch was collected. 
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In Reitz, we collected the plant roots and leaves from a traditional healer, Ms 
Mahlaba who had collected the plant material from a nearby farm. In Riverside, 
we collected the plant roots and leaves with the assistance of traditional healer 
Mr Seth Seroke. 
3.3. Ethnopharmacology of Dicoma anomala (Sand.) 
Dicoma anomala is known by other names in different languages (table 3.1). 













Afrikaans Koorsbossie, Maagbosie, Wurmbos 
English Toy Protea 
In Lesotho, the 8asotho people use root decoctions for intestinal worms, colic, 
diarrhoea, dysentery, toothache an as purgatives. The root decoctions are also 
used for gall-sickness in stock animals. The plant can also be used in powder 
form for sores and wounds in horses [Hutchings et aI., 1996]. 
In South Africa, the Zulus use D. anomala for coughs, respiratory complaints and 
dysentery. They also use root decoction for children suffering from blood 
disorders. For sores on the head, the roots are charred and a paste applied to 
the sores [Hutchings et aI., 1996; van Wyk & Gericke, 2000]. The Xhosas chew 
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the roots and swallow the sap to induce vomiting to get rid of ingested poisoned 
food. Whites in southern Africa use root decoction in gin for haemorrhoids or 
mixed with "melkbos" plants for fevers [Hutchings et aI., 1996]. 
In Zimbabwe and South Africa the roots are used as a panacea and the plant is 
known as a fever remedy in other parts of southern Africa [van Wyk and Gericke, 
2000]. In Tanzania, the plant is used for dysentery and as anthelmintic and in 
East Africa the plant roots are used for stomach complaints. In Zimbabwe, fever, 
abdominal pain, dizziness and cataracts are treated with plant tubers. For 
diarrhoea, the root powder is taken in food or a root decoction is drunk 
[Hutchings et aI., 1996, Neuwinger, 2000]. The dose regimen is half a cup of 
boiled ground roots two times a day [Hedberg & Staugard, 1989]. 
The plant is also used to treat gonorrhoea and other venereal diseases. 
Powdered roots are taken with porridge to treat pneumonia. For the treatment of 
uterine pain, powdered tubers are inserted into the vagina and for throat 
problems, tuber powder with salt is eaten with porridge. Tuber infusion is used to 
wash the body to calm body pains and is mixed with soot and drunk for extended 
labour pains [van Wyk & Gericke, 2000; Neuwinger, 2000]. 
Abscess and dermatosis are treated by eating or sniffing leaf ash. To treat 
scabies leaves are eaten, and for insanity and possession a leaf decoction is 
drunk. An extract of leaves and twigs is drunk for the treatment of malaria, fever, 
epilepsy and constipation. Leaves are also used for migraines and snakebites 
[Neuwinger, 2000]. 
Very little has been reported on the pharmacology of D. anomala. Although it is 
widely used, there have been reports that the extracts are hepatotoxic [Hedberg 
& Staugard, 1989]. This information contradicts the claims of traditional healers 
that Dicoma anomala is a very safe traditional medicine. 
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3.4. Phytochemical information on Dicoma anomala 
Compounds isolated from the aerial parts of D. anomala include diterpenes, 
triterpenes, sesquiterpene lactones, germacranolides, phytol, lupeol and lupeol 
acetate. The germacranolides and sesquiterpene lactones were also found in the 
subspecies of this medicinal plant [Bohlmann & Ie Van, 1978; Bohlmann et aI., 
1982; Zdero & Bohlmann, 1990]. The structures of these compounds were 
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4.1. Plant Collection and Extraction 
4.1.1. Plant collection, identification and documentation 
The roots of Dicoma anomala from Lesotho were collected at Morifi village, in 
the district of Mohale's hoek. The first batch (batch I) was collected in 
December 1996, the second batch (batch II) in October 2003. The plant 
material was taxonomically identified and authenticated by the Department of 
Botany, University of Cape Town. A voucher specimen of the plant (98142) 
has been deposited in the herbarium of the same department. 
The roots and leaves of Dicoma anomala from Reitz in the Free State 
Province, Riverside in Limpopo Province and Sterkspruit in the Eastern Cape 
Province were collected in October 2003. The collection of Dicoma anomala in 
Reitz was done with the assistance of traditional healer Ms Maria Mahlaba, in 
Riverside (Limpopo) with traditional healer Mr Seth Seroke and in Sterkspruit 
with a community member Ms Lentsoe. 
4.1.2. Preparation ofcold extractions of the plant material 
The leaves and twigs and the roots of Dicoma anomala were first washed, air­
dried at room temperature and ground to fine powder with a laboratory 
blender (Warring Commercial, Conneticut, USA). 
Cold extractions of a mixture of the dried powdered leaves and twigs and the 
roots from the four locations were done daily by leaving the plant material 
overnight in a solvent, at room temperature on a mechanical shaker (Labcon, 
California, USA). The leaves and twigs were extracted in AR grade 
dichloromethane (Merck, Darmstadt, Germany) while the roots were extracted 
respectively, in dichloromethane and purified deionised Millipore water 
(Waters, Milford, USA). The plant material was extracted to exhaustion (until 
the solvent remained clear). The extracts were then filtered through a 320 mm 
Rundfilter filter paper (Schleicher & Schuell, Dassel, Germany) and the 
dichloromethane (DCM) extracts were concentrated under vacuum (600 
mbar) at 45°C using a rotary evaporator. The rotary evaporator consisted of a 
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pump VaC® V-500, a heating bath B-490, a vacuum controller V-805 and a 
rotavapor R-205 (BUCHI Labortechnik AG, Flawil, Switzerland). Crude 
extracts of the roots collected from Lesotho were also prepared with 
chloroform, hexane, ethyl acetate, petroleum ether and methanol. The organic 
extracts were left to dry in pre-weighed beakers in the fume hood. The water 
(H20) extracts were concentrated by freeze-drying on a -85°C Dura-Dry ™ 
freeze-dryer (FTS Systems, Inc., New York, USA) and all the dried extracts 
were stored at 4°C until required. 
4.1.3. Preparation ofhot extractions of the plant material 
Hot extractions of the dried powdered roots from the four locations were 
prepared for 6 hours with DCM and Millipore water, respectively, on the 
Soxhlet extractor. A 1 L round-bottomed flask contained the solvent and anti­
bumping granules (BDH Chemicals Ltd, Poole, Dorset, England) to prevent 
overboiling of the solvent. The flask was placed in an isomantle heating 
apparatus (Isopad Ltd, GB-Washington England) connected to a temperature 
controller. The isomantle heating apparatus was labelled from 1 - 5, with 5 
being the high temperature. All the hot extractions were carried out with the 
temperature controller on number 3, which was medium heat. 
Another hot water extraction of the roots was prepared on a stirrer-hotplate 
(ChemLab, Essex, England). The powdered roots were extracted in water, on 
low heat and stirred with a magnetic stirrer for 2 and 6 hours. Tables 4.1 and 
4.2 show the mass of the plant material extracted and the volume of the 
solvent used for the extraction. 
.~ 
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Table 4.1. Cold and hot extractions of the leaves and twigs and the roots of Dicoma 
anomala collected from four locations (Lesotho, Sterkspruit, Limpopo and Reitz). 
Cold extractions Mass extracted 
(g) 
Solvent Volume of solvent 
(ml) 
Leaves and twigs 
Sterkspruit 10.69 OCM 150 
Limpopo 12.37 OCIVI 150 
Reitz 2.21 OCM 75 
Roots 
Sterkspruit 100 OCM 500 
10.25 H2O 200 
Limpopo 50.02 OCM 250 
10.40 H2O 200 
Reitz 50.04 OCM 250 
10.20 H2O 200 
Lesotho 200.43 OCM 1000 
5.02 CHCI3 100 
5.02 EtAC 100 
5.01 Hexane 100 
5.15 MeOH 100 
5.18 PE 100 
5.15 H2O 100 
Hot extractions 
(roots) 
Soxhlet: 6 hrs 
Lesotho 40.0 OCM 700 
40.0 H2O 700 
Sterkspruit 40.61 OCM 700 
40.50 H2O 700 
Limpopo 40.22 OCM 700 
41.19 H2O 700 
Reitz 20.20 OCM 350 
17.47 H2O 350 
Hotplate: 6 hrs 
Lesotho 5.0 H2O 500 
Sterkspruit 5.29 H2O 500 
Limpopo 5.37 H2O 500 
Reitz 5.60 H2O 500 
Hotplate: 2 hrs 
Lesotho 5.0 H2O 500 
Sterkspruit 5.24 H2O 500. 
Limpopo 5.50 H2O 500 
60 
Chapter 4 Materials and Methods 
4.1.4. Separation of the cold H20 root extract of D. anomala from 
Lesotho 
It was observed that as the roots of D. anomala from Lesotho were being 
successively extracted in water, the amount of plant material progressively 
decreased. This led to the preparation of a water root extract (5.16 g of the 
powdered roots in 100 ml Millipore water), which was carried out daily and 
four fractions (H201 - H204) of the water root extract were obtained as shown 
in figure 4.1 below. This extraction was done to determine whether the four 
fractions from the cold H20 root extract would display similar in vitro 
antiplasmodial activity and also to determine whether the activity would be 
similar or different to the cold H20 root extract that was not separated into 
fractions. 
cold H20 root extract 
Figure 4.1. A diagram showing four fractions (H201 - H204) obtained according to 
their colour intensities from the cold H20 root extract of D. anomala from Lesotho. 
The in vitro antiplasmodial activity of the four water extract fractions showed 
that the third and fourth fractions (H203 and H204) were active. The 
consistency of these results was determined by repeating the extraction 
procedure by extracting S.15 g of the powdered roots daily with 100 ml 
Millipore water. Four fractions were again obtained (H1 - H4) and were 
screened for in vitro anti plasmodial activity. 
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4.2. Solid Phase Extraction 
Solid Phase Extraction (SPE) is an extraction method that uses a solid phase 
and a liquid phase to isolate one or more analytes from a solution. A solution 
is loaded onto a column and the analytes allowed to bind under vacuum. Any 
unbound analytes are then washed off with water and the bound analytes are 
then eluted with one or more solvents. 
The crude DCM root extract solution was loaded onto a C18 SPE column, any 
unbound material was washed off with water and the bound material eluted 
with a step gradient of HPLC grade acetonitrile (Merck, Darmstadt, Germany) 
and Millipore water (MeCN:H20). All samples were collected and 
concentrated by rotary evaporation and freeze-drying. Figure 4.2 below shows 
the SPE of the crude DCM root extract. 
Figure 4.2. A schematic diagram of the fractionation of the cold DeM root extract of 
D. anomala from Lesotho into 10%, 5% and 1 % fractions using SPE. 
4.2.1. Preparation of crude DeM root extract from Lesotho for SPE 
The crude DCM root extract (cold extraction) from Lesotho was separated by 
SPE, eluting with a step gradient of decreasing polarity of a mixture of water 
and acetonitrile (MeCN:H20) mobile phases. An initial stock solution of 13 
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mg/ml in MeCN was sonicated for 1 hour in a UMC5 sonicator (Ultrasonic 
Manufacturing Company (pty) Ltd, Krugersdorp, South Africa). The stock 
solution was diluted with water to 4 mg/ml solution, which was sonicated for 
another hour to make sure that the crude DCM root extract was dissolved. 
The solution was filtered through a 320 mm Rundfilter filter paper to remove 
any particulate matter. 
4.2.2. SPE fractionation of the crude DeM root extract from Lesotho 
The fractionation of the crude DCM root extract of D. anomala from batch I 
and batch II of the plant root material was carried out using the Isolute C18 
(EC) cartridge of mass absorbent 10 g and 70 ml capacity (International 
Sorbent Technology, Glamorgan, United Kingdom). To facilitate binding of 
compounds, the column was conditioned sequentially with 50 ml AR grade 
methanol (Merck, Darmstadt, Germany) and 50 ml Millipore water. A 50 ml 
aliquot of the 4 mg/ml crude DCM root extract solution was then applied onto 
the column and eluted under vacuum at a flow rate of 17 ml/min. The eluant 
(percolate) was collected and the unretained material was rinsed off from the 
column with 200 ml water (water wash). The retained material was separated 
using 200 ml volumes of a step gradient of 10% increments of MeCN:H20 in 
the range 0% - 100%. The final 100% MeCN mobile phase was followed by a 
100 ml of AR grade acetone (acetone wash) (Merck, Darmstadt, Germany) to 
rinse off any remaining material from the column. 
The water wash fraction was concentrated by freeze-drying and the percolate 
and fractions 10 - 90 were concentrated by removing acetonitrile by rotary 
evaporation under vacuum (200 mbar) at 45°C and the remaining water 
displaced by freeze-drying. The 100% MeCN and the acetone wash fractions 
were also concentrated by rotary evaporation and dried in the fume hood in 
pre-weighed vials. 
All the fractions were tested for in vitro anti plasmodial activity and the results 
showed that the most active components were being eluted with 30%, 40% 
\ 
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and 50% of MeCN:H20 mobile phases. The three fractions were fluffy and 
cream in colour. 
No further work: was done on fraction 30 as it was part of an ongoing research 
in the Division of Pharmacology, University of Cape Town. 
Fractions 40 and 50 contained a lot of peaks and had to be purified further to 
obtain fractions with fewer or single peaks. SPE was then performed using 5% 
increments of MeCN:H20 mobile phases in the range 35% - 55% to expand 
fraction 40 and 50. The same SPE procedure was followed as before but the 
200 ml H20 wash was followed by 200 ml of 30% mobile phase to wash off 
compounds that might be carried over with the 35% mobile phase. Thereafter, 
compounds were eluted with 200 ml volumes of 35% - 55% mobile phases 
followed by a 100 ml acetone wash. 
The 5% fractions from batch I and batch II were also fluffy and cream in 
colour. Although these fractions exhibited in vitro antiplasmodial activity, their 
HPLC profiles showed that they contained a number of peaks. The HPLC 
profiles of fractions 35 - 55 from batch I, which were also similar to those from 
batch II are shown in Appendix C. The next step Was to further purify these 
fractions on SPE by eluting with 1% mobile phases of MeCN:H20. The first 
1 % fractions generated, were fractions 31 - 35 which were the expansion of 
fraction 35 as shown by the diagram in figure 4.4. 
31 32 I 33 ~1_3_4__---.l...-_3_5__--, 
Figure 4.3. A schematic representation of 1% fractions (fractions 31 - 35) that 
were expansions of fraction 35. 
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To generate 1% fractions, the same SPE procedure for generating 10% and 
5% fractions was followed. The 1% fractions were only generated from the 
crude OCM root extract of batch I of the plant roots. In an attempt to optimise 
separation of 1% fractions and generate pure samples, 300 ml volumes of 
31% - 35% mobile phases were used as opposed to 200 ml volumes used for 
the elution of 10% and 5% SPE fractions. SPE of the crude OCM root extract 
(4 mg/ml) was carried out using 1% increments of MeCN:H20 in the range 
31°A, - 35%. The 200 ml water wash was followed by 300 ml of 30% mobile 
phase to wash off any compounds that may be carried over with 31 % mobile 
phase. The bound components were eluted with 300 ml of 31 % - 35% mobile 
phases of MeCN:H20 followed by 100 ml of acetone. 
The fractionation resulted in fluffy and white 1 % fractions but as shown by 
their HPLC profiles (Appendix C), there was no reduction in the number of 
peaks. Nevertheless, the fractions were tested for in vitro antiplasmodial 
activity against 010, K1, RSA11 and FAC8 strains of P. falciparum. 
4.2.3. Approaches used to purify 1% fractions 
Several attempts were made to obtain pure compounds from the 1 % fractions 
(31 - 35) using different methods. 
4.2.3.1. Method 1: Fractions 31- 35 generated from fraction 40 
Instead of generating fractions 31 - 35 from the crude OCM root extract, the 
fractions were generated from fraction 40 since fractions 31 - 39 are the 
separations of fraction 40. Fraction 40 was reloaded (4 mgfmlr1onto the C18 
SPE column and eluted with 200 ml volumes of 31% - 35% mobile phases of 
lVIeCN:H20. This method did not result in the reduction of peaks. 
4.2.3.2. Method 2: Fractions 31 • 35 reloaded onto the SPE column 
More material of fractions 31 - 35 was generated and each fraction was 
reloaded onto the C18 SPE column, fraction 31 was eluted with 200 ml 
volumes of 30%, 31% and 32%. Fraction 32 with 200 ml volumes of 31%, 
32% and 33%, fraction 33 with 200 ml volumes of 32%, 33% and 34%, 
65 
Chapter 4 Materials and Methods 
fraction 34 was eluted with 200 ml volumes of 33%, 34% and 35% and 
fraction 35 was eluted with 200 ml volumes of 34%, 35% and 36%. It was 
expected that this method will result in the expansion of the peaks but all the 
samples got stuck onto the column. 
4.2.3.3. Method 3: Fraction 31 purified on TLC 
Thin Layer Chromatography (TLC) was used to separate the compounds in 
fraction 31. The fraction was run on 20 x 20 cm silica gel 60F254 (0.25 mm 
thickness) pre-coated aluminium TLC plates (Merck, Darmstadt, Germany) 
using combinations of mobile phases at different concentrations. 
In order to get a mobile phase that will elute as many compounds as possible, 
it is important that the sample completely dissolve in that mobile phase. 
Fraction 31 dissolved completely in benzene: acetone (50:50), benzene: 
ethylacetate (30:70), benzene: acetic acid (60:40), chloroform: methanol 
(50:50) and ethylacetate: acetate acid (60:40) and was therefore ran in these 
mobile phases. The sample was loaded onto the plates, 1 cm from the bottom 
of the plate and let to dry. After drying, the TLC plates were put in developing 
chambers (24.5 x 7.3 x 24 cm) containing 20 ml of the respective mobile 
phases and a piece of filter paper to keep the chamber vapourized: The 
chamber was covered with a lid and the TLC plate developed until the mobile 
phase was about 1 cm from the top of the plate. A line was drawn to mark the 
end of the run so as to obtain the Rf values of the bands. The plates were 
then viewed under ultra violet (UV) light at 254 nm (short wavelength) and 365 
nm (long wavelength). 
More bands were observed with the benzene: acetic acid (60:40) mobile 
phase and the concentrated bands were scraped off and redissolved in 1 ml 
MeCN. The samples were spun down in a Biofuge 13 centrifuge (Heraeus 
Sepatech, Osterode, Germany) at 13 000 rpm for 10 minutes. The 
supernatant was collected, dried under nitrogen . and the samples 
reconstituted in MeCN:H20 (50:50). 
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Although the TlC bands that were scraped off showed fewer peaks on the 
HPlC, they still needed to be purified further. Therefore, instead of generating 
fraction 31, run it on the TlC and then on the HPlC to collect individual 
peaks, the peaks were collected from fraction 31 and 32 since they contained 
major peaks compared to fractions 33, 34 and 35. 
4.2.4. SPE fractionation of the crude DeM root extract from Sterkspruit 
The HPlC profiles of the crude DCM root extracts (cold extraction) of D. 
anomala from lesotho and Sterkspruit were similar, therefore the crude DCM 
root extract (4 mg/ml) from Sterkspruit was fractionated to generate fractions 
30, 40 and 50. This was to determine whether their HPlC profiles would be 
similar to those generated from the crude DCM root extract from lesotho. The 
SPE fractionation procedure was the same as for the cold DCM root extract 
from lesotho but the 200 ml water wash was followed by 200 ml volumes of 
30, 40 and 50 mobile phases of MeCN and H20. 
4.3. High Performance Liquid Chromatography (HPLC) 
High Performance liquid Chromatography (HPlC) is the most applied 
separation technique for research and routine analysis purposes. There are 
two types of HPlC separation, namely isocratic and gradient elution. An 
isocratic elution, elutes compounds at a single concentration of the mobile 
phase, while with a gradient elution,· compounds are eluted with increasing 
concentrations of two or more different mobile phases. 
The HPlC system consisted of an automatic sample injector, two lC-10AS 
solvent delivery systems, an SPD -M10A diode array detector, a CBM-10A 
communications bus module (Shimadzu Corporation, Kyoto, Japan) and a 
Flexi 486 GV/DX2-66 computer (Sunonwealth Elec, Kaohsiung, Taiwan) with 
lC workstation software for data registration and analysis (Shimadzu 
Corporation, Kyoto, Japan). The computer was connected to a Deskjet 670C 
printer (Hewlett Packard, California, USA). The mobile phase consisted of 
purified deionised water from a Milli-Q Water System and HPlC grade 
acetonitrile (Merck, Darmstadt, Germany). 
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4.3.1. Analytical HPLC conditions 
Stock solutions (1 mg/ml) of the organic extracts and SPE fractions, were 
made up in 20% MeCN and 80% H20. All the stock solutions were sonicated 
for 15 minutes and centrifuged on a Biofl.lge 13 centrifuge at 13 000 rpm for 5 
minutes to pellet any undissolved particulate material. The analytical 
separations of the crude extracts were done on a C18 reverse-phase 
Phenomenex column (150 x 4.6 mm, 5 IJm) (Phenomenex, California, USA), 
which was connected to a C18 40 IJm guard column (Anatech Instruments, 
Cape Town, South Africa). The gradient used was 20% - 100% MeCN: H20 at 
a flow rate of 1 ml/min, the injection volume was 150 IJI and the HPLC runs 
were over 60 minutes and were monitored at 215 nm. 
The 10% and 1 % SPE fractions were run on a C 18 reverse-phase Haisil 
column (250 x 4.6 mm, 5 IJm) (Higgins Analytical, Inc., California, USA), which 
was connected to a C18 40 IJm guard column (Anatech Instruments, Cape 
Town, South Africa). The gradient was first set from 30% - 100% MeCN: H20 
then changed to 30% - 70% MeCN: H20 and finally to 50% - 70% MeCN: H20 
over 15 minutes. The HPLC runs were at a flow rate of 1 ml/min and were 
monitored at 215 nm. The injection volume was 150 IJI for the 10% SPE 
fractions and 250 IJI for the 1 % SPE fractions. 
The 5% SPE fractions were ran at a gradient of 30% - 70% MeCN: H20 on a 
C18 reverse-phase Phenomenex column (150 x 4.6 mm, 5IJm){Phenomenex, 
California, USA). The column was connected to a C18 40 IJm guard column 
(Anatech Instruments, Cape Town, South Africa). The HPLC runs were 
monitored at 215 nm over 40 minutes, at a flow rate of 1 mllmin and the 
injection volume was 150 IJI. 
4.3.1.1. Collection of peaks from fractions 31 and 32 
Fractions 31 and 32 (2 mg/ml) were purified on the Haisil analytical column 
(250 x 4.6 mm) by collecting individual peaks. Peaks MF4 and MF5 were 
collected from fraction 31 and peak MF7 from fraction 32 as shown in figures 
4Aa and 4Ab. The gradient was 50% - 70% MeCN: H20 at a flow rate of 1 
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mllmin and the injection volume was 250 j,J1. The runs were monitored at a 




Figure 4.4a. The HPLC chromatogram of fraction 31 (2 mg/ml) showing peaks MF4 and MF5 
eluting at 8.048 minutes and 8.353 minutes, respectively. The fraction was run on a Haisil 
analytical column (250 x 4.6 mm, 5 IJm) at a gradient of 50% - 70% MeCN: H20 and a flow 
rate of 1 ml/min. The injection volume was 250 IJI and the HPLC runs were monitored at a 
wavelength of 215 nm. 
Figure 4.4b. The HPLC chromatogram of fraction 32 (2 mg/ml) showing peak MF7 eluting at 
11.178 minutes. The fraction was run on a Haisil analytical column (250 x 4.6 mm, 5 IJm) at a 
gradient of 50% - 70% MeCN: H20 and a flow rate of 1 mllmin. The injection volume was 250 
IJI and the HPLC runs were monitored at a wavelength of 215 nm. 
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The collected peaks (MF4, MF5 and MF7) were concentrated by evaporating 
acetonitrile by rotary evaporation under vacuum (200 mbar) at 40·C and 
displacing the water by freeze-drying. All the samples were fluffy and white in 
colour. 
The MF5 sample changed from a white fluffy form to a brownish oily form after 
being removed from the freeze-drier. The colour first changed from white to 
reddish brown then to brownish oily form. This could have been due to 
exposure to air, which would result in the oxidation of peak MF5 and exposure 
to moisture, which would result in the shrinking of the compound due to being 
hygroscopic. To minimise the exposure of MF5 to air and moisture, the flask 
was covered with parafilm immediately after being removed from the freeze­
drier. This approach made a slight improvement as the sample changed after 
5 minutes. The collection of peak MF5 was therefore discontinued and the 
work continued with peaks MF4 and MF7. 
4.3.2. Preparative HPLC.conditions 
4.3.2.1. Collection ofMF4 and MF7 from fractions 40 and 50 
It was discovered that peaks MF4 and MF5 from fraction 31 and peak MF7 
from fraction 32 were present in fraction 40 and only peak MF7 was present in 
fraction 50. There was also more material generated for fractions 40 and 50 
as compared to 1 % fractions. Therefore, peaks MF4 and MF7 were both 
collected by semi-preparative reversed-phase HPLC from fraction 40 and only 
peak MF7 was collected from fraction 50 (Chapter 7, figures 7.2a and 7.2b, p. 
129). Fractions 40 and 50 (5 mg/ml) were loaded on a C18 Haisil100 reverse­
phase semi-preparative column (250 x 10 mm, 5 IJm) (Higgins Analytical, Inc., 
California, USA), which was connected to a C18 40 IJm guard column 
(Anatech Instruments, Cape Town, South Africa). A gradient elution of 50% ­
70% MeCN: H20 was used ata flow rate of 3 mllmin and the injection volume 
was 260 IJI. The detection wavelength was set at 215 nm. 
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4.4. Separation of the components in peak MF7 
Although peak MF7 eluted as a single peak, the NMR revealed that it was 
impure and the Mass spectrometry showed that there were a few components 
present in peak MF7 (Chapter 7, figures 7.4a and 7.4b, p. 130-131). Three 
approaches were tried in order to separate these components in peak MF7. 
4.4.1. Recrystallization 
A small amount of MF7 (1 mg) was dissolved in petroleum ether (50 1-/1) and a 
few drops of ethyl acetate were added until the solution was cloudy. The 
cloudy solution of MF7 was stored in a 4"C fridge for two weeks. This was to 
determine whether the major component of the mixture will crystallize. After 
two weeks, white crystals had formed. The crystals were collected by vacuum 
filtration in a BOchner funnel lined Whatman no. 6 filter paper (Whatman 
Limited, Maidstone, England). The filter paper was first moistened with 
hexane. The crystals were rinsed with hexane, under suction and dried in the 
fume hood. The recrystallization was unsuccessful as the Mass spectrometry 
analysis showed that all the components were present in the crystals. 
4.4.2. C16 amide column 
A less hydrophobic analytical column with amide groups, aC16 amide column 
(Supelco, Sigma-Aldrich, St Louis, Missouri, USA) was used to separate the 
three peaks in MF7 using gradient and isocratic elutions of MeCN and H20 
but no separations of the peaks were achieved. 
4.4.3. Isocratic elution of fraction 40 
Fraction 40 (4.5 mg/ml) was run isocratically at 50%, 60% and 70% MeCN in 
H20 on a C18 Haisil reverse-phase semi-preparative column, at a 'flow rate of 
2.5 ml/min and a detection wavelength of 215 nm. The injection volume was 
2501-/1. 
The MF7 peak separated into two peaks with the 60% isocratic elution, though 
the separation was not good. The injection volume was reduced to 1501-/1 and 
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the MF7 peak separated into three peaks although the resolution was not 
good. The three peaks of MF7 were designated MF7 A, MF7B and MF7C, of 
which the major peak was MF7 A. The same HPLC conditions used to elute 
fraction 40 were also used for the elution of fraction 50. MF7A was easier to 
collect since it was present in higher concentrations as compared to MF7B 
and MF7C. 
The procedure, therefore, of isolating compounds MF4 and MF7 A from 
fraction 40 and MF7A from fraction 50, was by loading 4.5 mg/ml of the 
fractions on a C18 Haisil 100 semi-preparative column (250 x 10 mm, 5 jJm) 
and eluting the fractions with an isocratic run of 60% MeCN: H20 at a flow 
rate of 2.0 ml/min. The injection volume was 150 jJl and the detection 
wavelength was set at 215 nm. 
4.5. Purification of Compounds MF4 and MF7 A 
Compounds MF4 and MF7 A (2 mg/ml) were purified on a Haisil analytical 
columns (250 x 4.6 mm, 5 jJm for MF7A and 150 x 4.6 mm, 5 jJm for MF4) at 
an isocratic elution of 60% MeCN: H20, the flow rate was 1 ml/min and the 
injection volume was 100 jJl. The compounds were monitored at a wavelength 
of 215 nm. The compounds were concentrated by rotary evaporating 
acetonitrile under vacuum (200 mbar) at 40 ·C and displacing the water by 
freeze-drying. 
4.6. In vitro Antiplasmodial Activity 
4.6.1. Reagents 
Chloroquine diphosphate, nitro blue tetrazolium, phenazine ethosulphate, 
APAD, D-sorbitol, glucose, hypoxanthine, HEPES buffer, Tris buffer, L-Lactate 
and NaHC03 were obtained from Sigma-Aldrich, Kempton Park, South Africa. 
Triton X-100, Giemsa stain and methanol were obtained from Merck, 
Modderfontein, South Africa. RPMI 1640 medium was obtained from Highveld 
Biological, Johannesburg, South Africa and gentamycin from Micro 
Healthcare, Bethlehem, Bloemfontein, South Africa. Albumax II was obtained 
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from Gibco-BRl, Auckland, New Zealand. The blood was obtained from the 
blood bank in Groote Schuur Hospital, Cape Town, South Africa. 
4.6.2. In vitro culture ofPlasmodium falciparum 
The four strains of Plasmodium falciparum, a chloroquine-sensitive (COS) 
strain (010) and chloroquine-resistant (COR) strains (RSA11, K1 and FAC8) 
were cultured continuously according to the methods of Trager and Jensen, 
1976. The parasite cultures were maintained in vitro in 0+ human red blood 
cells suspended in filter-sterilized complete medium. The complete medium 
contained 10.4 gIL RPMI 1640 medium with glutamine, supplemented with 40 
jJg/ml gentamycin, 0.088 gIL hypoxanthine, 4 gIL glucose, 6 gIL HEPES 
buffer, 5 gIL albumax II and 8.4 ml of 5% NaHCOa per 200 ml medium, which 
was added before use. 
The parasite cultures were kept in tissue culture flasks (Greiner Bio-One, 
Frickenhausen, Germany) in an atmosphere of filtered gas containing 4% 
C02. 3% 02 and 93% N2 and were incubated at 3rC in a C02 Water ­
Jacketed (IR Autoflow) incubator (Nuaire, Minnesota USA). The culture 
medium was changed daily by transferring the cultures from the flask into a 50 
ml tube (Greiner Bio-One, Frickenhausen, Germany) and centrifuging at 750 
rpm for 5 minutes in an eppendorf centrifuge 5804 (Eppendorf centrifuge, 
Hamburg, Germany). The medium was aspirated and a thin blood smear was 
prepared on a slide, fixed with methanol and stained with Giemsa stain (10% 
in PBS). The slide was examined under the microscope to monitor the 
parasitaemia. Fresh blood was added to maintain a 5% parasitaemia and 4% 
haematocrit. An aliquot of 45 ml complete medium (warmed at 37 CC) was 
added to the parasite cultures, put back in the culture flask, gassed for ± 1 
minute and put back into the incubator. The parasitemia was determined by 
examining a minimum of 500 red blood cells for infection by parasites. The 
parasitemia was calculated as follows: 
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% Parasitemia =number of infected red blood cells 
total number of red blood cells 
4.6.3. Parasite synchronization 
The parasites cultures were synchronized before each experiment as 
described by Lambros and Vanderberg, 1979. The cultures were 
synchronised by D-sorbitol lysis (5% w/v) when parasites were in the ring 
stage. Only red blood cells infected with mature trophozoites and schizonts 
are lysed, thereby killing the parasites. Red blood cells infected with ring 
forms or young trophozoites survive the treatment. ,. 
4.6.4. Parasite lactate dehydrogenase (pLDH) Assay 
Parasite survival was measured by parasite lactate dehydrogenase (pLDH) 
assay as described by Makler, 1993. This enzymatic assay involves the 
parasite lactate dehydrogenase, which is distinguishable from the host lactate 
dehydrogenase. Lactate dehydrogenase is an enzyme found in all the cells 
and catalyses the formation of pyruvate from lactate reducing a co-enzyme 
NAD (nicotinamide adenine dinucleotide) to NADH. In parasites the NAD 
analogue APAD (3-acetylpyridine adenine nucleotide) is reduced to APADH 
and upon this reduction the yellow NBT/PES (nitro blue tetrazolium + 
phenazine ethosulphate) is converted to purple formazan crystals. The 
formation of these crystals indicates the pLDH activity and therefore the 
survival of paraSites. 
4.6.5. Preparation of stock solutions for the Antiplasmodial Assay 
Stock solutions of the test samples were prepared in sterile eppendorfs at a 
concentration of 2 mg/ml. All test samples (2 mg), except for water extracts, 
were dissolved in 100 IJI acetonitrile and sonicated for 15 minutes. The stock 
solution was made up to 2 mg/ml by adding 900 IJI of Millipore water and 
sonicated for a further 15 minutes. The water extracts (2 mg) were dissolved 
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in 1 ml Millipore water and sonicated for 30 minutes. Sonication ensures that 
any bacteria or fungi that may be present in the stock solution are killed by 
breaking down their cell walls. The solvent control was prepared by adding 
1 00 ~I of acetonitrile to 900 ~I of Millipore water and sonicating for 30 minutes. 
This was to confirm that a final concentration of 0.1 % acetonitrile exhibited no 
antiplasmodial activity. The antimalarial drug, chloroquine (2 mg/ml in Millipore 
water) was prepared as a positive control. Dilutions (1 in 10) of test samples 
were prepared in culture medium to make up a starting concentration of 200 
~g/ml. For chloroquine, the starting concentration was 2000 ng/ml. 
4.6.6. Antiplasmodial Assay 
Assays were performed when parasite cultures were in trophozoite stages 
and were done in duplicates in 96-well culture plates on two separate 
experiments. 
In a sterile 96-well culture plate (Greiner Bio-One, Frickenhausen, Germany), 
arranged in 8 rows (A - H) and 12 columns (1 - 12), the complete medium 
(100 ~I) was added in all the wells except those in column 3. To the wells in 
column 3, 200 ~I of 200 ~g/ml test samples was added in duplicates. Two-fold 
serial dilutions of the test samples were made across the plate by removing 
1 00 ~I from the wells in column 3, transferring it to the wells in column 4 and 
resuspending. This was repeated up to column 12 and the remaining 1 00 ~I 
was discarded. The blank was prepared by adding 1 00 ~I of red blood cells 
with 2% haematocrit to column 1. To the remaining columns, 100 ~I of 2% 
parasitised red blood cells was added. Column 2 served as the control 
(medium and parasitised red blood cells only). The final concentrations of the 
test samples ranged from 1 00 ~g/ml to 0.195 ~g/ml and those of chloroquine 
ranged from 1000 ng/ml to 1.95 ng/ml. The parasites were exposed to a final 
solvent concentration of 0.1 % acetonitrile and the final haematocrit was 1 %. 
The plate was covered with a sterile lid, placed in a chamber and the chamber 
gassed with filtered gas containing 3% 02, 4% CO2 and 93% N2. The chamber 
was left for 48 hours at 37°C in a CO2 Water - Jacketed (IR Autoflow) 
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incubator (Nuaire, Minnesota USA). Figure 4.5 shows the plate set up for the 
experiment. 
1 2 3 4 5 6 7 8 9 10 11 12 
A C test sample 1 (CQ 
B r 0 
C lett 2 
0 100 50 25 12.5 8.25 3.125 1.562 0.781 0.311 0.1" 
E N R test samOle 3 
F K 0 
G L 1- .. 
H 
Figure 4.5. A plate set up for the antiplasmodial assay. 
Rows (A - H) contained 4 test samples done in duplicates as shown by the four 
different colours. Column 1 was a blank (medium and red blood cells) and column 2 
a control (medium and parasites). Columns 3 to 12 contained decreasing 
concentrations of the test samples from a 100 jJg/ml to 0.195 jJg/ml. 
After 48 hours, all the wells were re-suspended. In a separate 96-well culture 
plate, a 100 1-11 aliquot of Malstat reagent (4g L-Lactate, 1.32g Tris buffer, 400 
1-11 Triton X-100 and 22 mg APAD in 200 ml Millipore water, pH = 9 with HCI) 
was added to all the wells, followed by a 15 1-11 aliquot of the cell suspension to 
the respective wells. Thereafter, 25 1-11 of nitro blue tetrazolium/phenazine 
ethosulphate (NBT/PES) (160 mg NBT and 8 mg PES in 100 ml Millipore 
water) was added to all the wells and the plate was left to develop in the dark, 
as NBT/PES is light sensitive. The plate was read at 620 nm on an anthos htll 
plate reader (Anthos Labtec Instruments, Eugendorf, Austria) . 
The anti plasmodial activity of test samples was expressed by inhibitory 
concentrations that inhibit 50% growth of parasites (IC50). The inhibitory 
effects of the test samples were expressed as percentage parasite survival of 
the untreated parasitised red t)lood cells. The untreated parasitised red blood 
cells were referred to as 100% growth. Sigmoidal dose response curves were 
obtained by plotting the percentage survival against ttte logarithm of 
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concentrations using GraphPad Prism 4 software (GraphPad, California, 
USA). The ICso values were then calculated by non-linear regression analysis 
processed on dose-response curves. 
4.7. In vitro Cytotoxicity Assay 
The in vitro cytotoxicity of the test samples was estimated on Chinese 
Hamster Ovarian (CHO) cells and the cell growth was measured by MTT 
assay. 
4.7.1. Reagents 
MTT, HAMS F-12 were obtained from Sigma-Aldrich, Kempton Park, South 
Africa, foetal calf serum (FCS), trypsin and DMEM were obtained from 
Highveld Biological, Johannesburg, South Africa. DMSO was obtained from 
Merck. 
4.7.2. MITAssay 
The MTT assay is a colorimetric assay that utilizes the water-soluble yellow 
coloured MTT [3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide], a 
tetrazolium salt, which upon reduction is converted to a water-insoluble purple 
coloured formazan product [Sieuwerts et aI., 1995]. This assay measures the 
metabolic viability of cells in vitro, therefore it uses only viable cells. The 
metabolic viability is determined by measuring the activity of various 
dehydrogenase enzymes. This is supported by the fact that the tetrazolium 
ring is cleaved in functional mitochondria [Mosmann, 1983]. The amount of 
product formed is proportional to the metabolic activity and the number of cells 
in the test sample [Sieuwerts et aI., 1995]. 
The CHO cells were kept in complete medium, in tissue culture flasks with 
filter caps (Greiner Bio-One, Frickenhausen, Germany). The complete 
medium consisted of filter-sterilized 10% heat-inactivated (56°C for 30 
minutes) fqetal calf serum (FCS). 45% Dulbeccos Eagles Modified Medium 
(DMEM) (pH': 7.1) and 45% HAMS F-12 (PH = 7.1). DMEM and HAMS F-12 , 
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contained 500 I-IIIL of gentamycin to kill any bacteria that might contaminate 
the medium. 
4.7.3. Sub-culturing cells 
The cells were sub-cultured when they had reached confluency (when the 
entire flask is covered with elongated cells). The medium was removed from 
the flask and the cells rinsed twice with 10 ml sterile phosphate buffered 
saline (PBS) to remove FCS. An aliquot of 5 ml trypsin, warmed at 37°C was 
added to the cells and the flask incubated for 2 minutes. Trypsin detaches the 
cells from the flask. The flask was agitated slightly to lift cells off the flask and 
5 ml of complete medium added to inhibit trypsin reaction, which if not 
stopped in time, will digest the cells. The cell cultures were then transferred to 
15 ml cellstar tubes (Greiner Bio-One, Frickenhausen, Germany) and 
centrifuged at 750 rpm for 5 minutes. After centrifugation, the medium was 
poured off and the cell pellet resuspended in 5 ml of cornplete medium. A 1ml 
aliquot of the cell suspension, supplemented with 9 ml complete medium was 
transferred to a new flask and incubated at 37°C in 5% C02 -95% air humified 
atmosphere in a C02 Air - Jacketed (DHD Autoflow) incubator (Nuaire, 
Minnesota USA). 
The medium was changed every 2-3 days when cells had not reached 
confluency and when the medium was slightly yellow that is when the pH has 
dropped to acidic. A 5 ml aliquot of the acidic medium was removed and 
replaced with 5 ml fresh complete medium and the flask placed back into the 
incubator. 
4.7.4. Preparation ofstock solutions for the cytotoxicity assay 
Stock solutions of the test samples were prepared the day before the 
experiment was carried out otherwise they were stored at -20°C. Test 
samples were prepared at a concentration of 2 mg/ml by dissolving the test 
samples in 100 1-11 acetonitrile and sonicating for 15 minutes. This was made 
up to 1 ml by adding 900 1-11 of Millipore water and sonicating the stock solution 
for a further 15 minutes. On the day of the experiment, six 10-fold serial 
i 
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dilutions of the stock solution were prepared in complete medium from 200 
j..Ig/ml to 0.002 j..Ig/ml. 
4.7.5. Plating cells 
For plating cells, the sub-culturing method was followed. The cell pellet was 
resuspended in 5 ml of complete medium. A 20 IJI aliquot of the resuspended 
cells was mixed with 20 j..Il of the crystal violet solution in an eppendorf to stain 
the cells for counting. A 20 j..Il aliquot of this was removed, placed on a 
counting chamber of the hemacytometer (Sigma-Aldrich, Kempton Park, 
South Africa) and covered with a coverslip. Cells were counted from the 
central grid (5 x 5 squares). To ensure that the cells were viable and in their 
logarithmic stage, 1 x 104 cells were seeded at a density of approximately 1 x 
104 cells/ml per well. The following calculation was used: 
Number of cells/cubic millimeter (mm.:l) = 

Average number of cells counted x 25 x 2 x 104 cells /ml 

Where 25 = area of the central grid (5 x 5) 
2 = dilution factor 
mm3 =ml 
The initial stock solution of the cells was made up to 105 cells/ml, so that after 
addition of the medium in the wells the final density will be 1 x 104 cells Iml. 
Sterile 96-well microtitre culture plates (Greiner Sio-One, Frickenhausen 
Germany) arranged in 8 rows (A - H) and 12 columns (1 - 12) were used for 
plating cells. The plate was turned around so that rows A - H were now 
columns H - A and columns 1 - 12 were now rows 1 -12 (figure 4.6). To the 
wells used as blanks (column H), 200 j..Il of complete medium was added. To 
the rest of the wells 100 j..Il of cell suspension was added together with 100 j..Il 
of complete medium. The cells were resuspended after adding to every two 
rows since they settled down quickly. Column G was used as the control, with 
medium and cells only. The plate was incubated for 24 hours at 37°C in 5% 
CO2 - 95% air humified atmosphere to allow the cells to attach to the bottom of 
the wells, 
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4.7.6. Cytotoxicity Assay 
After 24 hours, all the wells were checked to see if the cells have attached. 
The medium was then aspirated from all the wells leaving a thin film of 
complete medium covering the cells to avoid aspirating the cells as well. 
Aliquots of 100 1-/1 of the test samples were added to the corresponding wells 
in triplicates (column F to column A) at concentrations from (200 I-/g/ml 
to 0.002 I-/g/ml), followed by 100 1-/1 of complete medium. The final 
concentrations therefore, ranged from 100 I-/g/ml to 0.001 I-/g/ml. To the wells 
used as blanks (column H, complete medium only) and control (column G, 
cells and complete medium only), 200 1-/1 of complete medium was added. The 
plate set up is shown in figure 4.6. 
Figure 4.6. A plate set up for the cytotoxicity assay. EMT = emetine. 
The control was referred to as 100% cell viability. Emetine served as a 
positive control and acetonitrile (0.1 %) as a negative control. The plate was 
covered with a lid and incubated for 48 hours at 37°C in 5% C02 -95% air 
humified atmosphere. The assays were done on two separate experiments. 
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After 48 hours, cell viability was measured by MTT assay. To each well, 25 IJI 
of MTT (5 mg/ml in Millipore water)' was added (protected from light since it is 
sensitive to light) and the plate was incubated for a further 4 hours at 37°C for 
the MTT cleavage. After incubation, the plate was centrifuged in an eppendorf 
centrifuge for 10 minutes at· 200 rpm and the medium was removed by 
aspiration. An aliquot of 100 IJI of dimethyl sulfoxide (OMSO) was added to 
each well and· the plate shaken vigorously on a vortex-genie microplate 
shaker, (Scientific Industries, New York, USA) at a low speed for 5 minutes. 
This was to ensure that the formed purple formazan crystals were dissolved. 
The optical density of each well was measured at 540 nm on an anthos htll 
microplate reader. 
The cytotoxicity effects of test samples were expressed as percentage cell 
viability of the drug-free cells. Sigmoidal curves were obtained by plotting 
percentage cell viability against logarithmic concentrations and the IC50 values 
were calculated by non-linear regression analysis processed on dose­
response curves. GraphPad Prism 4 software was used to plot all the graphs. 
4.7.7. Selectivity Index 
The selectivity index is obtained to determine whether a compound or extract 
is cytotOXic or anti plasmodial. The selectivity index of the test samples were 
determined by calculating the ratio of cytotoxicity to anti plasmodial activity, 
with the units used being the same. The higher the selectivity index, the less 
toxic the test sample. 
Selectivity Index = Cytotoxicity IC50 I Antiplasmodial IC50 
4.7.8. Resistance Index 
The resistance index is used to give an indication of the relative activity of the 
compounds in drug-resistant and sensitive strains. 
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Resistance Index = K1 IC501010 IC50 
4.8. Spectroscopy for Compounds MF4 and MF7 A 
1H and 13C NMR spectral analysis were recorded on a Varian UNITY Inova 600 
spectrometer (Varian Inc., California, USA) in COCI3 at 25°C with TMS as 
internal standard. The 1H and 13C NMR spectra were recorded at frequencies 
of 600 MHz and 150 MHz, respectively. The complete assignment for proton 
and carbon atoms was enabled by the extensive 20 NMR analysis which 
included 1H - 1H COSY, NOESY, HMQC and HSQC experiments. The low 
resolution mass spectra were run on API 2000 LC/MS/MS mass spectrometer 
(Applied Biosystems, California, USA). The HRMS (high resolution mass 
spectra) were run on a Waters API Q-TOF Ultima (Waters, Milford, USA). The 
conditions for the Electrospray ionisation (ESI) probe were a desolvation 
temperature of 350 °C and desolvation gas was at 400 Uh, the capillary 
voltage was 3.5 kV with a temperature of 100 °C, cone voltage was 35 V and 
cone gas was at 50 Uh. Mass range scanned was between 200 - 1900 
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5.1. INTRODUCTION 
The roots of D. anomaia, collected from Lesotho, Sterkspruit, Limpopo and Reitz 
were evaluated for antiplasmodial activity in vitro against the D10 strain of P. 
falciparum. The leaves and twigs (except for the plant collected in Lesotho) were 
also screened for in vitro antiplasmodial activity. 
The roots of D. anomala (Sond.) from Sterkspruit, Limpopo and Reitz were 
collected in October 2003 and those from Lesotho were collected in December 
1996 (batch I) and October 2003 (batch II). 
5.2. METHODS 
Cold and hot extracts of the roots of D. anomala were prepared with 
dichloromethane (DCM) and water (H20), while the cold extracts of the leaves 
and twigs were prepared with DCM only. In addition, cold extractions of the roots 
of D. anomala from Lesotho were prepared with methanol (MeOH), hexane, 
ethylacetate, petroleum spirit and chloroform. The cold extractions were prepared 
using the mechanical shaker and the hot extractions were prepared from the 
soxhlet extractor and the hotplate. 
The extracts which showed antiplasmodial activity against the cas strain, D10, 
were screened for cytotoxicity on the Chinese Hamster Ovarian (CHO) cells. 
Details of the methods used are in Chapter 4. 
5.3. RESULTS AND DISCUSSION 
The antiplasmodial activity and the cytotoxicity of the extracts were determined at 
50% inhibitory concentration (IC50). The antiplasmodial activity, the cytotoxicity 
and the selectivity .indices of the extracts from the four locations are shown in 
table 5.1. For antiplasmodial activity, the test samples with IC50 s 1 0 ~g/ml were 
considered active and worthy of further evaluation. 
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The OCM leaf and twig extracts from Sterkspruit, Limpopo and Reitz showed 
antiplasmodial activity against the 010 strain of P. fa/ciparum (3.14 ± 0.12 ~g/ml, 
1.67 ± 0.22 ~g/ml, 0.68 ± 0.025 ~g/ml, respectively). The two extracts (Limpopo = 
4.58 ± 1.02 ~g/ml and Reitz = 3.85 ± 0.13 ~g/ml) showed a high cytotoxicity but 
their selectivity indices (2.78 and 5.66, respectively) showed that the 
antiplasmodial activity was not due to the high cytotoxicity. The OCM leaf and 
twig extract from Sterkspruit would therefore be the good candidate extract for 
the isolation of antiplasmodial activity because it showed less cytotoxicity (31.12 
± 0.22 ~g/ml) and high selectivity index (9.91) compared to the other two 
extracts. These extracts contained fewer peaks as shown by their HPLC profiles 
(Appendix A). The results confirm the traditional use of the leaf and twig extracts 
of D. anoma/a for the treatment of malaria and fever [Neuwinger, 2000]. 
Table 5.1. The antiplasmodial activity of the extracts of D. anomala on the 010 strain of P. 
falciparum and the cytotoxicity of the antiplasmodial active extracts on the CHO cells. 
.Extract I Collection 
! Location 
IC50 mean ±S.D. 
(J,lg/ml) 
010 strain 






Leaves and twigs 
Cold OCM Sterkspruit ~12 31.12±0.22 9.91 
Limpopo . .22 4.58 ± 1.02 2.78 
Roots 
Reitz 0.68 ± 0.025 0.13 15.66 
Cold OCM Lesotho (81)* 2.48 ± 0.005 - -
Lesotho (8II)* 1.55 ± 0.07 9.82 ± 0.25 6.33 
Sterkspruit 1.02 ± 0.095 6.67 ± 0.93 6.54 
~opo 1.39 ± 0.20 5.34 ± 1.18 3.84 
'tz 0.48 ± 0.045 3.50 ± 0.39 7.29 
Hot OCM Lesotho 1.44 ± 0.27 19.43 ± 0.92 6.55 
Sterkspruit 1.07 ± 0.09 4.80 ± 0.24 4.48 
Limpopo 0.42 ± 0.04 2.90 ± 0.31 6.90 
Reitz 1.25 ± 0.15 2.84 ± 0.055 2.27 
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table 5.1. cont. 
! Extract Collection ICoo mean :t S.D. IC50 mean:t S.D. Selectivity 
Location (lJg/ml) (lJg/ml) Index 
010 strain CHO cells (SI) 
Cold H2O Lesotho 23.86 ± 0.90 ~ ~ 
Sterkspruit 21.85 ± 1.35 - -
Limpopo 13.92 ± 0.52 - -
Reitz 29.76 ± 2.90 - -
Hot H20 (soxhlet) 6 hrs Lesotho > 100 - -
Sterkspruit > 100 - -
Limpopo 61.15 ± 3.25 - -
Reitz 66.72 ± 6.74 - -
Hot H20 (hotplate) 6 hrs Lesotho 69.46 ± 2.16 - -
Sterkspruit 43.42 ± 1.44 - -
Limpopo ! 17.06 ± 1.22 - -
Reitz 48.74 ± 2.08 - -
Hot H20 (hotplate) 2 hrs Lesotho 24.16 ± 0.16 - -
Sterkspruit 19.54 ± 0.04v - -
Limpopo 8.44 ± 0.25 87.06 ± 6.70 10.32 
• 
i 
* Bl and BU = batch I and II of D. anomala roots from Lesotho. 
-Not done 
The cold and hot DCM root extracts of D. anomala from Lesotho, Sterkspruit, 
Limpopo and Reitz also showed antiplasmodial activity (lC5o S 1.55 ~g/ml) 
against the D10 strain of P. falciparum. The extracts were shown to be cytotoxic 
on the CHO cells (IC5o< 1 0 ~g/ml) but their selectivity indices indicated that they 
are more selective towards the parasites than to the cells (table 5.1). 
The cold and hot OCM root extracts from Lesotho (1.55 ± 0.07 ~g/ml and 1.44 ± 
0.27 ~g/ml, respectively) had similar antiplasmodial activity and this indicated that 
heat had no effect on the compounds, and similarly with cold and hot OCM 
extracts from Sterkspruit (1.02 ± 0.095 ~g/ml and 1.07 ± 0.09 ~g/ml, 
respectively). There was similarity in the HPLC profiles of the cold and hot OCM 
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extracts from Lesotho and Sterkspruit (figures 5.1 a, 5.1 b, 5.2a and 5.2b), which 
confirmed that no compounds were lost or destroyed during the hot extraction of 
the roots with OCM. The HPLC profiles of the cold OCM root extracts from 
Limpopo and Reitz were different to those from Lesotho and Sterkspruit 
(Appendix A). 
:nAbs 
2UOO O:c::L.h7.""2 -::"_:-:-'-n"-----=-­ -----­--­ -----­ --, 
40 
Figure 5.1 a. The HPLC chromatogram of the cold DCM root extract of D. anomala 
from Lesotho. 
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Figure S.2a. The HPLC chromatogram of the cold OCM root extract of D. anomala 
from Sterkspruit. 
88 
Chapter 5 Evaluation of D. anomala extracts for antiplasmodial activity 
mAb s 
2000 r-~~~~J ~nm ~ ~Ch 2 2 -5 --------~------~r---~--------------------------------------------------~ 
\,,;J \0 0 to 
CD co M...o 0 
'" <D o ~ M ..... .... I:' ~ ..; -< N ""'" ..... 
v "I'" ~ CD 
..... 
N 
... v,., ..... 
1500 
<"o& ~.o \0 




o..,.. '" ID 
"I 







<Xl.. '" 0 N '" '" 
"" '" '"N ... .... .... 
<T. N 
0> 















P"""I fI'1 0 1""'1 
O ~~~______________________~____~~_______ _________==-~__~=-__-=~~~~~~ __~("')-4- ~ M "' "'
o 2 0 40 60 
mi r. 
Figure 5.2b. The HPLC chromatogram of the hot OCM root extract of D. anoma/a from 
Sterkspruit . 
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Figure 5.3. The anti plasmodial dose response curves showing the DeM extracts of the leaves 
and twigs and the roots of D. anomala collected from four locations (Lesotho, Sterkspruit, Reitz 
and Limopo). 
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200 Sterkspruit: le so (1) = 3.64 ~m 
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Figure 5.4. The cytotoxicity dose response curves showing the OeM extracts of the leaves 
and twigs and the roots of D. anomala collected from four locations (Lesotho, Sterkspruit, 
Reitz and Limopo). 
The roots of O. anomala from Lesotho were also extracted in other organic 
solvents (table 5.2). The ethylacetate and chloroform extracts (1.56 ± 0.36 ~g/ml 
and 1.18 ± 0.08 ~g/ml) were active against the D10 strain of Plasmodium 
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extract (1.55 ± 0.07 jJg/ml). The (MeOH) extract showed a marginal activity 
(10.67 ± 0.32 jJg/ml) while the hexane extract (39.30 ± 0.70 jJg/ml) and the 
petroleum spirit extract (12.79 ± 2.44 IJg/ml) were inactive against the 010 strain 
of P. fa/ciparum. 
Table 5.2. The anti plasmodial activity and the cytotoxicity of the organic extracts of D. 
anoma/a roots from Lesotho on the cas (010) strain of P. fa/ciparum. 
Extract Polarity IC50 mean ± S.D. IC50 mean ±S.D. Selectivity 
Index (~g/ml) (~g/ml) Index 
(PI) 010 strain CHO cells (SI) 
MeOH 6.6 10.67 ± 0.32 
Hexane 0 39.30 ± 0.70 
Chloroform 4.1 1.18 ± 0.08 4.84 ± 0.62 4.10 
Ethylacetate 4.4 1.56 ± 0.36 16.46 ± 0.13 10.55 
Petroleum spirit 12.79 ± 2.44 
- Not done 
The cytotoxicity results showed that the chloroform extract (4 .84 ± 0.62 jJg/ml) 
had more cytotoxic effects on the CHO cells than the ethylacetate extract (16.46 
± 0.13 jJg/ml). However, the extracts were more potent to the parasites than to 
the cells as shown by the selectivity indices (chloroform extract = 4.10 and 
ethylacetate extract =10.55). The antiplasmodial and cytotoxicity dose response 
curves of these extracts are shown in figure 5.3. 
A comparison of the organic root extracts, using HPLC, indicated that the OCM, 
ethylacetate and chloroform extracts had similar HPLC profiles hence similar 
antiplasmodial activity. All the three extracts contained numerous peaks whilst 
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the MeOH, hexane and the petroleum spirit extracts contained fewer peaks 
(Appendix 8). The similarity and the difference in the HPLC profiles of these 
extracts could be explained by the polarity of the extracts according to the 
polarity index (PI) of the solvents (table 5.2). Hexane and the petroleum spirit 
solvents (PI =0) were more hydrophobic than chloroform, ethylacetate and DCM 
solvents (PI =4.4, PI =4.3 and PI =3.4, respectively). The MeOH was the only 
hydrophilic solvent (PI =6.6). 
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Figure 5.5. The anti plasmodial and cytotoxicity dose response curves of organic and 
water extracts of the roots of D. anoma/a collected from Lesotho. 
The cold and hot H20 root extracts of the roots of D. anomala collected from all 
four locations, did not show antiplasmodial activity against the D10 strain of P. 
falciparum (table 5.4 and figure 5.6) except for the hot H20 root extract from 
Limpopo (8.44 ± 0.25 IJg/ml) , prepared on a hotplate for 2 hours. 
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Figure 5.6. The antiplasmodial dose response curves of H20 extracts of the roots of D. 
anomala collected from four locations (Lesotho, Sterkspruit, Reitz and Limopo). 
The cytotoxic effect of the hot water root extract from Limpopo (hotplate: 2 hrs, 
87.06 ± 6.70 ~g/ml) (figure 5.7) was very low on the CHO cells and the selectivity 
of the antiplasmodial potency was 10 times high towards the parasites. This 
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cytotoxicity on the CHO cells and further supports the treatment of fevers, some 
of which may be malarial fevers with the roots of D. anomala. 
CHO: Hot H,O extract (Limpopo roota) CHO: Hot H,O extract (Limpopo roots) 
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Figure 5.7. The cytotoxicity dose response curves of the hot water root extract 
(hotplate: 2 hrs) of D. anomala from Limpopo. 
Four fractions (H201 - H204) were obtained from the cold H20 root extract from 
Lesotho. The fractions were obtained according to their colour intensity (details in 
Chapter 4) and the antiplasmodial activity was found in fractions H203 and H204 
(7.48 ± 0.07 I-lg/ml and 5.54 ± 0.16 I-lg/ml) (table 4.3 and figure 5.8). To confirm 
these results, four other fractions (H1 - H4) were obtained from the second H20 
extraction of the roots and the antiplasmodial activity was found in fractions H3 
and H4 (4.85 ± 0.18 I-lg/ml and 7.0 ± 1.20 I-lg/ml) (table 5.3 and figure 5.8). The 
antiplasmodial activity of the cold H20 root extract (23.86 ± 0.90 I-lg/ml), 
therefore, unfolded when the root extractions were separated into fractions. 
The cytotoxic effects of these samples were less on the CHO cells (H203 = 66.74 
± 2.92 I-lg/ml, H204 =60.43 ± 2.09 I-lg/ml, H3 =59.60 ± 2.20 f..Ig/ml, H4 =78.73 ± 
1.99 I-lg/ml and the hot H20 root extract from Limpopo (hotplate: 2 hrs, 87.06 ± 
6.70 I-lg/ml). The results indicated that the antiplasmodial activity of the samples 
was not due to the cytotoxicity and the selectivity of the antiplasmodial potency 
was high by a magnitude of 12 for fractions H204 and H3, 11 for fraction H4 and 
9 for fraction H203. 
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Table 5.3. The anti plasmodial activity and cytotoxicity of the fractions of the cold 

H20 root extract of D. anoma/a from Lesotho on the 010 strain of P. fa/ciparum. 

Extracts and fractions IC50 mean ± S.D. IC50 mean ± S.D. Selectivity 
(Roots) (lJg/ml) (lJg/ml) Index 
(batch II) 010 strain CHO cells (SI) 
First extraction 
Cold H20 extract 28.92 ± 1.76 
H201 > 100 
H202 15.23 ± 0.60 
H203 7.48 ± 0.07 66.74 ± 2.92 8.92 
H204 5.54 ± 0.16 60.43 ± 2.09 10.91 
Second extraction 
Cold H20 extract 23.86 ± 0.90 
H1 57.95 ± 8.42 
H2 15.19 ± 2.07 
H3 4.85 ± 0.18 59.60 ± 2.20 12.26 
H4 7.0±1 .20 78.73 ± 1.99 11 .25 
- Not done 
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Figure 5.8. The antiplasmodial and cytotoxicity dose response curves of the cold water 
root extract and the cold water root extract fractions of D. anomala from Lesotho. 
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The less cytotoxic effects of the H20 root extract fractions supports the claim by 
traditional healers that the H20 root extracts of the roots of D. anomala are safe 
although this claim is contradicted by the report that the extracts of D. anomala 
are hepatotoxic [Hedberg and Staugard, 1989]. It is therefore difficult to make 
any conclusions since it is not known if the extracts that exhibit the hepatotoxicity 
were organic or H20 root extracts or both or the plant was used in a preparation 
mixture with other plants. 
It could be that the extracts screened for hepatotoxicity were organic extracts as 
it has been shown in this chapter (table 5.6 and figure 5.5) that the active organic 
extracts had high cytotoxic effects than the active H20 fractions. Nevertheless, 
except for the chloroform extract, all these extracts had similar magnitude of 
selectivity towards the parasites (table 5.3). 
The organic extracts were dissolved in acetonitrile, which had no cytotoxic effects 
(IC5o => 100 tJg/ml) on the Chinese Hamster Ovarian (CHO) cells. This therefore 
rules.out the possibility that the cytotoxicity of the organic extracts may be due to 
the solvent 
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Table 5.4. Extraction yields of extracts of the leaves and twigs and the roots of D. anomaia 
collected from the four locations (Lesotho, Sterkspruit, Limpopo and Reitz). 
! 
Extract Collection Mass Mass of Extraction 
Location extracted extract yield 
(g) (g) (UfO) 
i Leaves and twigs 
! Cold OCM Sterkspruit 10.69 0.49 4.58% 
Limpopo 12.37 0.72 5.82% 
Reitz 2.21 0.13 5.88% 
Roots 
Cold OCM Lesotho 200.43 3.65 1.82% 
Sterkspruit 100.0 2.71 2.71% 
Limpopo 50.02 2.81 5.62% 
Reitz 50.04 2.38 4.76% 
Hot OCM Lesotho 40.0 0.62 1.55% 
Sterkspruit 40.61 0.53 1.30% 
Limpopo 40.22 0.77 1.91% 
Reitz 20.20 0.30 1.48% 
Cold H2O Lesotho 5.15 0.2182 4.24% 
Sterkspruit 10.25 2.05 20.0% 
Limpopo 10.40 1.51 14.52% 
Reitz 10.20 1.60 15.68% 
Hot H20 (soxhlet) Lesotho 40.0 112.52 31.3% 
Sterkspruit 40.50 8.57 21.16% 
Limpopo 41.19 10.37 25.18% 
Reitz 17.47 6.31 36.12% 
Hot H20 (hotplate) 6 hrs Lesotho 5.0 1.75 35.0% 
Sterkspruit 5.29 1.58 29.87% 
Limpopo 5.37 1.32 24.58% 
Reitz 5.60 1.60 28.57% 
Hot H20 (hotplate) 2 hrs Lesotho 5.0 1.70 34.0% 
Sterkspruit 5.24 1.55 29.58% 
Limpopo 5.50 1.35 24.54% I 
Table 5.4 shows the extraction yields of the OeM and H20 extracts from the four 
locations. All the hot H20 root extracts had high yields than the other extracts. 
The hot H20 root extracts from the hotplate had high yields than the hot H20 root 
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extract from the soxhlet and the cold H20 root extract. In the organic extracts 
(table 5.5 below), the MeOH extract had the highest yield followed by the hot 
DeM extract (table 5.1 and 5.2). This means that there are more compounds 
extracted in H20, in particular, hot H20 than in organic extracts. In addition, more 
compounds were extracted with MeOH than with other organic solvents used for 
the extraction. Most compounds extracted from the roots of D. anomala are 
therefore polar compounds since the H20 root extracts, in particular hot H20 root 
extracts and the MeOH extract had the highest yields. This is supported by the 
fact that H20 and MeOH are more polar than the other organic solvents used. 
, . 
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Table 5.5. Extraction yields of organic extracts and fractions of the cold water root 
extract of the roots of D. anomala from Lesotho. 
Extracts Mass extracted 
(g) 




Methanol 5.15 0.84 16.31% 
Hexane 5.01 0.03 0.60% 
I Chloroform 5.02 0.11 2.19% 
Ethylacetate 5.02 0.16 3.19% 
Petroleum spirit 5.18 0.05 0.96% 
Water root extract 
fractions 
First extraction 5.16 
H201 0.821 15.91% 
H202 0.039 0.76% 
H203 0.028 0.54% 
H204 0.016 0.31% 
Second extraction 5.15 
H1 0.771 14.9% 
H2 0.034 0.65% 
H3 0.029 0.56% 
H4 0.016 0.31% 
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5.4. CONCLUSION 
• 	 The antiplasmodial activity of the DCM leaf and twig extracts of D. 
anomala has confirmed their use for the treatment of malaria and fever 
[Neuwinger, 2000]. 
• 	 The use of D. anomala for the treatment of fevers, some of which could be 
malarial fevers, was also confirmed by the antiplasmodial activity of the 
organic extracts of the roots (cold and hot DCM extracts, chloroform, 
petroleum and ethylacetate extracts). 
• 	 Hot and cold H20 root extracts did not show antiplasmodial activity except 
for the hot H20 root extract from Limpopo. The cold H20 root extract from 
Lesotho have been shown to possess antiplasmodial activity only when it 
was separated into fractions. The activity was found in fractions (H203, 
H204, H3 and H4) which also showed less cytotoxicity. 
• 	 The roots of D. anomala have been shown to· contain more polar 
compounds as observed from the high yields of the H20 and the MeOH 
extracts. 
• 	 Further work has to be done on the organic extracts and the H20 root 
extract fractions from D. anomala. Compounds have to be isolated and 
screened for antiplasmodial activity to determine which compounds are 
responsible for the activity and also determine their cytotoxicity, in vivo 
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Chapter 6 Evaluation of SPE Fractions from the crude DCM extracts of D. anomala 
6.1. INTRODUCTION 
The hot and cold OCM extracts of the roots of D. anomala from Lesotho had 
similar antiplasmodial activity but only the cold OCM extract was fractionated. 
The cold OCM root extracts from batch I and II were subjected to solid phase 
extraction to obtain 10% and 5% fractions. In addition, 1% fractions were also 
obtained from the cold OCM root extract from batch I. The cold OCM root 
extract from Sterkspruit had similar antiplasmodial activity and similar HPLC 
profile to the one from Lesotho and was therefore, also subjected to SPE to 
obtain three fractions (fraction 30, 40 and 50). These fractions were the most 
active fractions in the bio-activity guided fractionation of the cold OCM root 
extract (batch I and II) from Lesotho. 
6.2. METHODS 
The cold OCM extract of the roots was subjected to bio-activity guided 
fractionation using SPE. The fractionation was carried out using the Isolute C 18 
(EC) cartridge of mass absorbent 10 g and 70 ml capacity, which was 
conditioned sequentially with 50 ml methanol and 50 ml Millipore water to 
facilitate binding of compounds. A 50 ml aliquot of the 4 mg/ml crude OCM 
extract solution was then applied onto the column and eluted under weak 
vacuum at a flow rate of 17 ml/min. 
A step gradient of increasing 10% mobile phases of acetonitrile and water 
(MeCN:H20) was used to elute bound compounds to afford 13 fractions 
(percolate, water wash, fractions 10 -100 and acetone wash). 
To achieve 'fractions with single peaks, further fractionation was carried out with a 
step gradient of 5% and 1% increment mobile phases of MeCN:H20 in the range 
35% - 55% and 31% - 35% respectively. The details of the methods are in 
Chapter 4. 
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6.3. RESULTS AND DISCUSSION 

Table 6.1. Extraction yields of 10% fractions from batch I and batch II of the cold OeM 
root extract of D. anomala from Lesotho. 
Percolate 43.80 19.91 58.88 21 .03 

Water wash 2.90 1.32 4.68 1.67 

10 4.35 1.98 3.03 1.08 
20 23.13 10.51 12.85 4.59 
30 50.58 22.99 50.62 18.08 
40 21 .07 9.58 23.13 8.26 
50 3.55 1.61 7.11 2.54 
60 2.24 1.02 2.59 0.92 
70 2.12 0.96 7.38 2.64 
80 1.12 0.51 4.13 1.48 
90 1.07 0.49 1.08 0.38 
100 1.10 0.50 2.47 0.88 
Acetone wash 
6.20 2.82 4.45 1.59 
The extraction yields obtained for the SPE fractions of the cold DCM root extract 
of D. anomala (batch I and II) from Lesotho were lower than 24% (table 6.1 and 
6.2). Although more material of the cold DCM root extract was loaded (400 mg 
and 662 mg, respectively) to obtain 5% and 1 % fractions, as compared to 280 
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mg for the 10% fractions, fractions with high yields (4.59% - 22.99%) were found 
in the 10% SPE fractions (percolate, fractions 20, 30 and 40). There were 
however, variations in the % yields of fractions 10, 20, 70, 80 and acetone wash 
of batch I and II. This was also observed with the % yields of fraction 50 from 
the 5% fractions. These could be explained as operator inconsistencies. As the 
cold OeM root extract was further purified, lower yields of the fractions were 
obtained. Purifying crude extracts has been a major challenge because of the low 
yields of fractions and compounds. 
Table 6.2. Extraction yields of 1 % and 5% fractions from batch I and batch II of cold 
OeM root extract of D. anomala from Lesotho. 
5% Mass obtained 
SPE Fractions 
35 20.45 6.60 18.05 4.51 
40 13.08 4.22 16.09 4.02 
45 3.46 1.12 4.96 1.24 
50 2.61 0.84 1.94 0.48 
55 1.39 0.45 1.49 0.37 
Cold extract (Batch I) 
1% % Yield 
SPE Fractions 
31 70.3 10.62 
32 69.3 10.47 
33 31 .8 4.80 
34 43.9 6.63 
35 50.1 7.57 
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Table 6.3. The in vitro anti plasmodial activity of 10% and 5% SPE fractions from batch I and II 
of the cold OCM root extract of D. anoma/a from Lesotho on cas (010) strain of P. fa/ciparum 
and the in vitro cytotoxicity of fractions 40 and 50 on CHO cells. 
Batch I 
Cold OCM extract 
Batch II 
Cold OCM extract 
Batch IT 
Cold OCM extract 
10% 
SPE Fractions 
ICso ± SO (lJg/ml) 
D10strain 
ICso ± SO (lJg/ml) 
D10 strain 
ICso ± SO (lJg/ml) 
CHO cells 
Percolate 4.04 ± 0.12 11.77 ± 0.50 
Water wash 5.74±1.15 7.62 ± 1.09 
10 4.32 + 0.67 5.46 + 0.27 
20 2.90 + 0.30 2.89 ± 0.32 
30 0.46 + 0.12 0.56 ± 0.065 
40 0.72 ± 0.20 0.63 ± 0.045 
3.76 ± 0.27 
JSI = 5.971 
50 0.63 + 0.1 0.54 ± 0.11 
3.50 ± 0.13 
_(SI = 6.481 
60 4.58 ± 0.30 6.70 ± 1.05 
70 16.04±1.92 16.10 ± 1.48 
80 12.27 ± 0.89 16.16 ± 3.16 
90 8.85 ± 0.32 6.15 ± 0.18 
100 30.70 ± 5.12 34.52 ± 4.74 
Acetone wash > 100 > 100 
5% 
SPE Fractions 
35 0.56 ± 0.09 0.23 ± 0.025 
40 0.50 ± 0.06 0.67 ± 0.065 
45 0.38 ± 0.02 0.29 ± 0.01 
50 0.81 + 0.04 0.40 ± 0.02 
55 1.09 ± 0.005 0.56 ± 0.005 
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The water wash, fractions 10 - 60 and 90 from batch I and batch II of the cold 
OCM root extract from Lesotho showed antiplasmodial activity against the cas 
(010) strain of P. fa/ciparum. The most active fractions were fractions 30, 40 and 
50. Fractions 70, 80, 100 and the acetone wash from both batches did not show 
significant antiplasmodial activity (table 6.3 and figures 6.1 a and 6.1 b). 
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Figure 6.1 a. The dose response curves showing the anti plasmodial activity of 10% SPE 
fractions from the cold OeM root extract (batch I) of D. anomala from Lesotho. 
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Figure 6.1 b. The dose response curves showing the antiplasmodial activity of 10% SPE 
fractions from the cold DeM root extract (batch II) of D. anomala from Lesotho. 
Compounds that did not bind to the SPE column were washed off with water, 
which means that the water wash (5.74 ± 1.15 jJg/ml:S; IC50 :s; 7.62 ± 1.09 jJg/ml) 
contained polar compounds with antiplasmodial activity. The antiplasmodial 
activity of the water extract fractions (H3, H4, H203 and H204) which was 
between 4.85 ± 0.5 jJg/ml and 7.48 ± 0.07 jJg/ml (table 5.3, Chapter 5), has 
confirmed that the roots of D. anoma/a contained polar compounds which are 
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Fractions 30,40 and 50 were more active (0.46 ± 0.12 jJg/ml :s; IC50 :s; 0.72 ± 0.20 
IJg/ml) than the cold OCM extract from batch I (2.48 ± 0.005 jJg/ml) and batch II 
(1.55 ± 0.07 jJg/ml) of the roots of D. anomala (table 4.1 , Chapter 4). This showed 
that the activity of the cold OCM root extracts was not lost due to fractionation 
and that it was more likely to be due to the activity of individual compounds rather 
than synergism between the compounds. 
The percolate from batch I of the cold OCM root extract exhibited antiplasmodial 
activity (4.05 ± 0.12 jJg/ml) whilst that from batch II did not show significant 
antiplasmodial activity (11 .77 ± 0.50 jJg/ml). The HPLC profiles of these 
percolates were different and showed that the active percolate contained more 
peaks than the inactive one (figures 6.2a and 6.2b) and the HPLC profiles were 
different. 







Figure 6.2a. The HPLC chromatogram of the percolate from the cold DCM root extract 
(batch J) of D. anoma/a from Lesotho. The analytical HPLC run was on a Phenomenex 
column (150 x 4.6 mm , 51-1m) at a gradient of 20% - 100% MeCN in H20 and a flow rate 
of 1 ml/min. The concentration was 1 mg/ml and the injection volume was 100 1-11. 
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Figure 6.2b. The HPLC chromatogram of the percolate from the cold DCM root extract 
(batch 11) of D. anomala from Lesotho. The analytical HPLC run was on a Phenomenex 
column (150 x 4.6 mm, 5 IJm) at a gradient of 20% - 100% MeCN in H20 and a flow rate 
of 1 ml/min. The concentration was 1 mg/ml and the injection volume was 100 IJI. 
The SPE fractionation of the cold OCM root extract (batch II) into 10% fractions 
was performed to determine if it was reproducible when compared to fractions 
from batch I of the cold OCM root extract. There was no significant difference in 
the antiplasmodial activity of 10% fractions from both batches, except for the 
percolate. Fractions 30, 40 and 50 were still the most active fractions. Although 
fractions 40 (3.76 ± 0.27 !-I9/ml, SI =5.97) and 50 (3.50 ± 0.13 !-Ig/ml, SI =6.48) 
were cytotoxic, the effect was more towards the parasites than to the CHO cells. 
The SPE fractionation of the cold OCM root extract of D. anomala (batch I and 
batch II) into 10% fractions was reproducible and the antiplasmodial activity of 
the cold OCM root extracts was not lost due to fractionation. The reproducibility of 
SPE fractionation of the cold OCM root extracts (batch I and batch II) is shown in 
figures 6.3a - f by the HPLC chromatograms of the most active 10% SPE 
fractions (fractions 30, 40 and 50). 
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Figure S.3a. The HPLC chromatogram of fraction 30 (1 mg/ml) from the cold DCM root extract 
(batch I) of D. anomala from Lesotho. The fraction was run at a gradient of 50% - 70% MeCN: H20 
on a C18 reverse-phase analytical Haisil column (250 x 4.6 mm, 5 IJm), at a flow rate of 1 mllmin 
and were monitored at 215 nm. The injection volume was 150 IJI. 
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Figure S.3b. The HPLC chromatogram of fraction 30 (4.5 mg/ml) from the cold DCM root extract 
(batch II) of D. anomala from Lesotho. The fraction was run isocratically at 60% MeCN: H20 on a 
C18 Haisil reverse-phase semi-preparative column, at a flow rate of 2.5 mllmin and a detection 
wavelength of 215 nm. The injection volume was 250 IJI. 
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Figure S.3e. The HPLC chromatogram of fraction 40 (1 mg/ml) from the cold DCM root extract 
(batch J) of D. anomala from Lesotho. The fraction was run at a gradient of 50% - 70% MeCN: H20 
on a C18 reverse-phase analytical Haisil column (250 x 4.6 mm, 5 iJm), at a flow rate of 1 ml/min 
and were monitored at 215 nm. The injection volume was 150 iJl. 
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Figure S.3d. The HPLC chromatogram of fraction 40 (4.5 mg/ml) from the cold DCM root extract 
(batch II) of D. anomala from Lesotho. The fraction was run isocratically at 60% MeCN: H20 on a 
C18 Haisil reverse-phase semi-preparative column. at a flow rate of 2.5 ml/min and a detection 
wavelength of 215 nm. The injection volume was 250 iJl. 
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Figure 6.3e. The HPLC chromatogram of fraction 50 (1 mg/ml) from the cold DCM root extract 
(batch 1) of O. anomala from Lesotho. The fraction was run at a gradient of 50% - 70% MeCN: H20 
on a C18 reverse-phase analytical Haisil column (250 x 4.6 mm, 5 \-1m), at a flow rate of 1 ml/min 
and were monitored at 215 nm. The injection volume was 150 \-II. 
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Figure 6.3f. The HPLC chromatogram of fraction 50 (4.5 mg/ml) from the cold DCM root extract 
(batch II) of O. anomala from Lesotho. The fraction was run isocratically at 60% MeCN: H20 on a 
C18 Haisil reverse-phase semi-preparative column, at a flow rate of 2.5 ml/min and a detection 
wavelength of 215 nm. The injection volume was 250 \-II. 
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The HPLC profiles of the most active 10% SPE fractions (fractions 30, 40 and 50) 
showed that these fractions were not pure compounds. The cold DCM root 
extract was further purified into 5% fractions in order to obtain pure compounds. 
Only fractions 40 and 50 were fractionated further since fraction 30 was part of 
an ongoing research in the Division of Pharmacology, University of Cape Town 
[Matsabisa, PhD thesis]. SPE was then performed using 5% increments of 
MeCN:H20 in the range 35% - 55% to expand fractions 40 and 50. 
As done with the 10% fractions, the 5% fractions were generated from both 
batches (batch I and II) of the cold DCM root extract of D. anomala. The 'fractions 
appeared fluffy and cream in colour and their in vitro antiplasmodial activity of the 
5% fractions is shown in table 5.3 and figure 6.4. All fractions were active (0.23 ± 
0.025 !-Ig/ml s IC50 S 1.09 ± 0.005 !-Ig/ml) against the 010 strain of P. falciparum. 
The purity of the 5% SPE fractions was checked on the HPLC and all fractions 
contained a number of peaks and were therefore not pure compounds. Fractions 
35 - 50 from both batch I and II had similar HPLC profiles while the HPLC 
profiles of fraction 55 (batch I and batch II) were different. The HPLC profiles of 
fractions 35 - 55 from batch I are shown in Appendix C. 
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Figure 6.4. The dose response curves showing the antiplasmodial activity of 5% SPE 
fractions from the cold OeM root extract (batch I and II) of D. anomala from Lesotho. 
The similarity or difference in the HPLC profiles of 10% and 5% fractions from 
both batches could explain why some fractions were more active than others and 
other fractions had similar antiplasmodial activities. 
The similar HPLC profiles of fractions 35 - 50 and the antiplasmodial activity on 
the 010 strain has shown that the SPE fractionation of the cold OCM root extract 
of D. anomala into 5% fractions was reproducible and that the activity of the cold 
OCM root extract, fractions 40 and 50 was retained. This further indicates that the 
compounds in the cold OCM root extract may not be acting in synergy for the 
antiplasmodial activity. 
To further achieve purification of the compounds, 1 % fractions generated only 
from the cold OCM root extract of batch I. The SPE fractionation was carried out 
using 1 % increments of MeCN:H20 mobile phases in the range 31 % - 35%. 
Fraction 35 was the first fraction generated in the 5% fractions and its peaks 
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In order to optimise separation of 1 % fractions and generate pure samples, 300 
ml volumes of 31 % - 35% MeCN:H20 mobile phases were used as opposed to 
200 ml volumes used for the elution of 10% and 5% SPE fractions. The higher 
volumes of elution were used to wash off any compounds that may be carried 
over to the next fraction, thereby obtaining pure compounds or fractions with very . 
few peaks. The 1 % SPE fractions were fluffy and white in colour as compared to 
cream for the 5% SPE fractions but the fractionation and the high volume of 
elution (300 ml) did not result in pure compounds. This was revealed by their 
HPLC profiles (Appendix C), which showed a lot of peaks compared to those of 
the 5% fractions (fraction 35 and 40). This means that more components were 
eluted with the 1 % mobile phases of MeCN:H20, indicating that the components 
in the cold DCM root extract were more separated with 1 % mobile phases of 
MeCN:H20 . These components could have been co-eluting when fractionating 
with the 10% mobile phases of MeCN:H20. 
To optimize the separation of the compounds in fraction 31, a TLC method was 
tried. The compounds in the fraction were eluted with benzene: acetone (50:50), 
benzene: ethylacetate (30:70), benzene: acetic acid (60:40), chloroform: 
methanol (50:50) and ethylacetate: acetate acid (60:40). More bands were 
observed with the benzene: acetic acid (60:40) mobile phase. The Rf values of 
the bands are shown in table 6.4. About 7 bands were observed at 254 nm and 5 
at 366 nm, although most were faint bands. The concentrated bands (bands 3 
and 5 at 254 nm and bands 3 and 6 at 365 nm) were scraped off and their purity 
checked on the HPLC. The HPLC profile of each band showed that there were 
about 6 peaks present (Appendix D). The TLC method did not therefore, result in 
pure compounds. 
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Table 6.4. The Rf values of bands from fraction 31 ran in benzene: acetic acid 
mobile phase on an aluminium coated TLC plate. The bands highlighted in blue 
were the most concentrated ones. 
Distance travelled by the mobile phase =18.6 cm 





1 1.5 0.081 
2 2.3 0.12 
3 4.1 0.22 
4 6.9 0.37 
5 12.1 0.65 
Band number at 
365 nm 
1 4.3 0.23 
2 6.2 0.33 
3 7.0 0.38 
4 9.8 0.53 
5 11 .5 0.62 
6 12.1 0.65 
7 12.7 0.68 
Fractions 31 - 35 were tested for in vitro antiplasmodial activity against the cas 
(010), COR (K1, RSA11 and FAC8) strains of P. fa/ciparum and all fractions 
showed good activity against all four strains of the malarial parasites (figure 6.5). 
As with the 10% and 5% SPE fractions, the fractionation of the cold OCM root 
extract into 1% fractions did not result in the loss of antiplasmodial activity 
against the 010 strain. 
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Figure 6.5. The dose response curves showing the antiplasmodial activity of 1 % SPE 
fractions from the cold OeM root extract (batch I) of D. anoma/a from Lesotho. 
Although all fractions were active against the 010, K1, RSA11 and FAG8 strains. 
Fraction 31, 32 and 35 were the most active fractions against the respective 
strains. Fraction 31 was most active against 010 strain, fraction 35 against K1 
strain and fraction 32 against RSA11 and FAG8 strains. Fraction 35 showed the 
lowest activity against FAG8 strain. The difference in the antiplasmodial activity of 
the fractions acting against the same strain could be attributed to differences in 
the compounds or their active sites. 
Some fractions showed similar antiplasmodial activity against the same strain of 
P. fa/ciparum (fractions 32, 34 and 35 against 010 strain; fractions 31 - 33 
against K1 strain, fractions 33 and 34 against RSA 11 strain and fractions 31 and 
33 against FAG8 strain. These findings suggest that the fractions might have the 
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similar active sites. There were also fractions which showed similar 
antiplasmodial activity against the cas and on CaR strains (fraction 33 against 
010 and FAC 8 and fraction 34 against 010 and K1 strains), indicating that these 
fractions might have a different mechanism of action to that of chloroquine. 
Others showed similar antiplasmodial activity against two CaR strains (fractions 
32 and 34 against RSA 11 and FAC8 strains and fractions 31 and 35 against K 1 
and RSA11 strains), suggesting that the fractions might not be sharing the 
mechanism of resistance of chloroquine. The results of fractions 31 - 35 obtained 
against both cas and CaR strains have shown that these fractions are a 
potential source of compounds that could be used for the treatment of both 
sensitive and resistant strains of P. falciparum. 
Table 6.5. The % yields and the anti plasmodial activity of 10% SPE fractions from the 
cold OeM root extract of D. anomala from Sterkspruit on the 010 strain of P. falciparum. 
10% SPE Mass loaded = 1.02 9 ICso ± SO 
Fractions 
Mass obtained % Yields 
ICso (lJg/ml) 
(mg) 
30 200.41 19.65% 0.17±0.03 
40 52.19 5.12% 0.42 ± 0.05 
50 13.55 1.33% 0.72 ± 0.22 
The cold OCM root extract of D. anomala (cold extraction) from Sterkspruit had a 
similar HPLC profile to the one from Lesotho (figure 5.1a, Chapter 5). It was 
therefore fractionated into fractions 30, 40 and 50 to see if these will have similar 
antiplasmodial activity and HPLC profiles to those obtained from the cold OCM 
root extract of D. anomala from Lesotho. These three fractions (30, 40 and 50) 
120 
Chapter 6 Evaluation of SPE Fractions from the crude OCM extracts of O. anomala 
were the most active fractions in the 10% SPE fractions from the cold OCM root 
extract of D. anomala (batch I and II) from Lesotho (table 6.3). 
Fractions 30, 40 and 50 from the SPE fractionation of the cold OCM root extract 
of D. anomala from Sterkspruit were as active against the 010 strain as those 
obtained from the cold OCM root extract of D. anomala from Lesotho. However, 
fraction 30 was more active than the one obtained from the cold OCM root extract 
of D. anomala from Lesotho. The results are shown in table 6.4 and figure 6.6. 
Fractions 30 • 50 from cold DCM root extract Fractions 30 • 50 from cold DCM root extract 
of D. ~ from Ster1aJpru~ of D. anoma/a from Sterkspruit 
125 125
• Fraction 30: IC50 (1) = 0.14 Wm • Fraction 30: IC 50 (2) = 0.20 Wml 
~ 100 • Fraction 40: IC50 (1) = 0.47 Wm • Fraction 40: IC 50 (2) = 0.37 Wml~ 100 

~ 
 • Fraction 50 IC50 (1) = 0.50 ~m 'E • Fraction 50: IC 50 (2) = 0.94 WmlJl 75 Jl 75 
.!" ~ 50 
:! ~ 50.. 
"- 25 ~ 25'* '* 
Figure 6.6. The dose response curves showing the antiplasmodial activity of 10% SPE 
fractions (fractions 30, 40 and 50) from the cold DeM root extract of D. anomala from 
Sterkspruit. Fractions 30 and 40 were screened at concentrations (50 ~g/ml- 0.098 ~g/ml) 
while fraction 50 was screened at concentrations (1 00 ~g/ml - 0.195 ~g/ml). 
·1 0 1 2 3 
Log [10% SPE fractions] Jllllmi 
~ 0 1 2 3 
Log [10% SPE fractions] "glmI 
The HPLC profiles of the three fractions are shown in figures 6.7a - c and were 
similar to those obtained from batch I and II of the cold OCM root extract of D. 
anomala from Lesotho. 
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Figure 6.7a. The HPLC chromatogram of fraction 30 (4.5 mg/ml) from the cold DCM root extract of 
O. anomala from Sterkspruit. The fraction was run isocratically at 60% MeCN: H20 on a C18 Haisil 
reverse-phase semi-preparative column, at a flow rate of 2.0 ml/min and a detection wavelength of 
215 nm. The injection volume was 150 1-11. 
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Figure 6.7b. The HPLC chromatogram of fraction 40 (4.5 mg/ml) from the cold DCM root extract of 
O. anomala from Sterkspruit. The fraction was run isocratically at 60% MeCN: H20 on a C18 Haisil 
reverse-phase semi-preparative column, at a flow rate of 2.0 ml/min and a detection wavelength of 
215 nm. The injection volume was 150 1-11. 
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Figure 6.7c. The HPLC chromatogram of fraction 50 (4.5 mg/ml) from the cold DCM root extract of 
O. anomala from Sterkspruit. The fraction was run isocratically at 60% MeCN: H20 on a C18 Haisil 
reverse-phase semi-preparative column, at a flow rate of 2.0 ml/min and a detection wavelength of 
215 nm . The injection volume was 150 1-11. 
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These results not only confirms that the roots collected in Sterkspruit are that of 
D. anomala but also indicate that they could be of the same subspecies (i.e. 
subspecies anoma/a). The findings could also be supported by the fact that 
Sterkspruit, which is in the north west of Eastern Cape Province is on the 
boundry with Free State Province and Lesotho. Mohale's Hoek (where the plant 
material was collected) is in the south west of Lesotho and is on the border with 
Sterkspruit. The distance between the two towns is about 42 km. The conditions, 
therefore, under which the plant is growing, would be similar. 
6.5. CONCLUSION 
• 	 The fractionation of the cold OCM root extract of D. anoma/a from Lesotho 
and Sterkspruit, by SPE method, into 10% fractions did not result in the 
loss of antiplasmodial activity against 010 strain of P. fa/ciparum. The 
most active fractions were fractions 30, 40 and 50. The activity was 
retained with the further fractionation of the cold OCM root extract into 5% 
and 1 %. This showed that the fractionation process did not result in the 
breakdown of compounds and that the antiplasmodial activity of the cold 
OCM root extract was not due to synergism between the compounds. 
• 	 The SPE method was reproducible in obtaining 10% and 5% fractions 
from the cold OCM root extract of D. anoma/a from Lesotho. This was 
supported by the antiplasmodial activity and the consistency in the HPLC 
profiles ottractions 30, 40 and 50 (batch I and II). 
• 	 Although the 1 % SPE fractions (fractions 35 - 55) did not result in pure 
compounds, their antiplasmodial activity against three COR strains of P. 
fa/ciparum (K1, RSA11 and FACS) and against the cas strain (010) has 
indicated that these fractions contain antiplasmodial compounds that are 
both active against the cas and COR strains of P. falciparum. Some 
fractions were more active than others against the same strain (e.g. 
fractions 31 against 010 strain and fraction 32 against FACS strain) and 
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some showed similar activity against different strains (e.g. fraction 32 
against RSA11 and FAC8 strains and fraction 34 against D10 and K1 
strains). 
• The roots of D. anama/a collected from Lesotho and Sterkspruit could are 
the same as was observed in the similarity of the HPLC profiles of the cold 
DCM root extracts and their SPE fractions 30, 40 and 50. 
• The roots of D. anoma/a, therefore, contain compounds that could act 
against both cas and COR strains of P. falciparum. Potential therefore 
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7.1. INTRODUCTION 
Fractions 40 and 50 were the most active 10% SPE fractions (fraction 40: 0.72 ± 
0.20 pgtmJ :s 1C50 ;::0.63 ± 0:0'45 pgtmf and fraction 50: 0.63 ±O.O pgtm1 :s lC50 ;:: 
0.54 ± 0.11 I-lg/ml) (Chapter 5, table 5.4) obtained from the fractionation of the 
cold DCM root extract of D. anomala from Lesotho. Two compounds, MF4 and 
MF7A, were isolated from these fractions. 
7.2. METHODS 
Compounds, MF4 and MF7A, were both isolated from fraction 40 and only 
compound MF7A was isolated from fraction 50 on semi-preparative HPLC. 
Although MF4 was collected as a single peak and MF7A collected separately 
from the other peaks, they were not pure and therefore were purjfjed further on 
analytical HPLC. 
Compounds MF4 and MF7A were tested for antiplasmodial activity against CQS 
(010) and CQR (K1 and RSA11) strains of P. fa/ciparum and their cytotoxicity 
was determined on the CHO cells. 
The chemical structure of compound MF7 A and the partial chemical structure of 
compound MF4 were identified by NMR and Mass Spectrometry analysis. The 
structures were elucidated by MS, 1H and 13C NMR and confirmed by 2D NMR 
methods (COSY, NOESY, HSQC and HMQC). NMR analyses were carried out 
on a Varian Inova 600 NMR spectrometer. The mass spectra were obtained 
using APCI in the positive ion mode on API 2000 LC1MS1MS mass spectrometer 
and the HRMS on Waters API Q-TOF Ultima. A detailed report of the methods 
used is in Chapter 4. 
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7.3 RESULTS AND DISCUSSION 
7.3.1. The Isolation of Compounds MF4 and MF7A 
Dichloromethane extract 
SPE (C18 column) 
SPE fractions 
(MeCN/H20) 
I I I I I 
0/100 10/90 20/80 30170 40160 50150 60/40 70/30 80/20 90/10 10010 
MF4 MF7A 
Figure 7.1. Separation scheme for obtaining compounds MF4 and MF7 A from the 
most active fractions, fractions 40 and 50 (bolded). 
Fractions 40 and 50 were first run with a gradient elution of 50% - 70% MeCN: 
H20 at a flow rate of 3 ml/min. The fractions (5 mg/ml) were loaded on a C18 
Haisil 100 reverse-phase semi-preparative column (250 x 10 mm, 5 (.1m), the 
injection volume was 260 (.II and the detection wavelength was set at 215 nm. 
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Figure 7.2a. Reverse phase semi-preparative HPLC for fraction 40 (5 mg/ml) run on a C18 Haisil 
100 column (250 x 10 mm, 5 ~m) at a gradient of 50% - 70% MeCN: H20. MF4 eluted at 
8.091minutes and MF7 at 10.307 minutes. The flow rate was 3 mllmin, the injection volume was 
260 ~I and the detection wavelength was set at 215 nm. 
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Figure 7.2b. Reverse phase semi-preparative HPLC for fraction 50 (5 mg/ml) run on a C18 Haisil 
100 column (250 x 10 mm, 5 ~m) at a gradient of 50% - 70% MeCN: H20. MF7 eluted at 10.332 
minutes. The flow rate was 3 ml/min, the injection volume was 260 ~I and the detection 
wavelength wa5set at 215 nm. 
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Figure 7.3. The UV spectra of MF4 (A) and MF7 (8). 
The NMR spectrum of peak MF7 was poorly resolved and its Mass Spectrometry 
showed molecular ions (M + H) at m/z 485, 487,489 (2.2: 1.7: 1) and others at 
m/z> 500 as shown in figure 7.4a. The major molecular ion in both samples was 
at m/z 485. This showed that the MF7 sample was not a pure compound and 
explained that the poor resolution of the NMR spectrum of MF7 was due to 













Figure 7.4a. LC/MS of peak MF7. 
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Figure 7.4b. NMR of peak MF7 run in GlaxoSmithKline (Middlesex UK), 
7.3.2. Separation of components in peak MF7 
Fraction 40 was eluted at isocratic elutions of 50%, 60% and 70% MeCN: H20 . 
The fraction was loaded at a concentration of 4,5 mg/ml on a Haisil semi­
preparative column (250 x 10 mm, 5 IJm) and the compounds eluted at a flow 
rate of 2.5 mllmin. The injection volume was 250 IJI and the detection wavelength 
was at 215 nm. Peak MF7 separated into two peaks with the isocratic elution of 
60% MeCN: H20, The HPLC chromatograms are shown in figures 7.5a, 7.5b and 
7.5c. 
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Figure 7.5a. Reverse phase semi-preparative HPLC for fraction 40 (4.5 mg/ml) run on a Haisil 
column (250 x 10 mm, 5 IJm), at an isocratic elution of 50% MeCN in H20 . The flow rate was 2.5 
mlimin, the injection volume was 250 IJI and the detection wavelength was set at 215 nm. Peak 
MF7 eluted at 21.297 minutes as a single peak, showing a small degree of separation. 
~~5·~~~__________________________________________________1 
SUU Ch2 2 1 :'n.:" 
j " 
60 0 
r 1. , ­
40 0 
I 
., /' a, I 
I r 







Figure 7.5b. Reverse phase semi-preparative HPLC for fraction 40 (4.5 mg/ml) run on a Haisil 
column (250 x 10 mm, 5 IJm), at an isocratic elution of 60% MeCN:H20 . The flow rate was 2.5 
ml/min, the injection volume was 250 IJI and the detection wavelength was set at 215 nm. Peak 
MF7 separated into two peaks, which eluted at 11 .649 minutes and 11 .866 minutes, respectively. 
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Figure 7.Se. Reverse phase semi-preparative HPLC for fraction 40 (4.5 mg/ml) run on a Haisil 
column (250 x 10 mm, 5 IJm), at an isocratic elution of 70% MeCN : H20. The flow rate was 2.5 
ml/min, the injection volume was 250 IJI and the detection wavelength was set at 215 nm. Peak 
MF7 is eluting at 8.080 minutes as a broad single peak. 
Since the isocratic elution of fraction 40 at 60% MeCN: H20 showed the 
separation of peak MF7 into two peaks, two parameters were changed to 
determine if peak MF7 would separate further. The flow rate and the injection 
volume were reduced to 2.0 ml/min and 150 !-II, respectively. The separation of 
MF7 into three peaks was achieved by an isocratic elution at 60% MeCN: H20 
and the three peaks were designated MF7 A, MF7B and MF7C with MF7 A as the 
major peak (figures 7.5d). 
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Figure 7.5d. Reverse phase semi-preparative HPLC for fraction 40 (4.5 mg/ml) run at an isocratic 
elution of 60% MeCN:H20 . The flow rate was 2.0 ml/min, the injection volume was 150 1-11 and the 
detection wavelength was set at 215 nm. The HPLC chromatogram showed the separation of 
peak MF7 into three peaks. Peak MF4 (a) eluted at 11 .191 minutes and peaks MF7 A (b), MF7B 





Figure 7.Se. The UV spectra of MF7A, MF7B and MF7C. 
The UV spectra of MF7A, MF7B and MF7C were similar (figure 7.5e), which 
explained the co-elution of these compounds. MF7A was present in higher 
amounts as compared to MF7B and MF7C and was easier to collect, 
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7.3.3. Purification of Compounds MF4 and MF7 A 
Compounds MF4 and MF7 A were purified further on analytical HPLC. The 
compounds were loaded at a concentration of 2 mg/ml on the Haisil analytical 
columns (250 x 4.6 rnm, 5 IJm for MF7A and 150 x 4.6 mm, 5 IJm for MF4) and 
eluted isocratically at 60% MeCN: H20. The flow rate was 1 ml/min, the injection 
volume was 150 IJI and the compounds were monitored at 215 nm. The yields of 
the compounds were very low [MF4 = 0.17 mg (0.38%) and MF7A = 0.08 mg 
(0.18%) from 45 mg of fraction 40]. Figures 7.6, 7.7 and 7.8 show the HPLC 
chromatograms and UV spectra of compounds MF4 and MF7A. 
Figure 7.6. The analytical HPLC chromatogram of compound MF4 (3.819 minutes). The 
compound was run on a Haisil analytical column (150 x 4.6 mm, 5 ~m) at an isocratic 
run of 60% MeCN: H20. The flow rate was 1 ml/min, the injection volume was 150 ~I and 
the compound was monitored at 215 nm. 
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Figure 7.7. The analytical HPLC chromatogram of compound MF7A (11.516 minutes). 
The compound was run on a Haisil analytical column (250 x 4.6 mm, 5 ~m) at an 
isocratic run of 60% MeCN: H20. The flow rate was 1 ml/min, the injection volume was 
150 ~I and the compound was monitored at 215 nm. 
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Figure 7.8. The UV spectra of compounds MF4 (A) and MF7A (8). 
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7.3.4. Mass Spectrometry 

The mass spectra were recorded on an API 2000 LC/MS/MS mass spectrometer . 
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Figure 7.9a. LC-MS of compound MF4. 
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Figure 7.9b. APCI of compound MF4. 
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Figure 7.9c. ESI-HRMS of compound MF4. 
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Figure 7.10a. LC-MS of compound MF7A. 
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Figure 7.10b. APel of compound MF7A. 
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Figure 7.10c. ESI-HRMS of compound MF7A. 
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Figure 7.11a. LC-MS of peak MF7B. 





























Figure 7.11b. APCI of peak MF7B. 
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Figure 7.12a. LC-MS of peak MF7C . 
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Figure 7.12b. APCI of peak MF7C. 
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Compounds MF4 and MF7 A showed the experimental mass [M + Ht of 
485.1962 and 485.1977, respectively, and the calculated mass of 485.1964 for 
both. The mass was consistent with the molecular formula of (C30H2906), 
therefore, the molecular formulae of compounds MF4 and MF7 A were 
(C30H2S06). The elemental composition of compounds MF4 and MF7 A are shown 
in Appendix E. Compounds MF4 and MF7 A had the same molecular mass, ion 
mass fragmentation patterns and molecular formulae but they eluted at different 
retention times on the HPLC (figure 7.5a). This strongly indicated that the two 
compounds are structural isomers. 
Compound MF7 A and peaks MF7B and MF7C had molecular ion masses m/z at 
[M + Ht which differed by two amu (485, 487 and 489, respectively) (figures 
7.1 Ga, 7.11 a and 7.12a). Their ion mass fragmentation patterns also differed by 
two amu (figures 7.1Gb, 7.11b and 7.12b), indicating the hydrogenation of the 
double bond/s. This showed that MF7B and MF7C have similar chemical 
structures to compound MF7A (figure 7.17) and is further supported by the 
similarity in the UV spectra of these peaks. The level of purity and quantity of 
MF7B and MF7C did not allow further purification for structural elucidation using 
NMR. 
A similar observation was made with peak MF8, which eluted after peak MF7C 
(Appendix E). Its molecular ion mass m/z at [M + H] was 491, indicating a 
difference of 2 amu from MF7C (489) and its ion mass fragmentation pattern also 
differed from that of MF7C by 2 amu. This means that compound MF7 A, peaks 
MF7B, MF7C and MF8 differed from each other by 2 amu, indicating the level of 
hydrogenation bondls and similar chemical structures. Peaks MF5 and MF6, 
which eluted after peak MF4 also had molecular ion masses which differed by 2 
amu (524 for MF5 and 526 for MF6B and 528 for MF6E) (Appendix E). Their ion 
mass fragmentation patterns also differed by 2 amu, indicating similar chemical 
structures. 
Another observation was that peaks MF5 and MF7C had common mass ions in 
their ion mass fragmentation patterns and similarly for peaks MF6B and MF8, 
142 
Chapter 7 The Isolation, Purification, Characterization and Antiplasmodial activity of 
Compounds MF4 and MF7A 
and MF7B and MF8 (Appendix E). Due to the difficulty in purifying peaks MF6B, 
MF6E and MF8 and obtaining sufficient amounts and the instability of peak MF5 
(Chapter 4, p. 70) which could have been to absorption of moisture and 
oxidation, the isolation of pure compounds could not be achieved. 
These results have shown that the roots of D. anomala contain compounds with 
similar chemical structures and which are possible dimeric sesquiterpenes. 
7.3.5. Nuclear Magnetic Resonance (NMR) 
The NMR spectra CH, 13C, COSY, NOESY, HSQC, HMQC and DEPT) were 
recorded on a Varian Inova 600 spectrometer at 25°C in CDCI3. The 1Hand 13C 
spectra were recorded at a frequency of 600 MHz and 150 MHz, respectively. All 
the chemical shifts (8) are reported in parts per million (ppm) relative to TMS (8 = 
0) as internal standard. 
7.3.5.1. NMR spectra of Compound MF7 A 
7.3.5.1.1. 1H-NMR spectrum 
Figure 7.13. 1H-NMR spectrum of compound MF7A (C30H2sOe). 
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7.3.5.1.2. 13C -NMR spectrum 
I J 1 lilll lIJ J J JUJ I 
I 
, , , , , , , , , , , , , , , , , , ,
I I I I I 
200 150 100 50 o 
ppm~1) 










Chapter 7 The Isolation, Purification, Characterization and Antiplasmodial activity of Compounds MF4 and MF7A 
7.3.5.1.3. Correlation Spectroscopy (COSY) 
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Figure 7.15. COSY spectrum of compound MF7A (C30H2S06) ' 
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7.3.5.1.4. 2D-NMR spectrum (HSQC) 
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Figure 7.16. HSQC spectrum of compound MF7A (C30H280e). 
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Table 7.1. 1H and 13C-NMR spectral data for compound MF7A (600 MHz and 150 MHz, CDCI3). 
H Position Chemical shift (l») HSQC HMQC COSY NOESY 
1 3.24 m 40.2 d C-2, C-3, C-4, C-5, C-10, C-14 H2a, H2~, H5 
2a 2.64 m 45.3 t C-1, C-3, C-4, C-5, C-10 H1 H1 
2~ 3.40 dd (18.9, 10.2) C-3, C4, C-5, C-10 H1 
3 220.0 s 
4 51 .9 s 
5 3.32 dd (10.2, 8.4) 50.1 d C-2', C-4, C-6, C-15 H6 H1, H7 
6 4.21 dd (10.2, 9.6) 84 .2 d C-4, C-8 H7 
7 3.05 m 43.5 d H8~ 
8a 1.91 m 31.9 t C-6 H9a, H8~ 
8~ 1.50 m H8a 
9a 2.61 m 39.6 t C-1 , C8, C10, C-14 H9~ 
9~ 2.31 m C-1 , C8, C10, C-14 
10 150.7 s 
11 138.7 s 
12 170.7 s 
13a 6.26 d (3.3) 121.6t C-7, C-11 , C-12 H13b 
13b 5.58 d (3.3) C-7, C-11 , C-12 H13a 
14a 5.07 s 114.3 t C-1, C-10 
14b 4.7 s C-1, C-10 
15a 2.25 m 31.6 C-3, C-4, C-5, C-15' 15~ 
15~ 1.88 m C-4, C-5, C-15' 15a 
l' 158.5 s 
2' 144.8 s 
3' 193.1 s 
4' 141 .2 s 
5' 3.75 d (10.8) 49.3 d C-1', C-2' , C-4' H6' HT 
6' 4.06 dd (10.8, 9.6) 83.2 d C-8' H5',H7' 
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Table 7.1. cant. 
H Position Chemical shift (5) 
J in Hz) 
HSQC HMQC COSY NOESY 











C-1', C-7', C-15' 
H7', H8~ 
H8a, H9' 
11' 138.2 s 







6.29 d (3.3) 








C-7', C-11', C-12' 
C-7', C-11', C-12' 
C-3', C-4', C-5' 
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7.3.5.1.5. Proton and Carbon Assignments for Compound MF7A 
The complete proton and carbon resonances were achieved from the 1 D and 2D­
NMR spectra (table 7.1). The 1H-NMR showed two sets of signals for 
exomethylene protons at D= 6.26 [d, J = 3.3 Hz, H-13a], D= 5.58 [d, J = 3.3 Hz, 
H-13b], D = 6.29 [d, J = 3.3, H-13'a], D = 5.56 [d, J = 3.3 Hz, H-13'b]. These 
signals are typical of exomethylene protons conjugated with the lactonic carbonyl 
of sesquiterpene lactones. This was supported by the HMQC spectrum, where 
the H-13a and H-13b protons correlated with C-7 (Dc = 43.5), C-11 ( Dc = 138.7) 
and C-12 (Dc = 170.7). The H-13'a and H-13'b protons correlated with C-T (Dc = 
46.9), C-11' (Dc = 138.2) and C-12' (Dc =169.5). Finally, the H-6 and H-6' proton 
resonances were at D = 4.21 dd and D = 4.06 dd were confirmed by their 
correlation in the HSQC spectra to carbon resonances at Dc = 84.2 and 83.2 
respectively. The COSY spectrum showed the correlations of H-13a with H-13b 
and H13'a with H-13'b. 
The lack of signals for H-1' and H-2' and the presence of the quarternary carbons 
corresponding to D = 158.5 (C-1') and D = 144.8 (C-2') indicated a 
tetrasubstituted C1' - C2' double bond. The other double bond at C-9' - C-10' was 
determined from the HSQC spectrum, C-9' (Dc = 130.9) and C-10' (Dc = 134.4) 
as well as the proton shift at D = 5.98 [d, J = 6.6 Hz, H-9']. The HMQC showed 
correlations of H-9' with C-1', C-T and C-15'. The presence of the double bond 
exomethylene protons (H-14'a and H-14'b) was confirmed by the absence of the 
proton signals at C-4' (Dc = 141.2) as shown in the HSQC spectrum and the 
HMQC correlations with C-3', C-4' and C-5'. The other double bond 
exomethylene protons (H-14a and H-14b) was situated at C-10 (Dc = 150.7) as 
confirmed by the HSQC. The carbonyl resonances at C-3 (Dc = 220.2) and C-3' 
(Dc = 193.1) were confirmed in the HMQC spectra by correlations from H-1, H­
2o, H-2~ , H-5, H-150 and H-14'a, H-14'b , respectively. 
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Compound MF7 A was established as an unsymmetrical dimeric sesquiterpene 
with an unusual six-membered ring linking the two monomers. The six-membered 
ring was deduced from the HMQC spectrum where H-15 (oc = 31.9) correlated 
with C-3, C-4, C-5 and C-15' and H-5 (oc =50.1) correlated with C-2' C-4, C-6 
and C-15 and H-9' (oc = 130.9) correlated with C-1', C-7' and C-15'. Both 
monomers contained five-membered rings fused to seven-membered ring and 
the lactone rings were attached at carbons 6 and 7. 
Examples of the chemical structures of dimeric guaianolides with different links 
between the two monomers [Trendafilova et aI. , 2006; Hou et aI., 2003; Wong & 
Brown, 2002] are shown in Appendix F. 
The chemical structure of compound MF7 A (figure 7.17) has shown that this 
compound is a novel dimeric sesquiterpene lactone of the guaianolide-type. 
Compound MF7 A has been included in a list of compounds that are in the 
process of being patented. The patent is held by the University of Cape Town 
and the Medical Research Council of South Africa. 
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7.3.5.2. NMR spectra of Compound MF4 
7.3.5.2.1. 1H-NMR spectrum 
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Figure 7.18. 1H-NMR spectrum of compound MF4 (C30H2806). 
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7.3.5.2.2. 13C -NMR spectrum 
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Figure 7.19. 13C-NMR spectrum of compound MF4 (C30H2SOs). 
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7.3.5.2.3. Correlation Spectroscopy (COSY) 
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Figure 7.20. COSY spectrum of compound MF4 (C30H2806)' 
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Figure 7.21. HMQC spectrum of compound MF4 (C30H2806). 
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Figure 7.22. HSQC spectrum of compound MF4 (C30H2S0S)' 
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Although compound MF4 had the same molecular mass as compound MF7A 
(485.1964), there was difficulty in elucidating its chemical structure. It can 
therefore be inconclusively said that compound MF4 is also a dimeric 
sesquiterpene since there was a strong indication that it is an isomer of 
compound MF7 A. The two compounds were screened for in vitro antiplasmodial 
activity against three strains of P. fa/ciparum. 
7.3.6. Antiplasmodial Activity and Cytotoxicity of Compounds 
MF4 and MF7A 
Table 7.2. The in vitro antiplasmodial activity of compounds MF4 and MF7 A on cas 





ICso ± S.D. 
(IJg/ml) 
K1 strain 
ICso ± S.D. 
(lJg/ml) 
RSA11 strain 
ICso ± S.D. 
(IJg/ml) 
CHO cells 
ICso ± S.D. 
(lJg/ml 
Sia Rib 
MF4 0.28 ± 0.01 0.94 ± 0.14 0.28 ± 0.075 4.41±0.47 15.75 3.36 
MF7A 0.20 ± 0.01 0.78 ± 0.2 0.40 ± 0.07 0.45 ± 0.01 2.25 3.90 
MeCN > 100 > 100 > 100 > 100 
Cae 11.68± 1.90 165.44 ± 4.38 197.68 ± 5.81 > 100 >100 14.16 
Emetine NO NO NO 0.053 ± 0.0045 
aSI = Selectivity index (SI) = CHO ICsoID10 IC50 
bRI = Resistance index (RI) = K1 ICsofD10 ICso 
cCQ = Chloroquine IC50 values in ng/ml 
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Figure 7.23. The dose-response curves of the antiplasmodial activity of MF4 and MF7A 
on 010, K1 and RSA11 strains of P. falciparum. Each point is the mean of 2 tests and 
the error bars are S.D. of the mean. 
Results of the antiplasmodial and cytotoxicity screening are summarized in table 
7.2 and figures 7.23, 7.24 and 7.25. Compounds MF4 and MF7A showed the 
highest antiplasmodial activity against the COS strain, 010 (0.28 ± 0.01 jJg/ml 
and 0.20 ± 0.01 jJg/ml, respectively) with compound MF7A being slightly more 
active than compound MF4. The two compounds also showed activity against the 
COR strains, K1 and RSA11, and were more active on the RSA11 strain (MF4: 
0.28 ± 0.075 jJg/ml; MF7A: 0.40 ± 0.07 jJg/ml) than on the K1 strain (MF4: 0.94 ± 
0.14 jJg/ml; MF7A: 0.78 ± 0.20 jJg/ml). 
The antiplasmodial activity of compound MF4 was the same against 010 and 
RSA11 strains and lower against the K1 strain. This indicated the possibility that 
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the RSA 11 strain does not have the mutant gene that would confer resistance to 
compound MF4. Compound MF7A was 2 times more active on the 010 strain 
than on the RSA 11 strain and as with compound MF4, the activity against the K1 
strain was lower. Compounds MF4 and MF7A showed resistance indexes of 3.21 
and 3.90, respectively, indicating that compounds MF4 and MF7A could have 
partial resistance to the parasites. The compounds did not show cross-resistance 
with chloroquine (RI =14.16). 
Although the two compounds possessed remarkable antiplasmodial activity, they 
exhibited higher cytotoxicity (MF4: 4.41 ± 0.47 I-Ig/ml, MF7A: 0.45 ± 0.01 I-Ig/ml). 
However, the antiplasmodial activity was not due to the toxicity except for the 
activity of compound MF7A against K1 strain. Compound MF4 was the most 
favourable with the selectivity index of approximately 16 times more potent to the 
parasites than to the cells while compound MF7 A was only 2 times more potent 
to the parasites than to the cells, showing lack of selectivity. 
The cytotoxicity of the two compounds was very high despite the fact that the 
results were averages of two independent experiments. The IC50 of the positive 
control, emetine (0.053 ± 0.0045 I-Ig/ml) indicated that the CHO cells were in a 
good state and therefore, the experiments worked well. The solvent control, 
acetonitrile, did not have any effect (lC50 = > 100 I-Ig/ml) on the antiplasmodial 
activity and the cytotoxicity of compounds MF4 and MF7A (figure 7.25). To 
confirm the cytotoxicity results of compounds MF4 and MF7A on CHO cells, the 
compounds were collected from newly prepared samples of fractions 40 and 50 
as previously described. After purification, the two compounds were screened for 
cytotoxicity on a new batch of CHO cells and the results obtained were still 
similar (figure 7.25). 
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Figure 7.24. The dose-response curves of the cytotoxicity of MF4 and MF7A on CHO 
cells. Each point is the mean of 3 tests and the error bars are SD of the mean. The 
areas marked with demarcated lines represent the area where the antiplasmodial activity 
of the compounds on the D1 0 strain of P. fa/ciparum was. 
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Figure 7.25. The cytotoxicity dose response curves of emetine, MF4 and MF7A. MF4 
and MF7 A were isolated from a new batch of fraction 40 and screened on a new batch 
of CHO cells, to confirm the cytotoxicity of the two compounds. Each point is the mean of 
3 tests and the error bars are S.D. of the mean. 
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Compounds MF4 and MF7 A had similar antiplasmodial activity (0.28 ± 0.01 
jJg/ml and 0.22 ± 0.03 jJg/ml, respectively) against the CO-sensitive strain, D10. 
(table 7.3, figures 7.23). Compound MF7A was slightly more active than 
compound MF4. Although the two compounds were cytotoxic (MF4: 4.41 ± 0.47 
jJg/ml and MF7A: 0.45 ± 0.01 jJg/ml)(table 7.3 and figures 7.24 and 7.25), their 
antiplasmodial activity was not due to the toxicity as indicated by their selectivity 
indexes (51). The selectivity index of MF4 showed that it was about 16 times 
more potent to the parasites than to the cells while that of compound MF7 A was 
2 indicating lack of selectivity. 
The remarkable antiplasmodial activity of compounds MF4 and MF7 A has shown 
that they have potential as lead compounds, but the low selectivity index of 
compound MF4 and the lack of selectivity of compound MF7 A indicated that 
these compounds have a narrow safety margin, which may hamper their potential 
as lead compounds. However, although the two compounds showed similar 
antiplasmodial activity against the D10 strain, there was a great difference in their 
cytotoxicity. Compound MF7A was about 10 times more cytotoxic on CHO cells 
than MF4. Therefore, based on these observations, it is possible that structural 
changes in both compounds could lead to derivatives that are highly active 
against the malaria parasites but less cytotoxic on the mammalian cells. 
The antiplasmodial activity of the compounds was higher than that of the crude 
DCM root extract (2.48 ± 0.005 jJg/ml s IC50 ;;:: 1.55 ± 0.07jJg/ml). fraction 40 (0.72 
± 0.20 jJg/ml s IC50 ;;:: 0.63 ± 0.045 jJg/ml) and fraction 50 (0.63 ± 0.005 jJg/ml S 
IC50 ;;:: 0.54 ± 0.11 jJg/ml). The activity was therefore not lost during the 
fractionation and the isolation of compounds MF4 and MF7 A. 
7.3.7. Compounds isolated 'fron1 Dicoma anomala 
Compounds isolated from Dicoma anoma/a 50nd. include sesquiterpene 
lactones, lupeol, lupeol acetate, phytol, germacrane D and were isolated from the 
aerial parts [Zderoand Bohlmann, 1990; Bohlmann et aI., 1982 and Bohlmann 
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and Ie Van, 1978]. Some of the sesquiterpene lactones isolated from D. anomala 




Figure 7.26. Sesquiterpene lactones isolated from the aerial parts of D. anomala Sond. 
ssp. anomala [Bohlmann, 1982 (1); Zdero, 1990 (2)]. 
Although Bohlmann et aI., isolated sesquiterpene lactones and other compounds 
from the roots of D. anomala. subsp. cirsioides (figures 7.27 and 7.28), they 
reported that the roots of D. anomala subsp. anomala gave no characteristic 
compounds. But, the findings by Dr. Matsabisa {PhD thesis, University Of Cape 
Town, 2001] have shown for the first time that the roots of D. anomala subsp. 
anomala contain sesquiterpene lactones, which had molecular formulae of 
C30H3607 ({M + 1t = 509.2545) and C30H3407 ({M + 1t = 507.2388). The 
presence of 30 carbon atoms suggested that the structures might be dimeric 
sesquiterpenes. The two compounds were isolated as a mixture and their 
structural elucidation was incomplete due to the difficulty in separating them. The 
problem of separating compounds and obtaining their structures was also 
experienced with the isolation of compounds MF4 and MF7A as discussed in 
section 7.3.2 of this chapter and in Chapter 4, section 4.4, p. 70-71). 
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o 
Figure 7.27. Sesquiterpene lactones isolated from the aerial parts of D. anoma/a Sond. 
ssp. cirsioides (Harv) Willd [Bohlmann, 1978]. 
o 
o 
Figure 7.28. Sesquiterpene lactones isolated from the roots of D. anoma/a Sond. ssp. 
cirsioides (Harv) Willd [Bohlmann, 1978]. 
Very little scientific work has been done on D. anomala. The work by Zdero and 
Bohlmann on D. anomala, reported on the isolation of the compounds but not the 
biological activity. Matsabisa has shown in his PhD thesis that a mixture of two 
compounds from the roots of D. anomala possessed antiplasmodial activity. 
The presence of dimeric sesquiterpene lactones in the roots of D. anomala Sond. 
has been confirmed in this thesis with the isolation of compounds MF4 
(C30H280S) and MF7A (C30H280S) and the structural elucidation of compound 
MF7A (figure 7.17). 
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7.3.8. The activities of sesquiterpene lactones 
Sesquiterpene lactones have been shown to exhibit a wide range of biological 
activities such as trypanocidal [Schinor et aI., 2004], anticancer [Ohno et aI., 
2005; Cho et aI., 2004; Jang et al., 1999; Sun et aI., 2003], antitumour [Beekman 
et aI., 1998], antifungal [Skaltsa et aI., 2000; Vajs et at, 1999; Inoue et aI., 1995]; 
antimycobacterial [Cantrell et aI., 1998; Fischer et al., 1998], antibacterial [Rabe 
et aI., 2002; Taylor & Towers, 1998] and inflammatory activity [Lindenmeyer et 
aI., 2006; Siedle et aI., 2004; Matsuda et aI., 2000; ROngeler et aI., 1999 arid Ly~ 
et aI., 1998]. Pharmacological effects include inhibitory effects on alcohol 
absorption [Yoshikawa et aI., 2000] and relaxing properties on smooth muscles 
[Campos et aI., 2003]. Sesquiterpene lactones have also been shown to possess 
herbicidal and insecticidal activity effects [Guillet et aI., Collins et aI., 2000; 
Macias et aI., 1999, 2000]. 
Some of the activities of sesquiterpene lactones have been shown to be due to 
the presence of the a-methylene-y-Iactone group shown in figure 7.29. 
,..--0 

Figure 7.29. The a-methylene-y-Iactone group. 
Lee et aI., and Matsuda et aI., have shown that the a-methylene-y-Iactone moiety 
was important for the inhibitory effects of sesquiterpene lactones on NO 
production. Compounds lacking this moiety showed weaker inhibitory activities. 
Reduction with the opening of the lactone ring also showed weaker inhibitory 
activity on NO production [Matsuda et aI., 2000]. The reductive opening of the 
lactone ring resulted in no activity against Mycobacteriun tuberculosis [Fisher et 
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aI., 1998] and against the inhibition of alcohol absorption [Yoshikawa et aI., 
2000]. 
The a-methylene-y-Iactone group is essential but not sufficient for the biological 
activity of sesquiterpene lactones. The activity of sesquiterpene lactones 
containing the a-methylene-y-Iactone group may be enhanced by the presence of 
epoxides, conjugated carbonyl, keto and aldehyde groups [Saroglou et aI., 2005; 
Siedle et aI., 2004; Fischer et aI., 1998]. On the other hand, the presence and the 
increasing number of hydroxyl groups have been shown to diminish or reduce the 
inhibitory activity of sesquiterpene lactones on the transcription factor NF-KB 
[Siedle et aI., 2004], the cytotoxicity on cancer cell lines [Sun et aI., 2003] and the 
antimycobacterial activity [Cantrell et aI., 19981. The hydroxyl groups increase the 
polarity of the compounds, which reduces their lipophilicity and therefore their 
penetration through the highly lipophilic cell walls and plasma membranes. 
However, the a-methylene-y-Iactone group is not a prerequisite for activity. This 
has been shown by sesquiterpenes lacking the a-methylene-y-Iactone group 
such as the antimalarial drug, artemisinin [Meshnick et aI., 19961, sesquiterpenes 
that inhibited the release of elastase from granulocytes [Siedle et aI., 2003] as 
well as those that had relaxant effects on smooth muscle [Campos et aI., 2003]. 
7.4. CONCLUSION 
• 	 Two compounds, MF4 and MF7 A have been isolated from Dicoma 
anomala subsp. anomala (Sond.) and were found to be dimeric 
sesquiterpenes. This was confirmed by their calculated mass [M + Ht of 
485.1964 consistent with the molecular formula of C30H2s0s. The chemical 
structure of compound MF7 A confirmed that this compound was a dimeric 
sesquiterpene of the guainolide-type. The same molecular mass, ion mass 
fragmentation patterns and molecular formulae of compound MF4 and 
MF7 A strongly indicated that these compounds are isomers, meaning that 
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compound MF4 has the same chemical structure as compound MF7 A. 
There was difficulty in elucidating the chemical structure of compound 
MF4, this suggested that compounds MF4 and MF7A have different 
structural conformations. 
• 	 Compound MF4 was more potent on the cas (010) strain (0.28 ± 0.01 
jJg/ml) than on the COR (K1) strain (0.94 ± 0.34 jJg/ml) indicating partial 
resistance of the parasites to compound MF4. The activity was the same 
for cas (010) strain as for COR (RSA 11) strain (0.28 jJg/ml). The 
antiplasmodial activity of compound MF4 was 16 times more potent than 
cytotoxic, showing the selectivity of the compound. 
• 	 Compound MF7A also showed high potency on the cas (010) strain 
(0.20 ± 0.01 jJg/ml) than on the COR strains (K1) (0.78 ± 0.20 jJg/ml) and 
(RSA 11) (0.40 ± 0.07 jJg/ml) indicating partial resistance of the parasites 
to compound MF7A. Compound MF7A showed lack of selectivity as it was 
only 2 times more potent to the parasites than to the cells. 
• 	 The antiplasmodial activity of compound MF4 was about 2 times more 
than that of fractions 40 and 50 and 6-8 times more active than that of the 
cold OCM root extract. The activity of compound MF7 A was about 3 times 
more active than that of fractions 40 and 50 and 8-12 times more active 
than of the cold OCM root extract. No loss of activity, therefore, resulted 
from the fractionation of the cold OCM extract. 
• 	 The results obtained have shown that D. anomala (Sand.) not only relieve 
malaria symptoms such as headache and fever but has the biological 
activity against the malaria parasite, P. falciparum. 
• 	 The two compounds, MF4 and MF7A, showed promising antimalarial 
activity but have narrow safety margin. The chemical structure of 
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compound MF4 still need to be elucidated and derivatives of both 
compounds prepared to determine whether they would be less cytotoxic 
with high antiplasmodial activity. These compounds may thus be 
potentially useful as lead compounds for the development of a new class 
of antimalarial drugs. 
• 	 The MS of peaks MF7B and MF7C and their UV spectra indicated that 
they have similar chemical structures to compound MF7A and are 
therefore dimeric sesquiterpenes. 
• 	 The MS of peaks MF5, MF6B, MF6E and MF8, which were present in 
fraction 40, have shown that the roots of D. anomaia (Sond.) contain 
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8.1. OBJECTIVES ACHIEVED 
The objectives of this project were: 
• 	 To screen the leaf and root extracts of Dicoma anomala for antiplasmodial 
activity against the CQS strain of P. falciparum. 
• 	 To isolate compounds from Dicoma anomala and screen them for 
antiplasmodial activity against the CQS and CQR strains of P. falciparum. 
• 	 To determine the chemical structures of the isolated compounds using 
spectroscopic techniques such as mass spectrometry and NMR 
• 	 To determine the cytotoxicity of the antiplasmodially active extracts and 
compounds on CHO cells. 
All of the objectives were achieved. The plant material was collected from four 
locations (Lesotho, Sterkspruit, Reitz and Limpopo). Cold and hot extracts of the 
leaves and twigs (a mixture) and the roots were prepared for the anti plasmodial 
screening. Any test sample that showed antiplasmodial activity s 10 f,Jg/ml was 
considered active. 
The cold OCM leaf extracts of the plant collected in Sterkspruit, Reitz and 
Limpopo were active against the CQS (010) strain of P. falciparum (0.68 ± 0.025 
f,Jg/ml s ICso s 3.14 ± 0.12 f,Jg/ml). The cold and hot OCM root extracts from the 
four locations also showed activity against the malarial parasites (ICso s 2.48 
f,Jg/ml). Although the selectivity indexes of the extracts were low (ranging from 2 ­
9). they showed that the antiplasmodial activity of the leaf and root extracts were 
selective for the malarial parasites and therefore the activity was not due to 
cytotoxicity . 
The cold H20 root extracts (13.92 ± 0.52 f,Jg/ml s ICoo s 29.76 ± 2.90 f,Jg/ml), the 
hot H20 root extracts prepared on the soxhlet for 6 hrs (ICoo ;::: 61.15 f,Jg/ml) and 
the hot H20 root extracts prepared on the hotplate for 6 hrs (17.06 ± 1.22 f,Jg/ml S 
ICso s 69.46 ± 2.16 J,lg/ml) did not show significant antiplasmodial actiVity. The 
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hot H20 root extracts from Lesotho and Sterkspruit, prepared on the hotplate for 
2 hrs also did not show significant activity (24.16 ± 0.16 jJg/ml and 19.54 ± 0.045 
jJg/ml, respectively) while the hot H20 root extract of Limpopo (IC5c = 8.44 ± 0.25 
jJg/ml) showed moderate activity. The activity could have been influenced by the 
short time exposure to heat (2 hrs as opposed to 6 hrs), the presence and the 
concentration of antiplasmodial compounds in the hot H20 root extract. The 
extract showed less cytotoxicity (87.06 ± 6.70 jJg/ml) on CHO cells. 
The plant roots from Lesotho were also extracted with other organic solvents. 
The chloroform and ethyl acetate root extracts showed good activity (1.18 ± 0.08 
jJg/ml and 1.56 ± 0.36 jJg/ml, respectively), which was similar to that of the cold 
DCM extract from batch II (1.55 ± 0.07 jJg/ml). The similar antiplasmodial activity 
was also supported by the similarity in the HPLC chromatograms of the three 
extracts. The selectivity indexes (4 - 10) indicated that the extracts were selective 
towards the malarial parasites and that their activity was not due to cytotoxicity. 
The hexane, petroleum spirit and methanol extracts of the roots did not exhibit 
any significant antiplasmodial activity (10.67 ± 0.32 jJg/ml s IC5c S 39.30 ± 0.70 
jJg/ml). 
Four fractions were obtained from the cold H20 extraction of the roots of D. 
anomala from Lesotho. These fractions differed from the most concentrated to 
the less concentrated extraction. The fractions were screened for antiplasmodial 
activity and the activity was found in the third and the fourth fractions. These 
results were observed in two separate extractions. In the first extraction, with 
fractions denoted by H201 - H204, H204 was more active than H203 and in the 
second extraction, with fractions denoted by H1 - H4, H3 was more active than 
H4. Fractions H203, H204, H3 and H4 (7.48 ± 0.07 jJg/ml, 5.54 ± 0.16 jJg/ml, 
4.85 ± 0.18 jJg/ml and 7.0 ± 1.20 jJg/ml, respectively) were active compared to 
the cold H20 root extract (23.86 ± 0.90 jJg/ml), which was not separated. The four 
fractions had less cytotoxic effects on the CHO cells (H203 = 66.74 ± 2.92 jJg/ml, 
H204 =60.43 ± 2.09 jJg/ml, H3 =59.60 ± 2.20 jJg/ml, H4 =78.73 ± 1.99 jJg/rnl) 
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and these results indicated that the antiplasmodial activity of the samples was not 
due to the cytotoxicity. The selectivity of the antiplasmodial potency was high by 
a magnitude of 12 for fractions H204 and H3, 11 for fraction H4 and 9 for fraction 
H203. The results have shown that the roots of D. anomala do not only treat 
malarial symptoms such as fever, but also have biological effects on the malarial 
parasites. 
The cold OCM root extract from Lesotho (batch I and II) was purified using SPE. 
The compounds in the crude OCM extract were separated using 10% (0% ­
100%) increment mobile phases of MeCN and H20 to afford 13 fractions. The 
most active fractions were fractions 30, 40 and 50 (0.46 ± 0.12 !-Ig/ml s IC50 S 
0.72 ± 0.20 !-Ig/ml) and the work was continued with fractions 40 and 50. To 
separate the compounds in fractions 40 and 50, the crude OCM extract was 
further separated with 5% (fractions 35 - 55) and 1 % (fractions 31 - 35) increment 
mobile phases of MeCN and H20. Fractions 35 - 55 showed activity against 010 
strain (0.23 ± 0.025 !-Ig/ml S IC50 S 1.09 ± 0.005!-1g/ml) but the fractions contained 
a lot of peaks. The SPE procedure for the fractionation of the cold OCM root 
extract (batch I and II) into 10% and 5% fractions and their antiplasmodial activity 
were reproducible. 
The crude OCM extracts (cold and hot extracts) from Sterkspruit had similar 
HPLC profiles to those from Lesotho. Since fractions 30, 40 and 50 were the 
three most active fractions from the SPE fractionation of the cold OCM extract 
from Lesotho, the cold OCM extract from Sterkspruit was fractionated into 
fractions 30, 40 and 50 using SPE. The HPLC profiles and antiplasmodial activity 
of these fractions were similar to those from the crude OCM extract from Lesotho. 
The HPLC profiles of fractions 31 - 35 (from batch I cold OCM root extract) 
showed no reduction in the number of peaks and most of the peaks that were 
present in 10% fractions (fractions 40 and 50) were also present in these 
fractions and were more enhanced. This was determined by observing their 
171 
Chapter 8 Discussion and Conclusions 
HPLC spectra. Fractions 31 - 35 were nevertheless screened for antiplasmodial 
activity and showed activity against 010 strain (0.35 jJg/ml S IC50 S 0.79 jJg/ml), 
K1 strain (0.47 jJg/ml S IC50 S 0.66 jJg/ml), RSA 11 strain (0.25 jJg/ml S IC50S 1.12 
jJg/ml) and FAC8 strain (0.21 jJg/ml S IC50 S 8.13 jJg/ml). 
Two compounds, MF4 and MF7A have been isolated from the roots of D. 
anoma/a from Lesotho. Compounds MF4 and MF7A were both isolated on semi­
preparative HPLC from fraction 40 and only compound MF7A was isolated from 
fraction 50. Both compounds had a mass of [M + Ht of 485.1964 which was 
consistent with the molecular formula of C30H2S06. The two compounds eluted at 
different retention times on the semi-preparative HPLC (MF4: 11.191 minutes 
and MF7A: 14.047 minutes) at 60% MeCN in H20 and flow rate of 2 ml/min. The 
chemical structure of compound MF7 A was elucidated by NMR, MS and HRMS 
spectroscopy and was found to be a novel dimeric sesquiterpene of the 
guaianolide type. The results from the HRMS and HPLC strongly indicated that 
the two compounds are possible isomers. The chemical structure of compound 
MF4 could not be fully elucidated due to difficulty in proton and carbon 
assignments. Since this compound is a possible isomer of compound MF7 A, it 
could be deduced that its chemical structure is similar to that of compound MF7 A 
and it is also a novel dimeric sesquiterpene (C30H2S06). 
Compound MF4 was highly active against the COS strain, 010 (0.28 ± 0.01 
jJg/ml) and the COR strain, RSA 11 (0.28 ± 0.075 jJg/ml). The activity against the 
two strains was similar and this indicated that compound MF4 might have a 
similar mode of action against 010 and RSA 11 strains or the RSA 11 strain had 
not developed resistance against this compound. Compound MF7 A was also 
highly active against the COS strain, 010 (0.20 ± 0.01 jJg/ml) and was less active 
against the COR strain, RSA 11 (0.40 ± 0.07 jJg/ml), which indicated that the 
mode of action could be different or the malarial parasites were showing 
resistance to this compound. Both compounds showed lower activity against the 
COR strain, K1 (MF4: 0.94 ± 0.34 jJg/ml; MF7A: 0.78 ± 0.20 jJg/ml) than against 
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the RSA11 strain. The results showed that the two compounds could have 
different modes of action against the two CaR strains and the resistance indexes 
of the two compounds (MF4: 3.36 and MF7 A: 3.90), indicated that compounds 
MF4 and MF7 A could have partial resistance to the paraSites. The compounds 
did not show cross-resistance with chloroquine (RI =14.16). 
Although compound MF7A showed lack of selectivity (51 = 2.25) towards the 
parasites, compound MF4 was the favourable one being 16 times more selective 
towards the parasites than the CHO cells. 
Compounds MF4 and MF7 A could therefore, be potential lead compounds for the 
development of potential antimalarial drugs since they showed antiplasmodial 
activity against cas (D10) strain and CaR (K1 and RSA1) strains. 
The results obtained from the crude extracts, SPE fractions, isolated compounds 
have shown that Dicoma anomala has a potential for the treatment of malaria 
and that there are still a lot of studies to be conducted on this plant. 
There were 6 peaks which could not be isolated due to instability (peak MF5), 
difficulty in separation, the level of purity and quantity (peaks MF6B, MF6E, 
MF7B, MF7C and MF8). All these peaks were present in fraction 40. Compound 
MF7 A and peaks MF7B and MF7C had molecular ion masses mlz at [M + Ht 
which differed by two amu (485, 487 and 489, respectively) and their ion mass 
fragmentation patterns also differed by two amu (Chapter 7, p. 138 - 141). This 
indicated the hydrogenation of the double bond/s and showed that MF7B and 
MF7C have similar chemical structures to compound MF7 A. This was further 
supported by the similarity in the HPLC spectra of these peaks (Chapter 7, p. 
134). The ion mass fragmentation patterns showed several losses of water and 
possibly (alcohol, acid, glycosides). 
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A similar observation was made with peak MF8, which eluted after peak MF7C 
(Appendix E). Its molecular ion mass m/z at [M + H] was 491, indicating a 
difference of 2 amu from MF7C (489) and its ion mass fragmentation pattern also 
differed from that of MF7C by 2 amu. This means that compound MF7 A, peaks 
MF7B, MF7C and MF8 differed from each other by 2 amu, indicating the level of 
hydrogenation bond/s and therefore similar chemical structures. Peaks MF5, 
MF6B and MF6E, which eluted after peak MF4 also had molecular ion masses 
which differed by 2 amu (524 for MF5 and 526 for MF6B and 528 for MF6E) 
(Appendix E). Their ion mass fragmentation patterns also differed by 2 amu, 
indicating similarity in chemical structures. 
Another observation was that peaks MF5 and MF7C had common mass ions in 
their ion mass fragmentation patterns and similarly for peaks MF6B and MF8, 
and MF7B and MF8 (Appendix E). 
These results have shown that the roots of D. anomaia contain compounds with 
similar chemical structures and which are possible dimeric sesquiterpenes. 
8.2. PROBLEMS ENCOUNTERED 
• 	 The isolation of compounds MF4 and MF7A was difficult due to these 
compounds co-eluting with other compounds, which had similar HPLC 
spectra to MF4 and MF7 A. 
• 	 The purification of compound MF7 A was more challenging than that of 
compound MF4. The HPLC separation between compound MF7 A and 
MF7B was very small and this made it difficult to purify MF7 A since the 
HPLC spectra of MF7A and MF7B were very similar. The purity of 
compound MF7 A was therefore constantly monitored by mass 
spectrometry and it took months to purify so as to obtain sufficient material 
for biological testing and chemical studies. 
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• 	 In addition to this, the yields were very low (MF4 =1.72 mg and MF7A = 
0.63 mg from 45 mg of fraction 40). The yield of the cold DCM root extract 
(3.65 mg) from the powdered roots (200.43 g) was also very low. 
8.3. FUTURE WORK 
1. Compounds MF4 and MF7A are dimeric sesquiterpenes and some in vitro 
studies would have to be done to determine whether upon the breaking down of 
the dimers into their respective monomers: 
• 	 The antiplasmodial activity would be retained or lost and if retained is it 
higher or lower than that of the dimers. 
• 	 The cytotoxicity would be higher or lower than that of the dimers. 
2. Compounds MF4 and MF7 A have shown a potential as lead compounds for 
the development of antimalarial drugs, but they first have to be screened for in 
vivo antimalarial activity and toxicity. This will determine if their suitable for 
human use. The in vivo screening would also address the following: 
• 	 The in vitro screening showed that compound MF4 was more selective to 
the parasites than to the cells as compared to compound MF7A but both 
compounds were cytotoxic on CHO cells, thereby indicating their marginal 
safety. It would be important to determine whether these compounds are 
toxic in vivo. 
• 	 If they are not toxic in vivo, then it has to be shown whether are they being 
metabolized to non-toxic metabolites and whether these metabolites are 
active antimalarials. 
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• 	 The bioavailability of the compounds, which is an important factor in 
determining the efficacy of drugs. 
3. The other important factor in the development of compounds MF4 and MF7 A 
as potential lead antimalarials is to have compounds with less or non-cytotoxic 
effects. Structural modifications on compounds MF4 and MF7 A could show 
whether their derivatives would retain. or lose the antiplasmodial activity and show 
less or no cytotoxicity. 
4. The water fractions (H203, H204, H3 and H4) and the OCM leaf extracts from 
Sterkspruit, Limpopo and Reitz showed antiplasmodial activity against cas 
strain (010). The compounds in these water fractions and OCM leaf extracts 
have to be isolated to determine which compounds are active against P. 
fa/ciparum parasites and how structurally different or similar are they to 
compounds MF4 and MF7 A. 
5. Other compounds from fraction 40 and 50 should be isolated, screened for 
antiplasmodial activity and determine how their structures and activity compare to 
those of MF4 and MF7 A. 
6. Peaks MF7B and MF7C (from fractions 40 and 50) and compound MF7 A had 
similar HPLC spectra and their masses were shown to differ by 2 amu (MF7 A: 
485, MF7B: 487 and MF7C: 489). It would be interesting to see how the 
antiplasmodial activity, cytotoxicity and chemical structures of MF7B and MF7C 
compare to those of MF7A and MF4. 
7. Studies on the mechanism of action, including proteomics (to determine drug 
targets and hence possible mechanism of action), genomics (to determine 
possible genotoxicity), metabolimics, structure-activity and structure-cytotoxicity 
relationships of compound MF4 and MF7A need to be done to understand this 
class of compounds. 
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8. The success of developing compounds MF4 and MF7 A as antimalarial lead 
compounds will depend on the availability of the plant material. The low yields of 
active compounds from natural sources is a major problem, which could lead to 
over-harvesting of the plant and in the long run could result in the extinction of 
the plant. The yields of compounds MF4 and MF7 A obtained from 45 mg of 
fraction 40 were 0.38 % (0.17 mg) and 0.18% (0.08 mg), respectively. In addition 
to this, it will be difficult to harvest D. anomala since it is a small and low-lying 
plant which grows on rocky hillsides. The solution to this problem would be: 
• 	 To cultivate D. anomala on a large scale and obtain the compounds from 
this plant. The cultivation of the plant would involve the communities for 
ensuring constant supply of raw materials. 
• 	 To have an efficient synthetic approach that will result in the synthesis of 
compounds with desired stereochemistry. The 6,12-guaianolides [Bargues 
et aI., 1998; 2002] and 8,12-guaianolides [Blay et aI., 2000] have been 
synthesized through photochemical rearrangement from santonin, a 
commercially available natural eudesmanolide. The chemical methods 
could be used for the synthesis of compound MF7A (a 6,12 -guaianolide) 
and the monomers linked chemically to obtain the desired dimer. 
• 	 Another approach for the organic synthesis of compounds MF4 and MF7 A 
would be the use of precursor building blocks, such as the C 15 precursor 
(5-7 -5-guaianolides). 
9. The in vivo antimalarial activity and in vivo toxicity (preclinical toxicology) of the 
compounds isolated as well as the crude extracts and fractions that showed in 
vitro antiplasmodial activity, have to be investigated. Once promising results have 
been achieved and it has been shown that the compounds could be obtained on 
a large production scale, the pharmaceutical interest and involvement could 
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occur for the manufacturing and production of antimalarials from Dicoma 
anomala. 
10. Peaks MF5, MF6B, MF6E, MF7B, MF7C and MF8 would have to be isolated 
and chemical structures obtained to determine how they differ from each other 
and from the chemical structure of compound MF7 A. Also, to determine their 
antiplasmodial activity, antimalarial activity and toxicity. 
11. Current research at the Medical Research Council, South Africa, is evaluating 
the toxicology of both the DCM and H20 root extracts on a velvet monkey model 
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THE HPLC CHROMATOGRAMS OF THE LEAF AND 
TWIG AND THE ROOT EXTRACTS OF D. anomala FROM 
STERKSPRUIT, LIMPOPO AND REITZ 
Appendices 
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Appendix A1. The HPLC chromatogram of the cold DCM leaf and twig extract of D. 
anomala from Sterkspruit. The analytical separation of the extract was done on a 
C18 reverse phase Phenomenex column at a gradient of 20% - 100% MeCN: H20. 
The flow rate was 1 ml/min, injection volume was 150 IJI and the concentration was 1 
mg/ml. 
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Appendix A2. The HPLC chromatogram of the cold DCM leaf and twig extract of D. 
anomala from Limpopo. The analytical separation of the extract was done on a C18 
reverse phase Phenomenex column at a gradient of 20% - 100% MeCN: H20. The 




Appendix A3. The HPLC chromatogram of the cold DCM leaf and twig extract of D. 
anomala from Reitz. The analytical separation of the extract was done on a C18 
reverse phase Phenomenex column at a gradient of 20% - 100% MeCN: H20. The 
flow rate was 1 ml/min, injection volume was 150 IJI and the concentration was 1 
mg/ml. 
Appendix A4. The HPLC chromatogram of the cold DCM root of D. anomala from 
Limpopo. The analytical separation of the extract was done on a C18 reverse phase 
Phenomenex column at a gradient of 20% - 100% MeCN: H20 . The flow rate was 1 
ml/min, injection volume was 150 IJI and the concentration was 1 mg/ml. 
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Appendix AS. The HPLC chromatogram of the cold DCM root extract of D. anomala 
from Reitz. The analytical separation of the extract was done on a C18 reverse 
phase Phenomenex column at a gradient of 20% - 100% MeCN: H20. The flow rate 




THE HPLC CHROMATOGRAMS OF ORGANIC ROOT 
EXTRACTS OF D. anomala FROM LESOTHO 
Appendices 
~ 21 Sn. 
Appendix 81. The HPLC chromatogram of the crude chloroform root extract of D. 
anomala from Lesotho. The analytical separation of the extract was done on a C18 
reverse phase Phenomenex column at a gradient of 20% - 100% MeCN: H20. The 
flow rate was 1 ml/min, injection volume was 150 IJI and the concentration was 1 
mg/ml . 
Appendix 82. The HPLC chromatogram of the crude ethylacetate root extract of D. 
anomala from Lesotho. The analytical separation of the extract was done on a C18 
reverse phase Phenomenex column at a gradient of 20% - 100% MeCN: H20. The 




Appendix 83. The HPLC chromatogram of the crude hexaneroot extract of D. 
anomala from Lesotho. The analytical separation of the extract was done on a C18 
reverse phase Phenomenex column at a gradient of 20% - 100% MeCN: H20 . The 






Appendix 84. The HPLC chromatogram of the crude methanol root extract of D. 
anomala from Lesotho. The analytical separation of the extract was done on a C18 
reverse phase Phenomenex column at a gradient of 20% - 100% MeCN: H20. The 
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Appendix 85. The HPLC chromatogram of the crude petroleum ether root extract of 
D. anomala from Lesotho. The analytical separation of the extract was done on a 
C18 reverse phase Phenomenex column at a gradient of 20% - 100% MeCN: H20. 










Appendix C1. The HPLC chromatogram of fraction 35 from batch I of the cold DCM extract 
from Lesotho. The analytical separation of the fraction was done on a C 18 reverse-phase 
Phenomenex column (150 x 4.6 mm, 5 IJm) at a gradient of 30% - 70% MeCN in H20 . The 
flow rate was 1 mllmin, injection volume was 150 IJI and the concentration was 1 mg/ml. 
Appendix C2. The HPLC chromatogram of fraction 40 from batch I of the cold DCM extract 
from Lesotho. The analytical separation of the fraction was done on a C18 reverse-phase 
Phenomenex column (150 x 4.6 mm, 5 IJm) at a gradient of 30% - 70% MeCN in H20 . The 




Appendix C3. The HPLC chromatogram of fraction 45 from batch I of the cold DCM extract 
from Lesotho. The analytical separation of the fraction was done on a C 18 reverse-phase 
Phenomenex column (150 x 4.6 mm, 5 11m) at a gradient of 30% - 70% MeCN in H20. The 
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Appendix C4. The HPLC chromatogram of fraction 50 from batch I of the cold DCM extract 
from Lesotho. The analytical separation of the fraction was done on a C18 reverse-phase 
Phenomenex column (150 x 4.6 mm, 5 11m) at a gradient of 30% - 70% MeCN in H20. The 
flow rate was 1 mllmin, injection volume was 150 111 and the concentration was 1 mg/ml. 
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Appendix CS. The HPLC chromatogram of fraction 55 from batch I of the cold OCM extract 
from Lesotho. The analytical separation of the fraction was done on a C 18 reverse-phase 
Phenomenex column (150 x 4.6 mm, 5 IJm) at a gradient of 30% - 70% MeCN in H20 . The 
flow rate was 1 ml/min, injection volume was 150 IJI and the concentration was 1 mg/ml. 
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Appendix CS. The HPLC chromatogram of fraction 31 from batch I of the cold OCM extract 
from Lesotho . The analytical separation of the fraction was done on a C18 reverse-phase 
Haisil column (250 x 4.6 mm, 5 IJm) was at a gradient of 50% - 70% MeCN in H20 MeCN: 








Appendix C7. The HPLC chromatogram of fraction 32 from batch I of the cold DCM extract 
from Lesotho. The analytical separation of the fraction was done on a C18 reverse-phase 
Haisil column (250 x 4.6 mm, 5 ~m) was at a gradient of 50% - 70% MeCN in H20 MeCN: 
H20 . The flow rate was 1 ml/min, injection volume was 250 ~I and the concentration was 1 
mg/ml. 
", 
Appendix C8. The HPLC chromatogram of fraction 33 from batch I of the cold DCM extract 
from Lesotho. The analytical separation of the fraction was done on a C 18 reverse-phase 
Haisil column (250 x 4.6 mm, 5 ~m) was at a gradient of 50% - 70% MeCN in H20 MeCN: 
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Appendix C9. The HPLC chromatogram of fraction 34 from batch I of the cold DCM extract 
from Lesotho. The analytical separation of the fraction was done on a C18 reverse-phase 
Haisil column (250 x 4.6 mm, 5 IJm) was at a gradient of 50% - 70% MeCN in H20 MeCN: 
H20. The flow rate was 1 ml/min, injection volume was 250 IJI and the concentration was 1 
mg/ml. 
Appendix C10. The HPLC chromatogram of fraction 35 from batch I of the cold DCM extract 
from Lesotho. The analytical separation of the fraction was done on a C18 reverse-phase 
Haisil column (250 x 4.6 mm, 5 IJm) was at a gradient of 50% - 70% MeCN in H20 MeCN: 
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Appendix 01 . The HPLC chromatogram of a TLC band (band 3, UV =254 nm) from 
fraction 31 . The fraction was run on a pre-coated aluminium TLC plate (20 x 20 cm 





'~I ~ ~I . a I 1.:11 
I ; ~ ~"I ~ 
-0. . ·' 1 
ot-~~ - - - - ~ --- - ~ -.. ~ . ~ ~-------~,0: """4 - - - -- - .:...- '--. - ­
4n20 
Appendix 02. The HPLC chromatogram of a TLC band (band 5, UV 254 nm) from 
fraction 31. The fraction was run on a pre-coated aluminium TLC plate (20 x 20 cm 
silica gel 60F
254 
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Appendix 03. The HPLC chromatogram of a TLC band (band 3, UV =366 nm) from 
fraction 31 . The fraction was run on a pre-coated aluminium TLC plate (20 x 20 cm 
silica gel 60F254 (0.25 mm thickness) and eluted with the benzene: acetic acid (60:40) 
mobile phase. 
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Appendix 04. The HPLC chromatogram of a TLC band (band 5, UV= 366 nm) from 
fraction 31. The fraction was run on a pre-coated aluminium TLC plate (20 x 20 cm 















HR-MS OF COMPOUNDS MF4 & MF7A and LC-MS OF 

PEAKS PRESENT IN FRACTION 40 

Appendices 
Single Mass Analysis 
Tolerance =200.0 PPM lOBE: min =-1 .5, max =100.0 
Isotope cluster parameters: Separation = 1.0 Abundance =1.0% 
Monolsotoplc Mass. Odd and Even Electron Ions 
1 formula(e) evaluated with 1 results within limits (up to 50 closest results for each mass) 
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Appendix E1. ESI-HRMS showing the experimental and calculated masses and the elemental composition of compound MF4. 
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MF_UCT_060801_ 2c 73 (0 .779) AM (Can,2, 80.00, Ar, 12600.0,785.84 ,100); 8m (SG, 2x3.00) ; Sb (1,40 .00), Cm (53:105) 
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Appendix E3. Reverse phase semi-preparative HPLC for fraction 40 showing peaks, 
MF5 (x), MF68 & MF6E (y) and MFa (z). The fraction was ran at an isocratic elution 
of 60% MeCN in H20 on a Haisil column (250 x 10 mm, 5 I-lm), the concentration was 
4.5 mg/ml, flow rate was 2.0 ml/min and the injection volume was 150 I-ll. 




'" fr 4.OeS 

i ­·cn 






 21t4 ~2S3 .2L S ' 1 ~545 .~ 
S .. " II l'~.>..---,,....&..-.........,..,.-.-.-,JLLj..,.J,.. 

50 100 150 200 2S0 300 350 400 450 SOO SSO 600 

mlz amu 

















tn.0104..6 1-41.4 W 178.2 
I I, I , .1 I~II "'IIJIJ ~I 






335.8 • .2 ...,. 
Appendix E4b. APCI of peak MF5. 
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Appendix E5b. APCI of peak MF6B. 
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Appendix E6b. APCI of peak MF6E. 
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Appendix E7a. LC/MS of peak MF8 (mlz 491). 
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CHEMICAL STRUCTURES OF DIMERIC 

GUAIANOLIDES SHOWING THE DIFFERENT LINKS 

BETWEEN THE TWO MONOMERS 

Appendix F1. Dimeric guaianolide isolated from the aerial parts of Artemisia 
myrianfha. The molecular weight of the compound could not be directly 
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Appendix F2. Dimeric guaianolide, mlz 503 [M-Hr isolated from Lactuca 
indica [Hou et aI., 2003]. 
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Appendix F3. Dimeric guaianolide, from the flower 
heads of Achillea collina aI., 
